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A B S T R A C T
Background
Different therapeutic strategies are available for treatment of multiple sclerosis (MS) including immunosuppressants, immunomodu-
lators, and monoclonal antibodies. Their relative effectiveness in the prevention of relapse or disability progression is unclear due to
the limited number of direct comparison trials. A summary of the results, including both direct and indirect comparisons of treatment
effects, may help to clarify the above uncertainty.
Objectives
To estimate the relative efficacy and acceptability of interferon ß-1b (IFNß-1b) (Betaseron), interferon ß-1a (IFNß-1a) (Rebif and
Avonex), glatiramer acetate, natalizumab,mitoxantrone,methotrexate, cyclophosphamide, azathioprine, intravenous immunoglobulins,
and long-term corticosteroids versus placebo or another active agent in participants with MS and to provide a ranking of the treatments
according to their effectiveness and risk-benefit balance.
Search methods
We searched the Cochrane Database of Systematic Reviews, the Cochrane MS Group Trials Register, and the Food and Drug Admin-
istration (FDA) reports. The most recent search was run in February 2012.
Selection criteria
Randomized controlled trials (RCTs) that studied one of the 11 treatments for use in adults with MS and that reported our pre-speci
ed efficacy outcomes were considered for inclusion.
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Data collection and analysis
Identifying search results and data extraction were performed independently by two authors. Data synthesis was performed by pairwise
meta-analysis and network meta-analysis that was performed within a Bayesian framework. The body of evidence for outcomes within
the pairwise meta-analysis was assessed according to GRADE, as very low, low, moderate, or high quality.
Main results
Forty-four trials were included in this review, in which 17,401 participants had been randomised. Twenty-three trials included relapsing-
remitting MS (RRMS) (9096 participants, 52%), 18 trials included progressive MS (7726, 44%), and three trials included both RRMS
and progressive MS (579, 3%). The majority of the included trials were short-term studies, with the median duration being 24 months.
The results originated mostly from 33 trials on IFNß, glatiramer acetate, and natalizumab that overall contributed outcome data for
9881 participants (66%).
From the pairwise meta-analysis, there was high quality evidence that natalizumab and IFNß-1a (Rebif ) were effective against recurrence
of relapses in RRMS during the first 24 months of treatment compared to placebo (odds ratio (OR) 0.32, 95% confidence interval
(CI) 0.24 to 0.43; OR 0.45, 95% CI 0.28 to 0.71, respectively); they were more effective than IFNß-1a (Avonex) (OR 0.28, 95% CI
0.22 to 0.36; OR 0.19, 95% CI 0.06 to 0.60, respectively). IFNß-1b (Betaseron) and mitoxantrone probably decreased the odds of
the participants with RRMS having clinical relapses compared to placebo (OR 0.55, 95% CI 0.31 to 0.99; OR 0.15, 95% CI 0.04 to
0.54, respectively) but the quality of evidence for these treatments was graded as moderate. From the network meta-analysis, the most
effective drug appeared to be natalizumab (median OR versus placebo 0.29, 95% credible intervals (CrI) 0.17 to 0.51), followed by
IFNß-1a (Rebif ) (median OR versus placebo 0.44, 95% CrI 0.24 to 0.70), mitoxantrone (median OR versus placebo 0.43, 95% CrI
0.20 to 0.87), glatiramer acetate (median OR versus placebo 0.48, 95% CrI 0.38 to 0.75), IFNß-1b (Betaseron) (median OR versus
placebo 0.48, 95% CrI 0.29 to 0.78). However, our confidence was moderate for direct comparison of mitoxantrone and IFNB-1b vs
placebo and very low for direct comparison of glatiramer vs placebo. The relapse outcome for RRMS at three years’ follow-up was not
reported by any of the included trials.
Disability progression was based on surrogate markers in the majority of included studies and was unavailable for RRMS beyond two
to three years. The pairwise meta-analysis suggested, with moderate quality evidence, that natalizumab and IFNß-1a (Rebif ) probably
decreased the odds of the participants with RRMS having disability progression at two years’ follow-up, with an absolute reduction of
14% and 10%, respectively, compared to placebo. Natalizumab and IFNß-1b (Betaseron) were significantly more effective (OR 0.62,
95% CI 0.49 to 0.78; OR 0.35, 95% CI 0.17 to 0.70, respectively) than IFNß-1a (Avonex) in reducing the number of the participants
with RRMS who had progression at two years’ follow-up, and confidence in this result was graded as moderate. From the network
meta-analyses, mitoxantrone appeared to be the most effective agent in decreasing the odds of the participants with RRMS having
progression at two years’ follow-up, but our confidence was very low for direct comparison of mitoxantrone vs placebo. Both pairwise
and network meta-analysis revealed that none of the individual agents included in this review were effective in preventing disability
progression over two or three years in patients with progressive MS.
There was not a dose-effect relationship for any of the included treatments with the exception of mitoxantrone.
Authors’ conclusions
Our review should provide some guidance to clinicians and patients. On the basis of high quality evidence, natalizumab and IFNß-1a
(Rebif ) are superior to all other treatments for preventing clinical relapses in RRMS in the short-term (24months) compared to placebo.
Moderate quality evidence supports a protective effect of natalizumab and IFNß-1a (Rebif ) against disability progression in RRMS in
the short-term compared to placebo. These treatments are associated with long-term serious adverse events and their benefit-risk balance
might be unfavourable. IFNß-1b (Betaseron) and mitoxantrone probably decreased the odds of the participants with RRMS having
relapses, compared with placebo (moderate quality of evidence). The benefit-risk balance with azathioprine is uncertain, however this
agent might be effective in decreasing the odds of the participants with RRMS having relapses and disability progression over 24 to 36
months, compared with placebo. The lack of convincing efficacy data shows that IFNß-1a (Avonex), intravenous immunoglobulins,
cyclophosphamide and long-term steroids have an unfavourable benefit-risk balance in RRMS. None of the included treatments are
effective in decreasing disability progression in patients with progressive MS. It is important to consider that the clinical effects of
all these treatments beyond two years are uncertain, a relevant point for a disease of 30 to 40 years duration. Direct head-to-head
comparison(s) between natalizumab and IFNß-1a (Rebif ) or between azathioprine and IFNß-1a (Rebif ) should be top priority on the
research agenda and follow-up of the trial cohorts should be mandatory.
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P L A I N L A N G U A G E S U M M A R Y
Comparative efficacy and risk-benefit balance of modulator and suppressant drugs of the immune system in people with
multiple sclerosis (MS)
Several immunotherapies have been used to treat MS, but their relative effectiveness is unclear due to the limited number of direct
comparison studies. The authors of this review tried to assess the efficacy and the extent of adverse events of immunotherapies commonly
used in people with MS. Eleven agents were studied, interferon ß-1b (IFNß-1b) (Betaseron), IFNß-1a (Rebif and Avonex), glatiramer
acetate, natalizumab, mitoxantrone, methotrexate, cyclophosphamide, azathioprine, immunoglobulins, and long-term corticosteroids.
Forty-four studies up to 2010 have been included in this review, comprising a total of 17,401 adults suffered from the relapsing-
remitting (RRMS) and the progressive types (PrMS) of MS. The treatments were short-term, the median duration being 24 months.
The results show that:
- there is high quality evidence that both natalizumab and IFNß-1a (Rebif ) can reduce relapses and disability progression compared to
placebo; and they are also more effective than IFNß-1a (Avonex) in people with RRMS. Natalizumab can induce progressive multifocal
leukoencephalopathy, especially with more than two years of treatment;
- IFNß-1b (Betaseron), glatiramer acetate, and mitoxantrone may also prevent relapse and disability progression in people with RRMS.
These treatments are associated with possible medium and long-term side effects, and the risk-benefit balance might be unfavourable;
- IFNß-1a (Avonex), intravenous immunoglobulins, cyclophosphamide, and long-term corticosteroids have an unfavourable risk-
benefit balance for people with RRMS;
- there are insufficient high quality data to clarify whether there is a favourable risk-benefit balance using azathioprine;
- nine drugs (IFNß-1b (Betaseron), IFNß-1a (Avonex and Rebif ), glatiramer acetate, mitoxantrone, methotrexate, cyclophosphamide,
intravenous immunoglobulins, and long-term corticosteroids) were also studied in people with PrMS. Few studies were of high quality
and no drug was shown to be effective in preventing disability progression in people with PrMS.
It is important to consider that the efficacy and the risk-benefit of all these treatments beyond two years are uncertain, and this is a
very relevant point for a lifetime disease such as MS. Thus, studies on the long-term efficacy and safety of immunotherapies for MS are
urgently needed. It is also worth considering that more than 70% of the included studies were sponsored by pharmaceutical companies.
This could have affected the results of this review.
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B A C K G R O U N D
Description of the condition
Multiple sclerosis (MS) is an inflammatory disease of the cen-
tral nervous system (CNS) resulting from the effect of an interac-
tion between unidentified environmental factors and susceptibil-
ity genes (Milo 2010). Several pathological processes occur inMS,
including engagement of the immune system, T cell-mediated and
B cell-mediatedmechanisms, demyelination, inflammatory injury
of axons and glia, post-inflammatory gliosis, and neurodegener-
ation (Bennett 2009; Vercellino 2009). The sequential involve-
ment of these processes influences the clinical course, character-
ized by attacks with recovery, attacks leaving persistent deficits,
and progression that causes fixed physical and cognitive disability
(Compston 2002).
MS is among the commonest causes of neurological disability in
youngpeople, with an annual incidence ranging from2 to10 cases/
100,000 persons/year and a north-south gradient, with a lower
incidence closer to equator. Its clinical manifestations typically oc-
cur between 20 and 40 years of age, with symptoms and signs
involving different CNS regions (optic nerve, brainstem, cerebel-
lum, cerebral hemispheres, spinal cord) (Compston 2002).
MS has a chronic course evolving over 30 to 40 years. The clinical
phenotypes include relapsing-remitting MS (RRMS), secondary
progressive MS (SPMS), primary progressive MS (PPMS), and
progressive-relapsing MS (PRMS) (Lublin 1996). The develop-
ment of disease progression (SPMS, PRMS, PPMS) is responsi-
ble for permanent long-term disability and it supervenes in about
80% of RRMS participants after 20 to 25 years. After 15 to 18
years, about 50% of participants need assistance to walk, are con-
fined to a wheelchair, bed, or have died (Kremenchutzky 2006).
PPMS (approximately 10% of all participants with MS) is char-
acterized, from the beginning, by a slow worsening of neurologi-
cal deficits without experiencing attacks, and PRMS by a progres-
sive course from onset with attacks and continuing progression
(Lublin 1996). Natural history studies provide little support for
the concept that progression is related primarily to a succession of
attacks, indicating that attacks do not play a major role in long-
term disability (Filippini 2007; Kremenchutzky 2006). Prevent-
ing progressive disability is the key therapeutic goal for MS.
Description of the intervention
Recombinant interferon ß-1b (IFNß-1b) (Betaseron), IFNß-1a
(Rebif and Avonex) and glatiramer acetate were approved bymany
national regulatory agencies (FDA 1993; FDA 1996; FDA 2001;
EMEA 2002; FDA 2002; FDA 2003) and are available for use
in MS free of charge from many national health services. Natal-
izumab is a recombinant monoclonal antibody that was approved
for the treatment of RRMS (FDA 2004). Following the recog-
nition of two cases of progressive multifocal leukoencephalopa-
thy (PML) in patients who had been receiving natalizumab, its
commercialisation was suspended. In July 2006 marketing of na-
talizumab resumed after an investigation of patients included in
clinical trials (including trials carried on in patients with Crohn’s
disease) (Yousry 2006). Natalizumab was commercialised world-
wide from that year on.Mitoxantronewas approved in 2000 (FDA
2000) under the description “for reducing neurological disability
and/or the frequency of clinical relapses in patients with SPMS,
PRMS or worsening RRMS”. In March 2005, the US Food and
Drug Administration (FDA 2005) warned about cardiotoxicity
and therapy-related acute leukaemia in mitoxantrone-treated pa-
tients. In many countries azathioprine is used for the treatment
of MS, however since the approval of IFNß for the same indi-
cation, azathioprine has not been recommended as a first line
therapy (Goodin 2002). Intravenous immunoglobulins may have
a role in patients with severe and frequent relapses for whom
other treatments are contraindicated, but they should not be used
routinely (Association of British Neurologists 2005). Severe ad-
verse events leading to discontinuation of the treatment with in-
travenous immunoglobulins were noted in 4% of 84 treatment
courses with a total 341 infusions under routine clinical condi-
tions. These included thrombosis of the jugular vein, an allergic
reaction, and retrosternal pressure (Elovaara 2008). Cyclophos-
phamide and methotrexate might benefit patients with progres-
sive MS (Goodin 2002) but these agents are less commonly used
because their toxicity is severe. Long-term pulsed regimens of cor-
ticosteroids may be effective for MS owing to their long-lasting
immunosuppressive effect, and they are reported to be well-toler-
ated and safe with only minor, dose-related side effects (Pozzilli
2004).
How the intervention might work
Immunomodulator or immunosuppressive effects are common to
all treatments included in this review. The exact mode of action
of immunomodulators is unknown, but they are thought to tar-
get various immune cells or cytokines important in MS patho-
genesis. The IFNß family have effects on the production of cy-
tokines byThelper lymphocytes, onmigrationof leukocytes across
the blood-brain barrier, and have antiviral activity (Billiau 2004).
Glatiramer acetate has a combined effect on anti-inflammatory
T-cell populations and regulatory type II antigen-presenting cells
(Lalive 2011). Natalizumab is a monoclonal antibody targeting an
integrin that blocks adhesion and transmigration of lymphocytes
through the vascular endothelium, thus avoiding inflammation
(Fontoura 2010).
Immunosuppressant agents suppress immune function by one
of several mechanisms of action; they also have anti-inflamma-
tory activity. Azathioprine, cyclophosphamide, mitoxantrone, and
methotrexate are classical cytotoxic immunosuppressants that act
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by inhibiting DNA synthesis. Azathioprine inhibits T-cell func-
tion (Tiede 2003); cyclophosphamide suppresses both cell-medi-
ated and humoral immunity (Calabresi 1991); mitoxantrone re-
duces the number of B-cells, inhibits T-cells, and enhances T-cell
suppressor activity (Fox 2004);methotrexate inhibits T-cell activa-
tion and suppresses intercellular adhesion molecule expression by
T-cells (Johnston 2005). Corticosteroids have many immunologi-
cal effects, they inhibit lymphocyte proliferation and the synthesis
of most pro-inflammatory cytokines and cell surface molecules re-
quired for immune function (Sloka 2005). The mechanism of ac-
tion of intravenous Immunoglobulins remains unclear although,
through the mediation of the effects of cytokines, remyelination
of demyelinated CNS axons may occur (Stangel 1999).
Why it is important to do this review
Although there is consensus that immunotherapies reduce the fre-
quency of relapses in MS, their relative effectiveness in the pre-
vention of new attacks or delaying disability progression remains
unclear. This uncertainty is due to the limited number of direct
comparison trials, which provide the most rigorous and valid re-
search evidence on the relative efficacy and safety of different treat-
ments for MS. A summary of the results of trials, including both
direct and indirect comparisons, may help to clarify the above un-
certainty (Caldwell 2005; Glenny 2005).
O B J E C T I V E S
To compare immunomodulators and immunosuppressants
against placebo or against one another in terms of response and ac-
ceptability. Given the wide spectrum of available comparisons, we
aimed to use themethodology of networkmeta-analysis, amethod
that allows the integration of data from direct comparisons (when
treatments are directly compared within a randomised trial) and
indirect comparisons (when treatments are compared between tri-
als by combining results against a common comparator treatment)
(Lu 2004; Caldwell 2005; Salanti 2008).
In summary, the aims of this overview were:
1. to estimate the relative effectiveness and acceptability of im-
munomodulators and immunosuppressants for MS;
2. to provide a ranking of the treatments according to their effec-
tiveness and acceptability in order to inform clinical practice.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) that studied one of the agents
for use in MS and that reported our pre-specified outcomes were
evaluated for inclusion. Trials for which it was unclear whether
the method of randomisation provided adequate allocation con-
cealment or open label studies were also included, but the quality
of these studies was taken into account. RCTs with follow-up less
than six months were excluded. Quasi-randomised trials and non-
randomised studies were excluded.
Types of participants
Participants 18 years age or older with a diagnosis of MS were
included. Only RCTs adopting the Poser (Poser 1983) or Mc-
Donald diagnostic criteria (McDonald 2001; Polman 2005) were
selected. We included all phenotypes: relapsing-remitting MS
(RRMS); secondary progressive MS (SPMS); progressive-relaps-
ing MS (PRMS); and primary progressive MS (PPMS), regardless
of age, sex, degree of disability, and duration of the disease.
Types of interventions
Interferon ß-1b (IFNß-1b), IFNß-1a (Rebif, Avonex), glatiramer
acetate, natalizumab, mitoxantrone, methotrexate, cyclophospha-
mide, azathioprine, immunoglobulins, and long-term corticos-
teroids versus placebo or versus another active agent. Regimens
were included irrespective of their dose as long as it waswithin ther-
apeutic range. IFNß-1b, IFNß-1a (Rebif ) and glatiramer acetate
are administered by subcutaneous injection; IFNß-1a (Avonex) by
intramuscular injection; natalizumab, mitoxantrone, cyclophos-
phamide, immunoglobulins by the intravenous route; methotrex-
ate and azathioprine orally. Corticosteroids are administered in-
travenously or by the oral route.
Types of outcome measures
Primary outcomes
Efficacy
Two primary outcomes were considered.
1. Clinical relapses: proportion of participants who
experienced new relapses over 12, 24, or 36 months after
randomisation or at the end of the study. A relapse is defined as
newly developed or recently worsened symptoms of neurologic
dysfunction that last more than 24 hours, occurring in the
absence of fever or other acute diseases, and separated in time
from any previous episode by more than 30 days (McDonald
2001). A relapse resolves either partially or completely.
2. Disability progression: proportion of participants who
experienced disability progression over 24 or 36 months after
randomisation or at the end of the study. Disability progression
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is defined as at least 1 point Expanded Disability Status Scale
(EDSS) (Kurtzke 1983) increase, or a 0.5 point increase if the
baseline EDSS was ≥ 5.5, confirmed during two subsequent
neurological examinations separated by an interval of at least six
months free of attacks. The EDSS is a common measure of MS
disability (where 0 is normal, 3 mild disability, 6 care
requirement, 7 wheelchair use, and 10 is death from MS). It is
frequently used to measure disability progression in clinical trials.
Acceptability
Treatment discontinuationwas used to assess acceptability andwas
measured by the dropout rate, that is the proportionof participants
who were lost to follow-up or definitely discontinued treatment
(withdrawals) but completed follow-up, out of the total number
of participants randomly assigned to each treatment arm.
Secondary outcomes
Adverse events (AE)
Number of participants with:
a) at least one AE;
b) at least one serious AE (SAE), as defined by the authors of the
primary study;
c) withdrawal due to AE at any time during the follow-up period;
d) serious infections, as defined by the authors of the primary
study;
e) a new diagnosis of leukaemia, lymphoma, or any other type of
cancer during the follow-up period.
Search methods for identification of studies
No language restrictions were applied.
Electronic searches
1. We searched the Cochrane Database of Systematic Reviews
(CDSR) (Issue 1 of 12, 2012) (Appendix 1).
Cochrane Multiple Sclerosis Systematic Reviews (SRs) retrieved:
1. Azathioprine for multiple sclerosis (Casetta 2007);
2. Corticosteroids for the long term treatment in multiple
sclerosis (Ciccone 2008);
3. Cyclophosphamide for multiple sclerosis (La Mantia 2007);
4. Glatiramer acetate for multiple sclerosis (La Mantia 2010);
5. Interferon in relapsing-remitting multiple sclerosis (Rice
2001);
6. Interferon beta for primary progressive multiple sclerosis
(Rojas 2010);
7. Interferon beta for secondary progressive multiple sclerosis
(La Mantia 2012);
8. Intravenous immunoglobulins for multiple sclerosis (Gray
2003);
9. Methotrexate for multiple sclerosis (Gray 2004);
10. Mitoxantrone for multiple sclerosis (Martinelli 2005);
11. Natalizumab for relapsing-remitting multiple sclerosis
(Pucci 2011).
Updated searches were run, for out of date reviews to retrieve
primary RCTs, which were limited from the date of their most
recent search to February 2012. The search strategies used are
those reported in the published reviews.
2. We searched the Cochrane Multiple Sclerosis Specialised Regis-
ter (February 2012) for direct comparison trials. Keywords for each
comparison are listed in Appendix 2. For information about the
Cochrane Multiple Sclerosis Review Group Trials Register please
see: Cochrane Multiple Sclerosis Group.
3. We searched the Food and Drug Administration (FDA) re-
ports on all the treatments included in this review (www.fda.gov)
(February 2012).
Searching other resources
Reference lists of published reviews and retrieved articles were
checked for additional trials.
Data collection and analysis
Selection of studies
The reference lists of selected SRs were screened. If a review was
not published in the CDSR, or it was incomplete or not updated,
titles and abstracts from the search results were independently as-
sessed by the two review authors to identify relevant trials for in-
clusion. The full text of the study was obtained, when necessary,
to confirm inclusion. Trials were selected if they met the pre-spec-
ified eligibility criteria. Discrepancies in judgements were resolved
by discussion among the two review authors (LV, GF).
Data extraction and management
Two review authors (GF, LV) independently extracted data using
a predefined data extraction form. If outcomes were not reported
at the predefined time points, we extracted data as close as possible
to that time point. Trial arms involving the same agent at different
fixed doses within the therapeutic range were converted into a
single arm by summing the number of events and the sample size.
Disagreements were resolved by discussion between the two review
authors. Data were extracted from:
1) the Cochrane SRs and additional information from the original
RCT reports, when necessary;
2) the original RCTs for treatments that were not included in
published Cochrane SRs or for direct comparison trials;
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3) FDA reports, which were consulted in order to obtain further
details on study characteristics or outcomes if these data were un-
clearly presented in the original articles.
Assessment of risk of bias in included studies
The risk of bias (RoB) was assessed for each included study us-
ing the Cochrane Collaboration criteria (Higgins 2011). These
included: random sequence generation, allocation concealment,
blinding of participants and outcome assessment, incomplete
outcome data, and selective outcome reporting. Other potential
sources of RoB were: sustained disability progression measured
after only three months’ follow-up, that is a surrogate marker for
unremitting disability (Ebers 2008), and role of the sponsor. The
RoB of each study was explicitly judged on each criterion and clas-
sified as ’low’, ’high’, or ’unclear’. Complete outcome data were
judged as ’low risk’ when the percentage of participants lost to
follow-up was low (arbitrarily set at values lower than 15%) and
when numbers and causes of losses to follow-up were balanced
between arms. Regarding selective outcome reporting bias, we as-
signed ’high risk’ when one or more outcomes of interest were not
reported or were presented incompletely and they could not be
analysed quantitatively.
To summarize the RoB overall for a study, we considered alloca-
tion concealment, blinding of outcome assessment, and incom-
plete outcome data in order to classify each study as: ’low risk of
bias’ when all three criteria were met; ’high risk of bias’ when at
least one criterion was unmet; and ’moderate risk of bias’ in the
remaining cases. Allocation concealment, blinding of outcome as-
sessment, and incomplete outcome data were not expected to vary
in importance across the two primary efficacy outcomes (relapses
and progression), and therefore we summarized the RoB of each
study considering the two outcomes together.
We assessed RoB for adverse events (AE) by considering specific
factors that may have had a large influence on the adverse events
data. We evaluated methods for monitoring and detecting an AE
for each study: did the researchers actively monitor for AEs (low
risk of bias), or did they simply provide spontaneous reporting of
AEs that arose (high risk of bias)? Did the authors define serious
AE according to an accepted international classification and report
the number of SAEs?
The RoB of each study was assessed independently by the two
review authors (GF, LV) and any disagreement was resolved by
discussion to reach consensus.
Measures of treatment effect
For each pairwise comparison and each outcome at each time
point, we used odds ratio (OR) with 95% confidence interval
(95% CI) as a measure of the association between the treatment
used and efficacy. As the outcomes are negative, ORs < 1 corre-
spond to beneficial treatment effects of the first treatment com-
pared with the second treatment.
Unit of analysis issues
Our unit of data extraction, evaluation, and analysis was the pri-
mary randomised trial.
Dealing with missing data
In order to assess the effect of patient withdrawal or loss to follow-
up on primary outcomes, we extracted data according to a likely
scenario, that is we assumed that the treated- and control-group
participants who dropped out and were not included in the study
analysis both had the outcome (relapse or disability progression).
Assessment of heterogeneity
Heterogeneity or inconsistency can be the result of an uneven dis-
tribution of important clinical and methodological effect modi-
fiers across studies (heterogeneity) or across comparisons (incon-
sistency). The presence of statistical heterogeneity was assessed by
visual inspection of the forest plots and by calculating the I2 statis-
tic and its confidence limits. Potential sources of heterogeneity or
inconsistency include: different participant baseline characteristics
(MS phenotype), different treatment dose, influence of funders.
We investigated the distribution of these characteristics and car-
ried out a subgroup analysis for the efficacy outcomes at each time
point.
Assessment of reporting biases
The possibility of reporting bias in networkmeta-analysis was eval-
uated by means of an adaptation of the funnel plot for pairwise
meta-analysis, the ‘comparison-adjusted’ funnel plot (Chaimani
2012). In a network of interventions each study estimates the rel-
ative effect of different interventions, so asymmetry in the funnel
plot could not be judged. To account for this, we subtracted from
each study-specific log odds-ratio of an active treatment versus
placebo the mean of the meta-analysis for the same comparison
and plotted it against the study’s standard error. We drew funnel
plots for the efficacy outcomes at 24 and 36 months and accept-
ability for all interventions versus placebo. As with regular funnel
plots, asymmetry might be caused by publication bias but other
reasons such as true heterogeneity are also possible. We used the
STATA routines available in www.mtm.uoi.gr to create the com-
parison-adjusted funnel plots.
Data synthesis
First, conventional pairwise meta-analyses was conducted for all
outcomes and comparisons, provided that at least two studies were
available, using a random-effects model (DerSimonian 1986).
We then performed a network meta-analysis for primary out-
comes (relapses, progression, and dropouts). Network meta-anal-
ysis is a method of synthesizing information from a network of
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trials addressing the same question but involving different in-
terventions. For a given comparison, say A versus B, direct evi-
dence is provided by studies that compare these two treatments
directly. In addition, indirect evidence for the A versus B com-
parison can be provided by synthesizing studies that compare A
versus C and B versus C (Higgins 1996; Caldwell 2005). Net-
work meta-analysis combines direct and indirect evidence across
a network of randomised trials into a single effect size, and un-
der certain assumptions it can increase the precision in the esti-
mates while randomisation is respected. We performed network
meta-analyses within a Bayesian framework, assuming an equal
heterogeneity parameter τ across all comparisons, and we ac-
counted for correlations induced by multi-arm studies (Lu 2006;
Salanti 2009). The analysis was performed using WinBUGS
(MRC Biostatistics Unit, Cambridge, UK) (http://www.mrc-
bsu.cam.ac.uk/bugs/winbugs/contents.shtml); the codes and de-
scription of the methodology can be found at www.mtm.uoi.gr/
howtodoanmtm.html. We used a normal prior with zero mean
and variance one restricted to positive values for the common het-
erogeneity standard deviation τ and non-informative vague priors
for all mean parameters, otherwise referred as treatment effects.
As a measure that reflects ranking and the uncertainty, we used
the Surface Under the Cumulative RAnking curve (SUCRA) as
described in Salanti 2011. This measure, expressed as percentage,
showed the relative probability of an intervention being among
the best options.
The adequacy of each model was evaluated by comparing the pos-
terior deviance to the number of data points (they should be close
for models that fit the data well) and by calculating the Deviance
Information Criterion (DIC), which is a measure equivalent to
Akaike’s Information Criterion and penalizes model fit for com-
plexity (lower values indicate better models) (Spiegelhalter 2002).
There are limitations in the use of the network meta-analysis
methodology and it is essential to check the assumptions of the
analysis before drawing conclusions. Themost important assump-
tion is that the network of comparisons is consistent, meaning that
direct and indirect evidence on the same comparisons agree. Joint
analysis can be misleading if the network is substantially inconsis-
tent. Inconsistency can be present if the trials in the network have
very different protocols and their inclusion and exclusion criteria
are not comparable, or may result from an uneven distribution
of effect modifiers across groups of trials that compare different
treatments.
In order to estimate network inconsistency we calculated the dif-
ference between indirect and direct estimates in each closed loop
formed by the network of trials (using the Bucher method) and
their relative 95% confidence interval (CI). Then we examined
whether there were any material discrepancies; if the 95% CI did
overlap with 0 the hypothesis of consistency was not rejected, as
described in Salanti (Salanti 2009). The code to assess consistency
is available at www.mtm.uoi.gr/howtodoanmtm.html. Further, we
compared theDIC between themodels with and without the con-
sistency assumption; a lower DIC for the consistency model in-
dicates that the consistency assumption is statistically supported.
In the case of important clinical or statistical inconsistency being
identified, we planned to investigate this further and possibly to
adjust for potential effectmodifiers using networkmeta-regression
or relaxing the consistency assumption and extending the model
as described in Lu and Ades (Lu 2006).
Subgroup analysis and investigation of heterogeneity
Subgroup analysis for the efficacy outcomes at each time point
were based on the following.
1. Clinical phenotype, distinguishing two groups of participants:
RRMS and SPMS, PRMS, PPMS.
2. Treatment dose: as we previously said, many immunotherapies
exist for the management of MS and some of them are admin-
istered at different doses. However, it is still unclear whether the
relative efficacy of the MS agents depends on the dose used and,
in particular, whether some agents given at higher doses are more
effective. For that reason, we explored whether the agent’s efficacy
on disability progression at 24 months was modulated by dose ad-
ministration. For this purpose we considered the network formed
of agents administered at different doses (so that each node in the
network was a treatment at a different dose). Any specific dose
used for each agent was transformed into a unique measure unit
(mg) ’dose per week’ (for example 0.02 mg three times a week
corresponded to a ’dose per week’ equal to 0.06). The network
was re-analysed and posterior ORs were summarized for each drug
and dose. We compared the DICs between models where doses
of the same agent were assumed to be equally effective with the
DIC from models where each dose was assumed to be a different
intervention. We also applied different assumptions regarding the
association between dose effects, such as linear and monotonic.
3. Funders: sponsorship from pharmaceutical companies or inde-
pendent trials.
Sensitivity analysis
The RoB in included studies was taken into account in the inter-
pretation of evidence using the GRADE approach.
Summary of findings table
Themain results of the review are presented in a summary of find-
ings (SoF) table, as recommended byTheCochraneCollaboration
(Schünemann 2011a). The SoF table was provided for the direct
estimates only and included an overall grading of the evidence for
relapses over 12, 24, and 36 months, and disability getting worse
over 24 and 36 months. For each treatment, data were pooled
across all types of MS, and the subgroups of RRMS and progres-
sive MS. The SoF table includes an overall grading of the quality
of evidence related to each of the outcomes, using the GRADE
approach (Schünemann 2011b). Quality of evidence was graded
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as high, moderate, low, or very low, considering within-study RoB,
directness of evidence, heterogeneity, precision of effect estimates,
and risk of publication bias. The control event rates used in the
calculation of absolute risks were based on the number of events
in the included studies.
R E S U L T S
Description of studies
Results of the search
Flow charts describe the results of the electronic search (Figure 1).
Thirty-eight studies were identified in 11 reviews available from
the Cochrane Database of Systematic Reviews (CDSR) and six
studies were identified in the Cochrane Multiple Sclerosis Review
Group Specialised Register.
Figure 1. Study flow diagrams
Included studies
Forty-four trials in which 17,401 participants had been ran-
domised were included in this review. Twenty-three trials included
RRMS (9096 participants, 52%), 18 trials included progressive
MS (7726, 44%), and three trials included both RRMS and pro-
gressive MS (579, 3%). The table Characteristics of included
studies provides details on the characteristics of the included stud-
ies. The duration of the trials ranged from six to 36 months with
the median duration being 24 months. The findings presented in
this review originated mostly from trials on the IFNβ family, glati-
ramer acetate, and natalizumab that overall contributed outcome
data for 12,275 patients (71%) included in 33 trials (Table 1).
Eleven Cochrane reviews of active treatments versus placebo were
included: IFNß for RRMS (Rice 2001), SPMS (La Mantia 2012)
or PPMS (Rojas 2010); glatiramer acetate (LaMantia 2010); natal-
izumab (Pucci 2011);mitoxantrone (Martinelli 2005);methotrex-
ate (Gray 2004); cyclophosphamide (La Mantia 2007); azathio-
prine (Casetta 2007); intravenous immunoglobulins (Gray 2003),
and corticosteroids for long-term treatment (Ciccone 2008).
Thirty-eight studies were included from the Cochrane reviews
(Achiron 1998; AFFIRM 2006; Andersen 2004; Bornstein 1987;
Bornstein 1991; BPSM 1995; British andDutch 1988; CCMSSG
1991; Comi 2001; Edan 1997; Ellison 1989; European Study
Group 1998; Fazekas 1997; Fazekas 2008; Ghezzi 1989; Goodkin
1991; Goodkin 1995; Hartung 2002; Hommes 2004; IFNB MS
Group 1993; IMPACT2002; Johnson 1995; Knobler 1993; Leary
2003; Lewanska 2002; Likosky 1991; Milanese 1993;Millefiorini
1997;Miller 1961;Montalban 2009;MSCRG1996;NASP2004;
OWIMS 1999; Pohlau 2007; PRISMS 1998; SENTINEL 2006;
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SPECTRIMS 2001; Wolinsky 2007). The two arms of calcium
aspirin and placebo in theMiller (Miller 1961) studywere grouped
as a single placebo arm by summing the number of events and the
sample size.
Six trials of treatments directly compared to each other (BEYOND
2009; Etemadifar 2006; EVIDENCE 2007; INCOMIN 2002;
Koch-Henriksen 2006; REGARD 2008) were retrieved by search-
ing the Cochrane Multiple Sclerosis Review Group Specialised
Register.
Excluded studies
Eight studies were excluded from the Cochrane reviews: two trials
of IFNα (Durelli 1994; Myhr 1999); one because active treat-
ment with natalizumab was confounded by glatiramer acetate
(GLANCE 2009); one of oral glatiramer acetate (Filippi 2006);
one of mitoxantrone in which the inclusion criteria were not de-
scribed (Van deWyngaert 2001); two trials because treatmentwith
cyclophosphamide was confounded by other treatments (Hauser
1983; Wender 1988); and a dose comparison trial of long-term
corticosteroids without a control group (Zivadinov 2001). In one
study (CCMSSG 1991) one arm with combined cyclophospha-
mide, plasmapheresis, and prednisone was excluded. Another 23
studies were excluded from the 29 full-text articles identified
through the Cochrane MS Review Group Specialised Register (see
Characteristics of excluded studies).
Risk of bias in included studies
The RoB of the included studies is summarized (Figure 2; Figure
3). Considering our predefined criteria (allocation concealment,
blinding of outcome assessment, and complete outcome data) to
assess RoB overall for a study, five out of 44 (11%) trials (Achiron
1998; AFFIRM 2006; British and Dutch 1988; Leary 2003;
PRISMS 1998) were judged at low RoB, 21 (48%) (Bornstein
1991; CCMSSG 1991; Comi 2001; Ellison 1989; Etemadifar
2006; EVIDENCE 2007; Fazekas 2008; Goodkin 1991; Hartung
2002; Hommes 2004; IFNB MS Group 1993; Johnson 1995;
Knobler 1993; Lewanska 2002; Likosky 1991; Montalban 2009;
Pohlau 2007; REGARD 2008; SENTINEL 2006; SPECTRIMS
2001; Wolinsky 2007) were evaluated at moderate RoB, and 18
(41%) (Andersen 2004; BEYOND 2009; Bornstein 1987; BPSM
1995; Edan 1997; European Study Group 1998; Fazekas 1997;
Ghezzi 1989; Goodkin 1995; IMPACT 2002; INCOMIN 2002;
Koch-Henriksen 2006; Milanese 1993; Millefiorini 1997; Miller
1961; MSCRG 1996; NASP 2004; OWIMS 1999) were judged
at high RoB.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sixteen of 44 trials (36%) reported adequate methods for allo-
cation concealment (low risk). Twenty-six trials (59%) did not
provide enough information to assess allocation concealment (un-
clear). Two trials (Bornstein 1987; Goodkin 1995) used an un-
concealed procedure (high risk).
Blinding
Twenty-eight of 44 trials (64%) reported adequate methods for
blinding of outcome assessment (low risk). Twelve trials (27%)
did not provide enough information to assess it (unclear). This
bias was judged at ’high risk’ for four open label trials (Edan 1997;
INCOMIN 2002; Koch-Henriksen 2006; Millefiorini 1997).We
suspected that most participants and treating physicians had be-
come aware of the treatment they were receiving during the course
of the trial because all the agents included in this review have well-
documented side effects, for example injection-site reactions and
influenza-like symptoms after IFNß injection.
Incomplete outcome data
Twenty-six of 44 (59%) included studies were judged to meet
this criterion because missing outcome data were less than 15%
and were balanced in numbers across intervention groups with
similar reasons for missing data across groups. In 13 (29%) trials
(Andersen 2004; BEYOND 2009; BPSM 1995; European Study
Group 1998; Fazekas 1997; Ghezzi 1989; IMPACT 2002; Koch-
Henriksen 2006; Milanese 1993; Miller 1961; MSCRG 1996;
NASP 2004; OWIMS 1999) more than 15% of participants were
lost to follow-up, or incomplete outcome data were not balanced
in numbers or the reasons across groups (high risk). In five studies
insufficient information was provided (unclear).
Selective reporting
Just half the studies (22 of 44; 50%) reported outcomes of interest
at two years’ follow-up, and only eight (18%) (Andersen 2004;
British andDutch 1988; CCMSSG 1991; Ellison 1989; European
Study Group 1998; Milanese 1993; NASP 2004; SPECTRIMS
2001) reported outcomes at three years. One or more outcomes
of interest were not reported or were presented incompletely
in 12 studies (27%) (AFFIRM 2006; BPSM 1995; British and
Dutch 1988; Comi 2001; Etemadifar 2006; EVIDENCE 2007;
Fazekas 2008; Knobler 1993; Koch-Henriksen 2006; Leary 2003;
Lewanska 2002; OWIMS 1999) that were considered at high risk
of reporting bias.
Other potential sources of bias
Sequence generation : 22 trials (50%) did not provide enough
information to assess sequence generation (unclear), and 21 (48%)
reported adequate methods (low risk). One of the trials (Bornstein
1987) used a sequence generated by alternation and was assigned
’high risk’.
Other bias : 24 (54.5%) of 44 studies used an inadequate defini-
tion of sustaineddisability progression (confirmed at threemonths’
follow-up) and 31 (70.5%) were pharmaceutical industry-funded
studies.
Method of adverse event (AEs) monitoring (Table 2): in 20
(45%) trials, AEs were actively monitored and the RoB was judged
to be low. Nineteen trials (43%) reported insufficient information
about the method of AEs monitoring so that it was uncertain
whether or notAEsweremonitored appropriately. RoBwas judged
to be unclear in these studies. Spontaneous reporting of AEs as they
occurred was reported in four studies (Bornstein 1987; Bornstein
1991; EVIDENCE 2007; Goodkin 1991); one study (Etemadifar
2006) was lacking in safety assessment. These five trials (16%)
were judged at high RoB.
Serious adverse event (SAEs) de nition and reporting: neither
the definitions nor methods of quantification were specified for
most of the included studies. In 23 (52%) trials SAEs were not
reported and the RoB was judged to be high. In 20 (45%) tri-
als SAEs were reported but insufficient information on their de
nition was given and we judged the RoB to be unclear. Only one
study (BEYOND 2009) provided a de nition of SAEs and the
RoB was judged to be low.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table
1. Efficacy
1.1 Pairwise meta-analysis (direct comparisons)
Summary of findings for themain comparison provides a summary
of the risk estimates for each major outcome and the grading of
the evidence.
Recurrence of relapses over 12 months
See: Summary of findings for the main comparison; Analysis 1.1;
Analysis 1.2; Analysis 1.3
a) Treatments compared to placebo: 17 studies with 3581 partici-
pants (21% of those included in this review) were available.
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Data for RRMS was provided in 13 out of 17 trials, with 2770
(77%) participants (Achiron 1998; AFFIRM 2006; Bornstein
1987; BPSM 1995; Comi 2001; Fazekas 2008; Goodkin 1991;
Knobler 1993; Lewanska 2002,Millefiorini 1997;MSCRG 1996;
OWIMS 1999; PRISMS 1998). Nine agents (IFNß-1b, IFNß-
1a (Avonex, Rebif ), glatiramer acetate, natalizumab, azathioprine,
mitoxantrone, intravenous immunoglobulins, and long-term cor-
ticosteroids) were assessed.
Data for progressive MS was provided in only two trials. One as-
sessed azathioprine (Ellison 1989) in 99 participants and the other
(Hommes 2004) evaluated intravenous immunoglobulins in 318
participants. Two studies of azathioprine (British andDutch 1988;
Milanese 1993) presented grouped data as RRMS or progressive
MS (394 participants, 11%).
The following results for participants with RRMS were found.
• Natalizumab reduced the odds (OR 0.38, 95% CI 0.28 to
0.51), a 62% reduction in the number of participants who had
relapses compared with placebo.
• Mitoxantrone probably reduced the odds (OR 0.14, 95%
CI 0.04 to 0.48), a 86% reduction in the number of participants
who had relapses compared with placebo, but the quality of
evidence for this treatment was moderate.
• Azathioprine reduced slightly the odds (OR 0.63, 95% CI
0.44 to 0.89) when data across all trials that studied this agent
were pooled, but meaningful odds estimates, specific for RRMS
and progressive MS, were uncertain since there was only one
small study for each of the two phenotypes (Ellison 1989;
Goodkin 1991). The two studies (British and Dutch 1988;
Milanese 1993) that included grouped data for participants with
RRMS or progressive MS were excluded from the analysis.
• IFNß-1b (Betaseron), IFNß-1a (Avonex), IFNß-1a (Rebif )
and long-term corticosteroids might have slightly reduced the
odds (OR 0.60, 95% CI 0.10 to 3.49; OR 0.72, 95% CI 0.45 to
1.14; OR 0.66, 95% CI 0.25 to 1.78; OR 0.46, 95% CI 0.12 to
1.84 ) of the participants with RRMS, but the quality of
evidence for all these treatments was low.
• There was uncertainty regarding the effect of glatiramer
acetate and intravenous immunoglobulins for RRMS since the
quality of the evidence for these two treatments was very low.
The study of intravenous immunoglobulins (Hommes 2004) re-
porting relapse outcome in progressive MS stated that the num-
bers of participants who had experienced relapses over 12 months
were not statistically significantly different from those observed in
the placebo group.
b) Treatments compared to each other: three studies with 2036
RRMS participants (14% of those included in this review) com-
pared natalizumab with IFNß-1a (Avonex) (SENTINEL 20066),
IFNß-1a (Avonex) with IFNß-1b (Betaseron) (INCOMIN 2002),
and IFNß-1a (Rebif ) versus IFNß-1a (Avonex) (EVIDENCE
2007).
• Natalizumab reduced the odds compared with IFNß-1a
(Avonex) (OR 0.40, 95% CI 0.32 to 0.51), a 60% reduction in
the number of RRMS participants who had relapses over 12
months.
• IFNß-1a (Rebif ) also might have decreased the odds
compared to IFNß-1a (Avonex) (OR 0.79, 95% CI 0.58 to
1.07).
• INCOMIN 2002 was judged to have very low quality
evidence to allow a meaningful comparison between IFNß-1b
(Betaseron) and IFNß-1a (Avonex).
Mitoxantrone might have decreased the odds of the participants
with progressive MS, compared to long-term corticosteroids (OR
0.25, 95% CI 0.07 to 0.90) but the CI around the estimate of
treatment effect was very wide (Edan 1997).
Recurrence of relapses over 24 months
See: Summary of findings for the main comparison; Analysis 2.1;
Analysis 2.2; Analysis 2.3
a)Treatments compared to placebo: 20 studieswith 4695 participants
(27% of those included in this review) were available.
Eleven trials in RRMS (2812 participants, 60% of those com-
pared to placebo) (Achiron 1998; AFFIRM 2006; Bornstein
1987; BPSM 1995; Fazekas 1997; Goodkin 1991; IFNB
MS Group 1993; Johnson 1995; Millefiorini 1997; MSCRG
1996; PRISMS 1998) assessed 10 agents, IFNß-1b (Betaseron),
IFNß-1a (Avonex), IFNß-1a (Rebif ), glatiramer acetate, natal-
izumab, azathioprine, methotrexate, mitoxantrone, intravenous
immunoglobulins, and long-term corticosteroids.
Six trials in progressive MS (1304 participants, 28% of those
compared to placebo) (Ellison 1989; Goodkin 1995; Hartung
2002; Hommes 2004; IMPACT 2002; Pohlau 2007) evaluated
five agents, IFNß-1a (Avonex), azathioprine,methotrexate,mitox-
antrone, and intravenous immunoglobulins. Three trials (British
and Dutch 1988; Ghezzi 1989; Milanese 1993) assessed azathio-
prine in 579 (12%) participants with RRMS and progressive MS
combined.
The following results for participants with RRMS were found.
• Both natalizumab and IFNß-1a (Rebif ) reduced the odds
(OR 0.32, 95% CI 0.24 to 0.43; OR 0.45, 95% CI 0.28 to
0.71, respectively), a 68% and 55% reduction in the number of
participants who had relapses over 24 months compared with
placebo.
• IFNß-1b (Betaseron) and mitoxantrone probably decreased
the odds (OR 0.55, 95% CI 0.31 to 0.99; OR 0.15, 95% CI
0.04 to 0.54, respectively) compared with placebo, but the
quality of evidence for these treatments was moderate.
• Azathioprine reduced the odds (OR 0.64, 95% CI 0.44 to
0.94) when all the included trials of azathioprine were
aggregated, but this treatment was not statistically significantly
different from control when data for RRMS and progressive MS
were analysed separately. Azathioprine might have decreased
slightly the odds of the participants with RRMS (OR 0.36, 95%
CI 0.11 to 1.21).
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• For the other five treatments (IFNß-1a (Avonex), glatiramer
acetate, methotrexate, intravenous immunoglobulins, and long-
term corticosteroids), the numbers of RRMS participants
experiencing new relapses were not statistically significantly
different from the numbers in the placebo groups.
IFNß-1a (Avonex), methotrexate, azathioprine, mitoxantrone,
and intravenous immunoglobulins were not effective for progres-
sive MS.
b)Treatments compared to each other: four trials in RRMS
(4427, 25% of those included in this review) provided direct
comparisons between treatments, natalizumab versus IFNß-1a
(Avonex) (SENTINEL 2006), IFNß-1b (Betaseron) versus IFNß-
1a (Avonex) (INCOMIN 2002), IFNß-1b (Betaseron) versus
glatiramer acetate (BEYOND 2009), and glatiramer acetate ver-
sus IFNß-1a (Rebif ) (REGARD 2008). One three-arm trial
(Etemadifar 2006) compared IFNß-1b (Betaseron), IFNß-1a
(Avonex), and IFNß-1a (Rebif ).
• Natalizumab, IFNß-1b (Betaseron), and IFNß-1a (Rebif )
were significantly more effective than IFNß-1a (Avonex) (OR
0.28, 95% CI 0.22 to 0.36; OR 0.44, 95% CI 0.26 to 0.75; OR
0.19, 95% CI 0.06 to 0.60, respectively) for RRMS participants.
• The quality of the evidence was too low to allow
meaningful comparisons of glatiramer acetate with IFNß-1b
(Betaseron) or IFNß-1a (Rebif ).
Relapses over 36 months
See: Summary of findings for the main comparison; Analysis 3.1
Information on this outcome was not available for RRMS. Four
trials in 2127 progressive MS participants (14% of those included
in this review) compared IFNß-1b (Betaseron) (European Study
Group 1998; NASP 2004), IFNß-1a (Rebif ) (Andersen 2004),
azathioprine (Ellison 1989) versus placebo. Two studies (British
and Dutch 1988; Milanese 1993) assessed azathioprine in 394
participants with RRMS and progressive MS combined.
• Azathioprine (OR 0.45, 95% CI 0.27 to 0.76) and IFNß-
1b (Betaseron) decreased slightly (OR 0.71, 95% CI 0.56 to
0.90) the odds of experiencing new relapses over three years in
progressive MS, compared with placebo.
• IFNß-1a (Rebif ) may have resulted in little or no difference
in this outcome compared to participants with progressive MS
who took placebo, but the quality of evidence was low so our
confidence in this result was low.
Disability progression over 24 months
See: Summary of findings for the main comparison; Analysis 4.1;
Analysis 4.2; Analysis 4.3
a)Treatments compared to placebo: 24 studieswith 6160 participants
(41% of those included in this review) were available.
Ten studies in RRMS (2776 participants, 45%) (Achiron 1998;
AFFIRM 2006; Bornstein 1987; Fazekas 1997; Goodkin 1991;
IFNB MS Group 1993; Johnson 1995; Millefiorini 1997;
MSCRG 1996; PRISMS 1998) assessed eight agents, IFNß-1b
(Betaseron), IFNß-1a (Avonex), IFNß-1a (Rebif ), glatiramer ac-
etate, natalizumab, azathioprine, mitoxantrone, and intravenous
immunoglobulins versus placebo.
Twelve studies in progressive MS (3159 participants, 51%)
(Bornstein 1991; Goodkin 1995; Hartung 2002; Hommes
2004; IMPACT 2002; Leary 2003; Likosky 1991; Miller 1961;
Montalban 2009; Pohlau 2007; SPECTRIMS 2001; Wolinsky
2007) evaluated nine agents, IFNß-1b (Betaseron), IFNß-1a
(Avonex), IFNß-1a (Rebif ), glatiramer acetate, methotrexate, mi-
toxantrone, cyclophosphamide, intravenous immunoglobulins,
and long-term corticosteroids. Two studies of azathioprine (Ghezzi
1989; Milanese 1993) reported the outcome in 225 (4%) RRMS
and progressive MS participants combined.
The following results for participants with RRMS were found.
• Natalizumab and IFNß-1a (Rebif ) probably reduced the
odds (OR 0.56, 95% CI 0.42 to 0.74; OR 0.65, 95% CI 0.45 to
0.93, respectively) by 44% and 35% compared with placebo.
• Mitoxantrone might have reduced the odds (OR 0.13, 95%
CI 0.03 to 0.70) but the CI around the estimate of treatment
effect was very wide.
• None of the other treatments were statistically significantly
different from placebo in terms of the number of RRMS
participants experiencing disability progression over 24 months.
There was no effect of all these treatments for progressive MS.
b)Treatments compared to each other: direct comparisons of active
agents were available from five two-arm studies with 4668 RRMS
participants (31% of those included in this review) comparing na-
talizumab versus IFNß-1a (Avonex) (SENTINEL 2006), IFNß-
1b (Betaseron) versus IFNß-1a (Avonex) (INCOMIN 2002),
IFNß-1b (Betaseron) versus IFNß-1a (Rebif ) (Koch-Henriksen
2006), glatiramer acetate versus IFNß-1b (Betaseron) (BEYOND
2009), and glatiramer acetate versus IFNß-1a (Rebif ) (REGARD
2008).
• Natalizumab and IFNß-1b (Betaseron) were significantly
more effective (OR 0.62, 95% CI 0.49 to 0.78; OR 0.35, 95%
CI 0.17 to 0.70, respectively) than IFNß-1a (Avonex) for RRMS.
• The quality of the evidence was too low to allow
meaningful comparisons of IFNß-1b (Betaseron) with IFNß-1a
(Rebif ), and glatiramer acetate with IFNß-1b (Betaseron) or
with IFNß-1a (Rebif ).
One small trial (Edan 1997) comparing mitoxantrone with long-
term corticosteroids in progressive MS patients did not find a
difference between the two treatments.
Disability progression over 36 months
See: Summary of findings for the main comparison; Analysis 5.1
This outcome was not reported in trials for RRMS. Data for
this outcome were available from seven two-arm studies in 2896
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progressive MS participants (19% of those included in this
overview). The trials compared IFNß-1b (Betaseron) (European
Study Group 1998; NASP 2004), IFNß-1a (Rebif ) (Andersen
2004; SPECTRIMS 2001), azathioprine (Ellison 1989; Milanese
1993), cyclophosphamide (CCMSSG 1991) versus placebo.
Although results for these four agents did not reach statistical
significance, azathioprine was associated with the least number of
participants experiencing disability progression (OR 0.47, 95%
CI 0.19 to 1.17) and cyclophosphamide was associated with the
most number of participants who had disability progression in
comparison to placebo (OR1.60, 95%CI 0.76 to 3.39).However,
we judged the quality of these studies as very low, so our confidence
in these results was very low.
1.2 Network meta-analysis (combination of direct and
indirect comparisons)
Figure 4 shows the networks of the treatments for recurrence of
relapses and disability progression at each time point, and accept-
ability of treatments over 24 months of follow-up. Each line links
treatments directly compared in trials. The thickness of the line is
proportional to the number of comparisons included in the net-
work; the width of the circle is proportional to the number of
studies involving the specific treatment.
Figure 4. Networks of the treatments for recurrence of relapses and disability progression at each time
point and acceptability of treatments over 24 months of follow-up
There was no statistical or clinical indication that the assumption
of consistency was inappropriate. No loop was found to be statis-
tically inconsistent (Figure 5), the DIC of the consistency model
was always lower compared to the inconsistency models, and the
pairwise meta-analyses were not dissimilar in trial methods and
populations. Table 3 reports model fit and parsimony measures
for all the primary outcomes along with the DIC values for the
consistency and inconsistency models.
Summary ORs (posterior values and their 95% credible intervals
(CrI)) of all active interventions versus placebo and SUCRA values
expressed as a percentage are reported in Table 4 for relapses over
12, 24, and 36 months; in Table 5 for disability progression over
24 and 36 months; in Table 6 for relapses over 12 and 24 months
and progression over 24 months in the subgroup of participants
with RRMS. In the subgroup of progressive MS, only pairwise
meta-analyses were done as the number of studies was small for
each outcome and time point.
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Figure 5. Evaluation of consistency within first order closed loops for recurrence of relapses and disability
progression at each time point. Difference in log odds ratios between indirect and direct evidence is reported
on x-axis.
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Relapses over 12, 24, and 36 months
See: Table 4
a) Relapses over 12 months were provided in 20 studies (
Achiron 1998; AFFIRM 2006; Bornstein 1987; BPSM 1995;
British and Dutch 1988; Comi 2001; Edan 1997; Ellison 1989;
EVIDENCE2007; Fazekas 2008;Goodkin 1991;Hommes 2004;
INCOMIN2002;Knobler 1993; Lewanska 2002;Milanese 1993;
Millefiorini 1997;MSCRG 1996; OWIMS 1999; PRISMS 1998;
SENTINEL 2006) and 5628 participants with MS (37.5% of
those included in this review). Mitoxantrone was the best drug
(median OR versus placebo 0.12, 95% CrI 0.03 to 0.55; SUCRA
=95%) followed by natalizumab (medianORversus placebo 0.35,
95% CrI 0.12 to 1.06; SUCRA = 72%). The heterogeneity stan-
dard deviation τ was 0.60 (95% CrI 0.22 to 1.18).
b) Relapses over 24 months were provided in 25 studies (
Achiron 1998; AFFIRM 2006; BEYOND 2009; Bornstein 1987;
BPSM 1995; British and Dutch 1988; Ellison 1989; Etemadifar
2006; Fazekas 1997; Ghezzi 1989; Goodkin 1991; Goodkin
1995; Hartung 2002; Hommes 2004; IFNB MS Group 1993;
IMPACT2002; INCOMIN2002; Johnson 1995;Milanese 1993;
Millefiorini 1997; MSCRG 1996; Pohlau 2007; PRISMS 1998;
REGARD 2008; SENTINEL 2006) and 9186 participants with
MS (61% of those included in this review). Different agents
seemed to be significantly correlated to relapse at 24 months’ fol-
low-up. The most effective drug appeared to be natalizumab (me-
dian OR versus placebo 0.29, 95% CrI 0.17 to 0.51; SUCRA =
92%), followed by IFNß-1a (Rebif ) (median OR versus placebo
0.44, 95% CrI 0.24 to 0.70; SUCRA = 73%), mitoxantrone (me-
dian OR versus placebo 0.43, 95% CrI 0.20 to 0.87; SUCRA =
71%), glatiramer acetate (median OR versus placebo 0.48, 95%
CrI 0.38 to 0.75; SUCRA = 66%), IFNß-1b (Betaseron) (median
OR versus placebo 0.48, 95% CrI 0.29 to 0.78; SUCRA = 65%).
The heterogeneity standard deviation τ was 0.20 (95% CrI 0.01
to 0.53).
c) Relapses over 36 months were available from six studies
(Andersen 2004; British andDutch 1988; Ellison 1989; European
Study Group 1998; Milanese 1993; NASP 2004) (2521, 17% of
those included in this review) comparing each agent azathioprine,
cyclophosphamide, IFNß-1b (Betaseron), IFNß-1a (Rebif ) versus
placebo. Only azathioprine appeared to be effective (mean OR
0.43, 95% CrI 0.17 to 0.88; SUCRA = 94%). The heterogeneity
standard deviation τ was 0.30 (95% CrI 0.02 to 1.27).
Disability progression over 24 and 36 months
See: Table 5
a) Disability progression over 24 months was available from
30 studies (Achiron 1998; AFFIRM 2006; BEYOND 2009;
Bornstein 1987; Bornstein 1991; Edan 1997; Fazekas 1997;
Ghezzi 1989; Goodkin 1991; Goodkin 1995; Hartung 2002;
Hommes 2004; IFNB MS Group 1993; IMPACT 2002;
INCOMIN 2002; Johnson 1995; Koch-Henriksen 2006; Leary
2003; Likosky 1991; Milanese 1993; Millefiorini 1997; Miller
1961; Montalban 2009; MSCRG 1996; Pohlau 2007; PRISMS
1998; REGARD 2008; SENTINEL 2006; SPECTRIMS 2001;
Wolinsky 2007) and 10,828 participants with MS (72%% of
those included in this review). Mitoxantrone appeared to be the
most effective agent at 24 months’ follow-up (median OR versus
placebo 0.42, 95% CrI 0.20 to 0.87; SUCRA = 89%). Natal-
izumab and glatiramer acetate showed a similar effect (medianOR
versus placebo 0.61, 95% CrI 0.41 to 0.91; 0.67, 95%CrI 0.49 to
0.88). The heterogeneity standard deviation was 0.20 (95% CrI
0.03 to 0.38).
b) Disability progression over 36 months was available in seven
trials with IFNß-1b (Betaseron) (European Study Group 1998;
NASP 2004), IFNß-1a (Rebif ) (Andersen 2004; SPECTRIMS
2001), azathioprine (Ellison 1989; Milanese 1993), and cyclo-
phosphamide (CCMSSG 1991) compared to placebo. None of
the four agents was effective in preventing progression at this time.
The heterogeneity standard deviation τ was 0.39 (95% CrI 0.05
to 1.33).
Subgroup and sensitivity analyses
• Participants with RRMS (Table 6)
a) Relapses over 12 months were provided in 16 trials (4817
participants, 32% of those included in this review) (Achiron
1998; AFFIRM 2006; Bornstein 1987; BPSM 1995; Comi 2001;
EVIDENCE 2007; Fazekas 2008; Goodkin 1991; INCOMIN
2002; Knobler 1993; Lewanska 2002;Millefiorini 1997;MSCRG
1996; OWIMS 1999; PRISMS 1998; SENTINEL 2006) and
nine treatments, IFNß-1b (Betaseron), IFNß-1a (Avonex), IFNß-
1a (Rebif ), glatiramer acetate, natalizumab, azathioprine, mitox-
antrone, intravenous immunoglobulins, and long-term corticos-
teroids versus placebo. In the network meta-analysis there was no
statistically significant effect of these treatments compared to the
control groups.
b) Relapses at 24 months were provided in 16 trials (7269,
48% of those included in this review) (Achiron 1998; AFFIRM
2006; BEYOND2009; Bornstein 1987; BPSM 1995; Etemadifar
2006; Fazekas 1997; Goodkin 1991; IFNB MS Group 1993;
INCOMIN 2002; Johnson 1995; Millefiorini 1997; MSCRG
1996; PRISMS 1998; REGARD 2008; SENTINEL 2006) and
nine treatments, IFNß-1b (Betaseron), IFNß-1a (Avonex), IFNß-
1a (Rebif ), glatiramer acetate, natalizumab, mitoxantrone, aza-
thioprine, intravenous immunoglobulins, long-term corticos-
teroids, and placebo. Mitoxantrone was the most effective agent
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with a median OR of 0.14 (95% CrI 0.03 to 0.55; SUCRA =
92%) followed by natalizumab (median OR 0.31, 95% CrI 0.19
to 0.55; SUCRA = 75%), intravenous immunoglobulins (median
OR 0.34, 95% CrI 0.13 to 0.69; SUCRA = 70%), azathioprine
(medianOR 0.34, 95%CrI 0.08 to 1.30; SUCRA = 65%), IFNß-
1a (Rebif ) (median OR 0.46, 95% CrI 0.25 to 0.71; SUCRA =
53%), IFNß-1b (Betaseron) (median OR 0.50, 95% CrI 0.31 to
0.82; SUCRA = 45%), and glatiramer acetate (median OR 0.50,
95% CrI 0.29 to 0.77; SUCRA = 46%). The heterogeneity stan-
dard deviation was 0.17 (95% CrI 0.01 to 0.73).
c) Progression at 24 months was provided in 15 two-arm studies
(7444 participants, 50%of those included in this review) (Achiron
1998; AFFIRM 2006; BEYOND 2009; Bornstein 1987; Fazekas
1997; Goodkin 1991; IFNB MS Group 1993; INCOMIN
2002; Johnson 1995; Koch-Henriksen 2006; Millefiorini 1997;
MSCRG 1996; PRISMS 1998; REGARD 2008; SENTINEL
2006) and eight treatments, IFNß-1b (Betaseron), IFNß-1a
(Avonex), IFNß-1a (Rebif ), glatiramer acetate, natalizumab,
mitoxantrone, azathioprine, intravenous immunoglobulins, and
placebo. Mitoxantrone seemed to be the most effective agent in
reducing the number of participants with disability progression
at 24 months (median OR 0.11, 95% CrI 0.01 to 0.65; SUCRA
= 96%), followed by glatiramer acetate (median OR 0.52, 95%
CrI 0.28 to 0.88; SUCRA = 70%). The heterogeneity standard
deviation was 0.29 (95% CrI 0.03 to 0.80).
• Dose effects (Figure 6)
Figure 6. Forest plot: disability progression over 24 months in MS of all types according to each agent-dose
compared to placebo.
Thirty studies were available comparing 24 agent doses for pro-
gression at 24 months. When each dose was assumed to be a dif-
ferent treatment the DIC was 125 compared to 117 when each
dose had a fixed agent-specific effect, indicating that the dose did
not alter the agent’s effectiveness much. The dose by week anal-
ysis suggested that mitoxantrone was the most effective drug in
delaying disability progression at 24 months when administered
intravenously at 12 mg/m²/body surface area every three months
(median OR 0.11, 95% CrI 0.01 to 0.62; SUCRA = 91%). Over-
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all the ranking of the agents was consistent with this result ob-
tained when the dose-effects were ignored, as presented in Table 5.
Exploration of models that assumed a monotonic or linear dose-
effect association did not improve fit or parsimony and similar
observations were made for the analysis of relapses at 24 months
(Del Giovane 2013).
• Priors for heterogeneity
We re-analysed the primary efficacy outcomes using a uniform
prior between 0 and 3 for standard deviation; no important
changes were observed in the results.
• Sponsoring
Thirty-one out of 44 (70.5%) studies were sponsored by phar-
maceutical companies; eight studies (18%) (Bornstein 1987;
Bornstein 1991; BPSM 1995; Goodkin 1995; INCOMIN 2002;
Lewanska 2002; Likosky 1991; Miller 1961) were supported by
public institutions or had no funding; and five studies (11%)
(Edan 1997; Etemadifar 2006; Ghezzi 1989; Koch-Henriksen
2006; Millefiorini 1997) did not provide enough information to
understand if any sponsor had a role in the trial (see Characteristics
of included studies). As the number of studies and treatments eval-
uated in publicly sponsored studies were very small, we did not
undertake a sensitivity analysis as planned.
2. Acceptability of the interventions
See: Table 7
The network meta-analysis showed that there was no difference
among treatments in the number of participants who dropped out
(withdrawals or lost to follow-up) due to adverse events through-
out the studies, up to 24 months. The heterogeneity standard de-
viation was 0.16 (95% CrI 0.01 to 0.46). No sensitivity to prior
for heterogeneity was observed.
Secondary outcomes
Results of pairwise meta-analyses are summarized below.
1. Participants with at least one AE: most of the trials reported only
the number of events; the number of participants was reported
rarely. Moreover, definitions and reporting of AEs were so differ-
ent among the included studies that it was impossible to extract
quantitative data (Table 2).
2. Serious adverse events (SAEs): there was no statistically significant
effect of the treatments compared to the placebo groups (Analysis
6.1). In one study (Hartung 2002) mitoxantrone (12 mg/m²) was
associated with increased odds of participants who had SAEs com-
pared with placebo (OR 2.58, 95% CI 0.48 to 13.81); in another
two trials with this agent (Edan 1997; Millefiorini 1997) no SAEs
were reported. Trials of azathioprine reported the occurrence of
AEs, although severity was not detailed. The number of deaths
(related or unrelated to the agent) or number of participants who
committed or attempted suicide were not significantly more fre-
quent (P = 0.91; P = 0.86) in the active treatment arms compared
to placebo (data not shown).
3. Withdrawals due to AEs: overall, there was a statistically signifi-
cant effect of the treatments as a group compared to placebo (OR
2.41, 95%CI 1.92 to 3.03; P = 0.001) (Analysis 6.2). Agents asso-
ciated with significantly increased odds of participants who were
withdrawn due to AEs compared with placebo were interferons
(OR 3.08, 95% CI 2.23 to 4.26; P < 0.001), glatiramer acetate
(OR 3.48, 95% CI 1.55 to 7.84; P = 0.003), natalizumab (OR
1.36, 95% CI 0.99 to 1.85; P = 0.06), azathioprine (OR 6.35,
95% CI 2.50 to 16.11; P < 0.001), and intravenous immunoglob-
ulins (OR 1.99, 95% CI 1.07 to 3.71; P = 0.03). No difference
in withdrawals due to AEs was found for mitoxantrone, however
only one study was included, which was likely to lead to type-
II error. There were no significant differences in withdrawals in
direct comparison trials of the interferons compared to each other
or to glatiramer acetate (data not shown).
4. Serious infections: two cases of progressive multifocal leukoen-
cephalopathy, one of which was fatal, were reported in natal-
izumab-treated participants (SENTINEL 2006). Overall, there
was not a statistically significant effect of the treatments as a group
compared with the placebo groups (data not showed).
5. Leukaemia, lymphoma, or any other type of cancer: no increased
odds for active treatments compared with placebo were reported
in the included trials (data not showed).
6. Other AEs are reported in the Cochrane reviews on inter-
ferons (La Mantia 2012; Rice 2001; Rojas 2010), glatiramer
acetate (La Mantia 2010), natalizumab (Pucci 2011), azathio-
prine (Casetta 2007), mitoxantrone (Martinelli 2005), intra-
venous immunoglobulins (Gray 2003), cyclophosphamide (La
Mantia 2007), methotrexate (Gray 2004), and long-term corti-
costeroids (Ciccone 2008).
Reporting bias
The funnel plots for recurrence of relapses and disability progres-
sion over 24 and 36 months and acceptability over 24 months
are showed in Figure 7. For outcomes at 36 months there are not
enough data to judge the reporting bias; for recurrence of relapses
over 24 months there is an indication of small study effects where
asymmetry in the plot is present due to ’missing’ studies on the
right side. For the other outcomes, the plots suggested that there
was no association between the study size and its effect.
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Figure 7. ‘Comparison-adjusted’ funnel plots. In the horizontal axis the differences between the observed
log-odds ratios of each active treatment versus placebo and their summary effect obtained from the pairwise
meta-analysis are presented; in the vertical axis the standard errors of the log-odds ratios are presented.
Differences on the left of null represent studies with estimates larger than the comparison-specific mean.
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D I S C U S S I O N
Summary of main results
This review of the effects of treatments for MS included 44 RCTs
with 17,401 randomised participants. Themajority of studieswere
short-term trials, with themedianRCTdurationbeing24months,
therefore the effects of these treatments beyond two years remain
uncertain.
In terms of a protective effect against recurrence of relapses in
RRMSduring the first two years of treatment, natalizumab, IFNß-
1a (Rebif ), IFNß-1b (Betaseron), glatiramer acetate, and mitox-
antrone outperformed other drugs, being statistically significantly
more effective than IFNß-1a (Avonex), azathioprine, methotrex-
ate, cyclophosphamide, intravenous immunoglobulins, and long-
term corticosteroids. The relapse outcome at three years’ follow-
up was not reported by any of the included trials for RRMS.
There were few studies providing data for the risk of clinical re-
lapses in patients with progressive MS. Direct comparisons sug-
gested that azathioprine decreased and IFNß-1b (Betaseron) de-
creased slightly the odds of participants with progressive MS hav-
ing relapses over three years.
Disability progression was based on surrogate markers in the ma-
jority (55%) of included studies that used serial in-trial upward
changes of 0.5 or 1.0 point on the EDSS scale, confirmed at three
months’ follow-up or unconfirmed, reflecting an effect on relapse-
related disability. Beyond two to three years, disability outcome
data were unavailable or dropouts compromised the interpreta-
tion. From the network meta-analysis, mitoxantrone appeared to
be the most effective agent at two years’ follow-up, but our con-
fidence in this result was graded as ’very low’ using the GRADE
approach. The direct comparison analysis suggested that natal-
izumab and IFNß-1a (Rebif ) probably decreased the odds of par-
ticipants with RRMS having disability progression at two years’
follow-up, with an absolute reduction of 14% and 10%, respec-
tively. However, these findings also should be interpreted with
caution because only one study was available for each of the two
agents and both studies used a surrogate outcome to measure dis-
ability progression.
Both direct and indirect comparison revealed that none of the
nine agents (IFNß-1b (Betaseron), IFNß-1a (Avonex or Rebif ),
glatiramer acetate, mitoxantrone, methotrexate, cyclophospha-
mide, intravenous immunoglobulins, and long-term corticos-
teroids) that were evaluated in included studies were effective in
preventing disability worsening over two or three years in patients
with progressive MS.
We found that there was not an important dose-effect relation-
ship for any of the included treatments except for mitoxantrone,
which appeared to be the most effective drug in delaying disability
progression when administered intravenously at 12 mg/m²/body
surface area every three months.
All the agents included in this review were associated with a sta-
tistically significant higher rate of total withdrawals due to ad-
verse events (AEs) compared to placebo, even if the network meta-
analysis revealed that these agents did not differ from each other
with regards to total withdrawals due to AEs. Information on seri-
ous adverse events (SAE) was available only for interferons, glati-
ramer acetate, natalizumab, mitoxantrone, and intravenous im-
munoglobulins. All of them, except interferons, were associated
with a non-significantly higher rate of total SAEs compared with
the control treatment during a median two years’ follow-up pe-
riod. Lack of statistical significance in our analyses was likely to
have been caused by low quality, that is no active monitoring, an
overall poor reporting of SAEs, and short follow-up in the included
studies, as described in the limitations section.
Safety data from observational and registry studies need to be
considered for medium and long-term SAEs associated with these
treatments. Cutaneous necrosis (Nakamura 2008), thyroiditis (
Nonchev 2010), ophthalmological complications (Fragoso 2011),
grade 3 or higher hepatotoxicity (Byrnes 2006), severe depression
(Fragoso 2010), and haematological side effects (Nabavi 2011)
were reported as significantly related to interferon ß treatment.
Glatiramer acetate is associated with a number of SAEs including
immediate post-injection reaction, anaphylaxis or hypersensitivity
requiring emergency medical care, dyspnea, chest pain, lipoatro-
phy and skin necrosis, immunosuppression and infections, and
decrease in pulmonary function. The most common adverse re-
actions (≥ 10% and ≥ 1.5 times higher than placebo) reported
in controlled studies were injection site reactions, vasodilatation,
rash, dyspnea, and chest pain (FDA 2011).
Treatment with natalizumab is associated with an increased risk
of progressive multifocal leukoencephalopathy (PML). A risk of
PML of 11/1,000 users has been estimated for patients with all
the following risk factors: the presence of anti-JC virus antibod-
ies; longer duration of treatment, especially beyond two years; and
prior treatment with an immunosuppressant medication (for ex-
ample mitoxantrone, azathioprine, methotrexate, cyclophospha-
mide, or mycophenolate mofetil) (Bloomgren 2012).
A French cohort of 5354 MS patient-years was prospectively fol-
lowed from 2001 to at least five years after initiation of mi-
toxantrone therapy (Le Page 2011). One out of 802 patients
(0.1%) presented with acute congestive heart failure and 39 out
of 794 patients (4.9%) presented with asymptomatic left ventric-
ular ejection fraction reduction under 50% (persistent in 11 pa-
tients (28%), transient in 27 patients (69%), on the last scan at
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year five in one patient). Two cases of therapy-related leukaemia
(0.25%) were detected 20 months after the start of mitoxantrone
(one death and one with eight years confirmed remission). Of the
317 women treated before the age of 45 years, 17.3% developed
a persistent age-dependant amenorrhoea.
A possible long-term risk of cancer from azathioprine may be
related to a treatment duration above 10 years and cumulative
doses above 600 g (Casetta 2007).
Severe AEs leading to discontinuation of the treatment with in-
travenous immunoglobulins were noted in 4% of 84 treatment
courses with a total 341 infusions under routine clinical condi-
tions. They included thrombosis of the jugular vein, allergic reac-
tion, and retrosternal pressure. However, based on the available lit-
erature, intravenous immunoglobulins can generally be regarded
as a relatively safe treatment (Elovaara 2008).
Overall completeness and applicability of
evidence
All eligible trials (up to November 2010) of agents that are cur-
rently used for treatment of MS were included in the review with
the exception of fingolimod, for which trials had been not pub-
lished when we were planning our review.
The findings presented in this review originated mostly from trials
on the interferon ß family, glatiramer acetate, and natalizumab,
which overall contributed outcome data for 9881 participants
(66%) included in 33 trials (75%). The majority of the studies
included RRMS participants, who represented 60% of those in-
cluded in the review. Due to the few studies and data for partic-
ipants with SPMS, PRMS, and PPMS, we decided to combine
data for these phenotypes considering also that natural history
studies show a similar disease course once onset of progression has
manifested, independent of the prior history (Ebers 2006), and
certainly over the two to three year time frame of the included
trials.
Our review was not intended to be a comprehensive review of
all effects of these treatments. We focused on three main clinical
outcomes (relapses, disability progression, acceptability of treat-
ment) that we considered clinically meaningful. Patient reported
outcomes such as behavioural functions or quality of life were not
included. They are certainly important outcomes for participants
but are reported rarely in clinical trials, often without adequate
monitoring and availability of appropriate published results. Dif-
ferent scales used and at different assessment time points do not
allow comparisons to be made. Moreover, these measures may be
susceptible to bias in trials in which many, if not most, treated
participants have become aware of the treatment they are receiv-
ing owing to the well documented side effects of the treatments
included in our review. Short duration trials and poor reporting
of AEs were other major limitations in determining the overall
completeness and the most favourable balance between benefits
and risks of the included treatments.
Although magnetic resonance imaging (MRI) measures are widely
used in trials of MS, we did not include them in this review since
MRI alone adds little if anything to the clinical outcomes (Daumer
2009). Moreover, it was not possible to compare MRI outcomes
adequately across trials from the published results since MRI cri-
teria, measures, and the timing of the scans differed between trials.
Quality of the evidence
Five (11%) out of 44 trials were judged to be at low risk of bias,
when allocation concealment, blinding of outcome assessors and
complete outcome data were met. In more than 50% of studies
allocation concealment was judged to be ’unclear’ due to the lack
of details provided in the articles. Only two RCTs were judged
at a ’high’ risk of bias for allocation concealment. Blinding of
outcome assessment was reported in the majority of the included
studies; however side effects of each treatment make it likely that
treated participants had become aware of the treatment they were
receiving during the course of the trial, and most of these trials
should be regarded as single-blind.
In our review a primary outcome was disability progression and its
definition was taken from the original articles. All studies defined
progression as a sustained (three month or six month) increase in
EDSS (Kurtzke 1983) score by at least one point recorded outside
of exacerbations throughout the follow-up.This is a validatedmea-
sure of unremitting disability inMS, provided it is confirmed after
a sufficient period of time (at least six months is necessary and one
year would be better) (Ebers 2008). Twenty-four (54.5%) of the
44 included trials required only three months of confirmation to
assess sustained disability progression. Although we had to accept
the definition given in the original papers, we considered the three
month criterion to be at high risk of bias because this definition
meant that participants who recovered slowly from exacerbations
were regarded as having unremitting disability progression.
There were greater than 85% of participants followed-up in more
than 50% of the included studies. Six trials were stopped early,
two for benefit, three for futility, and one for lack of funding.
Although protocols of the included studies were not available, the
majority of them reported the number of participants who had
relapses or disability progression, which were the primary efficacy
outcomes in this review. However, in most trials these outcomes
were reported at only two years’ follow-up, that is a too short
period to establish valid treatment efficacy in MS.
Only 20 RCTs reported that AEs were actively monitored, and
only one study provided sufficient information on how a SAE was
defined.More than 50% of studies did not report SAEs.Moreover,
due to the short duration of follow-up in the majority of the trials,
rare and long-term adverse events were not available. Therefore
caution is needed in interpreting the apparent safety reported for
most of the agents (“treatments appeared not statistically signifi-
cantly different from placebo in terms of the number of partici-
pants with SAEs”). Given the low quality of monitoring adverse
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events and overall poor reporting in the included studies, it is dif-
ficult to understand whether an event actually did not happen or
it happened but was not detected or was selectively not reported.
Potential biases in the review process
The studies were deemed sufficiently similar across comparisons
and we believe that the consistency assumption is reasonable in
this type of data. The models fit the data well, no loops were found
to be inconsistent and model parsimony was always higher for the
consistency model; this provided support for our assumption of
consistency. However the power of these tests and approaches to
detect inconsistency are low, particularly for networks with a small
number of included studies. The possible presence of publication
bias, partially supported by the contour-enhanced funnel plot, can
never be totally excluded.
A small number of studieswith few comparisonswere recognised as
having low risk of bias and inmany cases results came from a single
study. We couldn’t predict the impact of industry sponsorship as
most of the presented studies were sponsored by industry or the
information was not reported.
In this review pairwise meta-analyses were performed in a frequen-
tist approach while network meta-analyses were performed in a
Bayesian context. Implementation of the models in the Bayesian
framework yielded wider confidence intervals than frequentist im-
plementation in STATA because the framework accounted for the
uncertainty in the estimation of the heterogeneity. For some com-
parisons the estimate of network meta-analysis was less precise
that the estimate from the pairwise meta-analysis. This happened
when there was no heterogeneity in the pairwise comparison but
there was heterogeneity overall in the network and random-effects
models were used. This was because the network meta-analysis as-
sumes a common ’average’ heterogeneity parameter τ for all pair-
wise comparisons.
Agreements and disagreements with other
studies or reviews
Our findings agree with and extend the findings of a previous re-
view (Smith 2010) that examined all availableRCTs (up toDecem-
ber 2009) of glatiramer acetate, IFNß-1a, IFNß-1b,mitoxantrone,
and natalizumab. They also reported that there was fair evidence
that IFNß-1a (Avonex) was less effective than IFNß-1a (Rebif )
and IFNß-1b for preventing relapse in patients with RRMS. They
found no difference between the interferons on changes in dis-
ability but did find IFNß-1b to be superior to IFNß-1a (Avonex)
on disease progression (relative risk 0.48, 95% CI 0.27 to 0.86)
in RRMS. They confirmed our findings that evidence was insuf-
ficient to make any judgments regarding effectiveness in primary
progressive or secondary progressive MS. They did not find any
difference in withdrawal rates among the interferon ß family in
head-to-head trials.
Zintzaras 2012 performed a network meta-analysis of 109 trials
and compared different therapies commonly used forMS, but also
many agents that are not currently in clinical use, such as bovine
myelin, or that were rejected by the FDA and the EMA because
they were found to cause toxicity, such as cladribine. The meta-
analysis considered 145 arms as different treatments (that is one
for each dose of each treatment) compared to IFNß-1b (250 µg)
(that is the chosen reference treatment for analysis) and provided
about 90 estimates based on eight direct comparisons with IFNß-
1b. Thus, the remaining estimates were obtained through the use
of indirect analysis. The authors reported that their results needed
to be interpreted with caution because the network was dominated
by indirect comparisons, but they claimed that combination ther-
apies could be more promising than monotherapies. Important
facts invalidate this conclusion in our opinion. First, this claim
came only from indirect comparisons. Second, combined treat-
ments did not affect clinical outcomes any more than the compar-
ison treatment alone or resulted in a worst outcome. For example,
methylprednisolone in combination with IFNß-1a did not affect
disability progression any more than IFNß-1a alone (Ravnborg
2010), or atorvastatin combined with IFNß-1a resulted in in-
creasedMRI and clinical disease activity (Birnbaum 2008). Third,
some of the primary studies included in the indirect analysis were
phase two small trials (Birnbaum 2008; Goodman 2009; Weiner
1993) or used no validated clinical outcomes to assess treatment
effects (Khoury 2010). Fourth, combination therapies increased
the frequency of SAEs.
In a retrospective cohort study (Shirani 2012) based on prospec-
tively collected data (1985 to 2008) from British Columbia,
Canada, patients with RRMS treated with interferon ß (n = 868)
were compared with untreated contemporary (n = 829) and his-
torical (n = 959) cohorts. The median active follow-up times (first
to last EDSS measurement) were 5.1, 4.0, and 10.8 years, respec-
tively. The authors concluded that among patients with RRMS,
administration of interferon ß was not associated with a reduction
in progression of disability.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review includes direct and indirect comparisons of im-
munotherapies forMS and should provide some guidance to clini-
cians and patients on their efficacy. On the basis of high quality ev-
idence, natalizumab and IFNß-1a (Rebif ) are superior to all other
treatments for preventing clinical relapses and disability progres-
sion in the short-term (24 months) in patients with RRMS. Natal-
izumab can induce progressive multifocal leukoencephalopathy,
especially with more than two years of treatment.
Moderate quality data support the efficacy of IFNß-1b (Be-
taseron), glatiramer acetate, and mitoxantrone for preventing re-
lapse and disability progression in RRMS in the short-term. All
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these treatments are associatedwithmedium and long term serious
adverse events and the benefit-risk balance might be unfavourable.
There are insufficient high quality data for a definitive conclusion
on whether there is a favourable benefit-risk balance with azathio-
prine, however this agent might be effective in decreasing the odds
of participants with RRMS having clinical relapses and disability
progression over 24 to 36 months.
The lack of convincing efficacy data from both direct and indi-
rect comparisons shows that IFNß-1a (Avonex), intravenous im-
munoglobulins, cyclophosphamide, and long-term corticosteroids
have an unfavourable benefit-risk balance in RRMS.
Few randomised studies are available for patients with progressive
MS. In comparison with placebo, IFNß-1b (Betaseron) and aza-
thioprine decrease slightly the odds of these patients having clin-
ical relapses over three years. IFNß-1a (Avonex or Rebif ), glati-
ramer acetate, mitoxantrone, methotrexate, cyclophosphamide,
intravenous immunoglobulins, and long-term corticosteroids are
not effective in decreasing disability progression in patients with
progressive MS.
There is a dose-effect associated with mitoxantrone administered
intravenously at 12 mg/m²/body surface area every three months,
but the risk of serious adverse events (cardiotoxicity and therapy-
related leukaemia) unfavourably influences the benefit-risk bal-
ance. There is not a dose-effect associated with the use of all the
other treatments included in our review.
It is important to consider that the clinical effects of all these
treatments beyond two years are uncertain, and this is a relevant
point for a disease of 30 to 40 years duration.
More than 70% of included studies were sponsored by pharma-
ceutical companies and this could have influenced the results of
our review.
Implications for research
We believe that there are two urgent needs that the research agenda
should address. First, large randomised trials of direct compar-
isons are needed and follow-up of the original trial cohorts should
be mandatory. Direct head-to-head comparison(s) between natal-
izumab and IFNß-1a (Rebif ) or between azathioprine and IFNß-
1a (Rebif ) should be top priority on the research agenda.
Second, more studies regarding the medium and long-term effi-
cacy and safety of immunotherapies and the comparative safety
of different agents are needed. As the number of drugs, including
biologics, that are available for treatment of MS increases, more
options will become available to participants and clinicians. In
the absence of comparative trials, national and international reg-
istries and other types of large non-randomised studies might be
relevant sources for providing complementary data regarding the
long-term effectiveness and safety of immunotherapies for MS.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Achiron 1998
Methods RCT
Participants Age: 19-60 years; definite RRMS; mean disease duration 4 years; mean EDSS 3.0
Interventions Loading dose of intravenous immunoglobulins 0.4 g/kg/body weight per day for 5
consecutive days followed by additional booster doses of intravenous immunoglobulins
0.4 g/kg/body weight once daily every 2 months for 2 years (n 20)
placebo consisting of 0.9% saline administered with the same schedule as the active
treatment (n 20)
Outcomes Relapses at 12 and 24 months. Progression at 24 months
Notes Funding: Miles Inc. Cutter Biological, Bayer and Promedico
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were assigned to receive immunoglobulin or placebo
by a block-stratified randomisation procedure, performed at the
pharmacy
Allocation concealment (selection bias) Low risk Allocation made in pharmacy. Bottle of immunoglobulin or
placebo were wrapped in sealed opaque bags and brought to the
patients’ rooms. Use also of an opaque plastic bag for fluid
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All patients and evaluators were blinded to treatment...the bottles
of immunoglobulin or placebo were wrapped in sealed opaque bags
and brought to the patients’ rooms. The entire IV set was covered by
an opaque plastic bag to ensure that any possible fluid turbidity or
frothing would not be evident to the investigators or patients”. Page
399
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All patients and evaluators were blinded to treatment”. Page 399
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Two patients discontinued treatment after the first year (one in each
group).” Page 400.The intention-to-treat analysiswas performed
including the 2 withdrawals
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
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Achiron 1998 (Continued)
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up
AFFIRM 2006
Methods RCT
Participants Age: 18-50 years; clinical definite RRMS; disease duration 0-33 years; EDSS 0-5.0; ≥ 1
relapses in the year before randomisation
Interventions Natalizumab 300 mg by intravenous infusion every 4 weeks for up to 116 weeks (n.
627)
Placebo (unspecified) (n. 315)
Outcomes Relapses at 12 and 24 months. Progression at 24 months.
Notes Funding: Biogen Idec, Inc. and Elan Pharmaceutical.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned to treatment that was stratified
according to study site in blocks of three (two active, one placebo)
with the use of a computer-generated block randomization schedule.
” Page 900
Allocation concealment (selection bias) Low risk “Amultidigit identification number, implemented by an interactive
voice-response system was used.” Page 900
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All study personnel, patients, sponsor personnel involved in the
conduct of the study, and the investigator advisory committee were
unaware of treatment assignments throughout the study (Page 900)
... Treating neurologists were responsible for all aspects of patient
care, including the management of adverse events and the treatment
of relapsing disease.” Page 901
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Examining neurologists performed objective evaluation with use
of the EDSS and neurologic examination during all study visits;
they were not in contact with patients in any other capacity, so as to
reduce the possibility of being unblinded by side effects or laboratory
assessments.” Page 901
Incomplete outcome data (attrition bias)
All outcomes
Low risk “8% of patients in the natalizumabgroup and 10% of those in the
placebo group withdrew from the study”. Pages 902-903
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AFFIRM 2006 (Continued)
Selective reporting (reporting bias) High risk The number of patients who progressed at 2 years were not
available
Other bias High risk Data analysis performed by Biogen Idec and Elan Pharmaceu-
ticals. Sustained disability progression confirmed at 3 months’
follow-up. Relapses assessed also as adverse events. The number
of lost to follow-up at 1 year were not available
Andersen 2004
Methods RCT
Participants Age: 18-65 years; clinical definite SPMS defined as ≥ 1 EDSS point increase in 4 years
before randomisation, with or without superimposed exacerbations; EDSS < 7.0
Interventions IFNß-1a (Rebif ) 22 µg subcutaneously weekly for 36 months (n.188)
Placebo (unspecified) (n. 183)
Outcomes Relapses at 36 months. Progression at 36 months
Notes Funding: Serono International, Geneva, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk “equal allocation.” Page 707
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Patients were instructed to cover injection sites.” Page 707
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Neurologists blinded to dose assignment were responsible for neu-
rological assessments”. Page 707
Incomplete outcome data (attrition bias)
All outcomes
High risk The study had ended prematurely due to negative results from
SPECTRIMS study. Only 83% of randomised patients com-
pleted about 3 years. Losses to follow-up not included in anal-
ysis: treatment 21%; placebo 16%. More AE and patients’ de-
cision in the treated group. The median time on treatment was
35.2 months (mean 32.0) for placebo and 35.0 months (mean
31.1) for IFNß-1a
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
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Andersen 2004 (Continued)
Other bias Low risk The study appears to be free of other sources of bias
BEYOND 2009
Methods RCT
Participants Age: 18-55 years; clinical or laboratory-supported definite RRMS; EDSS 0-5; disease
duration 3-8 years; ≥ 1 relapses in the year before randomisation
Interventions IFNß-1b 250 µg subcutaneous every other day (n. 897)
IFNß-1b 500 µg subcutaneous every other day (n. 899)
glatiramer acetate 20 mg subcutaneous every day (n. 448)
Outcomes Relapses at 24 months. Progression at 24 months
Notes Funding: Bayer HealthCare Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Use of SAS-based block randomisation with regional stratifica-
tion”. Page 890
Allocation concealment (selection bias) Low risk “Patients were randomly assigned in a 2:2:1 ratio ... by the central
randomisation group...” Page 890
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Physicians and patients were double-blind to comparisons between
the two doses of IFNß-1b... Ibuprofen or acetaminophen were given
at the same time as random assignment to IFNß-1b, at least during
the rst 3 months, to
reduce u-like symptoms. The treating physicians and the
patients were therefore aware of treatment assignments”. Page 891
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “ The masked evaluating physicians did all neurological assessments
and ascertained functional system and EDSS scores...The evaluating
physicians were not involved in the care of patients and had no access
to patient les or previous
assessments. ... Patients covered their injection sites during neuro-
logical examination and did not discuss any adverse events with the
evaluating physician”. Page 891-2
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up not included in analysis: 500 µg IFNß-1b
13%; 250 µg IFNß-1b 20%; glatiramer acetate 16%
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
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BEYOND 2009 (Continued)
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up
Bornstein 1987
Methods RCT
Participants Age: 20-35 years; definite RRMS; EDSS 0-6.0; disease duration ≥ 1 year; at least 2
relapses in the 2 years before randomisation
Interventions Glatiramer acetate 20 mg subcutaneous every day (n. 25)
Placebo bacteriostatic saline subcutaneous every day (n. 25)
Outcomes Relapses at 12 and 24 months. Progression at 24 months
Notes Funding: Grants from the NINCDS and the NIH, Bethesda, Md.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “The random assignment of the first patient of a pair determined
the assignment of both”. Page 409
Allocation concealment (selection bias) High risk An open allocation schedule was used: “Treatment assignments
were made known to the clinical assistant responsible for the pro-
duction, labelling and distribution of medication”. Page 409
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The patient’s self evaluation of ... side effects were reported to the
clinical assistant, how was not blinded to the treatment”. Page 409
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A neurologist unaware of the patient’s treatment group completed
a neurologic examination and status evaluation”. Page 409
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up excluded from the study analysis: 2 of 25
placebo patients
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
and those outcomes that were pre-speci ed in the methods sec-
tion
Other bias High risk Sustained disability progression was confirmed at 3 months’ fol-
low-up
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Bornstein 1991
Methods RCT
Participants Age: 20-60 years; progressive MS; EDSS 2-6.5; progression ≥ 18 months; ≤ 2 relapses
in the 2 years before randomisation
Interventions glatiramer acetate 30 mg subcutaneous twice a day (n. 51)
placebo, saline alone, subcutaneous twice a day (n. 55)
Outcomes Progression at 24 months
Notes Funding: Grants from the NINCDS and the NIH, Bethesda, Md.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “... by randomized block design with two baseline EDSS strata <
5.0 and 5.0 or greater” Page 534
Allocation concealment (selection bias) Unclear risk “The investigator notified the statistical center, which assigned a
randomization code number. Shipment of glatiramer acetateto the
patients at their individual centers were totally at random and
were dictated by the patients’ date of entry into the trial. Only
the statistician and the clinical assistant at Albert Einstein College
of Medicine, who distributed medication, were aware of patients
assignments”. Page 534
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Side effects were reported to a clinical assistant”. Page 534
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The blinded neurologist performed a complete neurological exami-
nation... Side effects were not discussed with the study neurologist...
Another blinded neurologist was available to examine patients with
severe or unusual side effects.” Page 534
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up and 20 withdrawals were included in the
data analyses. Page 536
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
and those outcomes that were pre-speci ed in the methods sec-
tion
Other bias High risk Sustained disability progression was confirmed at 3 months’ fol-
low-up
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BPSM 1995
Methods RCT
Participants Mean age: 35 years; clinical definite RRMS; EDSS < 5.5; disease duration: not reported;
no relapses in the previous 45 days before randomisation
Interventions Intravenous methylprednisolone 2 g in saline solution for 12 hours, every 45-60 days
for two years or until relapse (n. 17)
Placebo i.v. saline solution at the same schedule (n. 19)
Outcomes Relapses at 12 and 24 months
Notes Funding: None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Themethod of randomisation was centralised” (Cochrane review)
Allocation concealment (selection bias) Low risk “Allocation were generated by computer by personnel not involved
in patients management” (Cochrane review)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “the study was double blind” (Cochrane review)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “the study was double blind” (Cochrane review)
Incomplete outcome data (attrition bias)
All outcomes
High risk “There were 10 patients (7 treated) lost to follow-up (28% overall).
Moreover, patients experiencing an exacerbation were not followed
up although a two year follow-upwas planned”. (Cochrane review)
Selective reporting (reporting bias) High risk “Patients were not followed-up after the first exacerbation, contrary
to what was planned. Since patients not experiencing a relapse in
the two years of the study were just 2, we did not have any data on
disability progression for the majority of the patients”. (Cochrane
review)
Other bias High risk “Prematurely interrupted at 36 out of 72 planned patients for or-
ganisational reasons and lack of funding”. (Cochrane review)
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British and Dutch 1988
Methods RCT
Participants Age: 30-65 years; definite RRMS, SPMS or PPMS; disease duration 5-15 years; EDSS
2.5-6.5; ≤ 1 relapses in the 2 years before randomisation
Interventions Azathioprine 2.5 mg/Kg body weight oral daily (n. 174)
Placebo (n. 180)
Outcomes Relapses at 12, 24 and 36 months
Notes Funding: Wellcome Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence was generated for each centre by
the trial statistician “by randomized block design”. Page 534
Allocation concealment (selection bias) Low risk “The investigator notified the statistical center, which assigned a
randomization code number” Page 534. The packs of trial tablets
were issued to individual pharmacies labelled with a code. The
treatment and placebo tablets were identical
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients were blind to treatment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A masked assessor recorded the number of relapses, the ambu-
latory index and the Kurtzke scale
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up not included in the study analysis (at the
end of the study): Treatment arm 8%; placebo 6%
Selective reporting (reporting bias) High risk Proportion of participants who progressed at 2 years was not
available
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up
CCMSSG 1991
Methods RCT
Participants Mean age: 32 years; clinically or laboratory-supported SPMS, PPMS or PRMS; ≥ 1.0
EDSS in the year before randomisation; mean disease duration 10 years; mean EDSS 5.
8 (0.6)
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CCMSSG 1991 (Continued)
Interventions Cyclophosphamide 1 g intravenous three times weekly + 40 mg prednisone tapered for
16 days (total dose ≤ 9 gm) (n. 55)
Placebo (n. 56)
Outcomes Progression at 36 months
Notes Funding: BRISTOL Myers; Upjohn
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “A randomisation sequence was generated separately for each centre.
Patients were stratified by centre and EDSS score.” Page 442
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients with exacerbation or progression were seen by the mon-
itoring neurologist... who was aware of the treatment allocation”.
Pages 442, 444
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The evaluating neurologist (not involved with the patients’ ongoing
care) was blinded”. Page 444
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Subjects who did not complete the allocated treatmentwere followed
and their outcome was assigned to the group to which they were
randomised (intention to treat analysis)”. Page 443
Selective reporting (reporting bias) Low risk The published reports included patients who progressed at 36
months
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up
Comi 2001
Methods RCT
Participants Age: 18-50 years; clinical or laboratory-supported definite RRMS; EDSS 0-5.0; disease
duration ≥ 1years; ≥ 1 relapses in the 2 years before randomisation
Interventions Glatiramer acetate 20 mg subcutaneous every day (n. 119)
Placebo (not described) (n. 120)
Outcomes Relapses at 9 months
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Comi 2001 (Continued)
Notes Funding: Teva Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The randomization list, stratified by centers, was computer-gen-
erated by the TEVA Statistical Data Management Department.
Equal allocation of the two treatment groups was used“. Page 291
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk ”A treating neurologist was responsible for the overall medical man-
agement of the patient including safety monitoring... All personnel
were unaware of treatment allocation... both the treating neurologist
and the patient were informed on the importance of not discussing
safety issue with the examining neurologist“ . Page 291
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ” An examining neurologist was responsible for all scheduled neu-
rological examinations and exacerbation follow-up“. Page 291
Incomplete outcome data (attrition bias)
All outcomes
Low risk ”Analyses were based on an intention to treat dataset. The last
observation carried forward (LOCF) method was implemented to
account for early discontinuation and missing data.“ 7 (6%) pa-
tients dropped out in each arm”. Page 292
Selective reporting (reporting bias) High risk Progression was not measured in the trial.
Other bias High risk Teva Pharmaceutical was involved in the trial.
Edan 1997
Methods RCT
Participants Age: 18-45 years; definite SPMS or PRMS; disease duration < 10 years; ≥ 2 relapses or
≥ 2 EDSS points increase in the year before randomisation; EDSS ≤ 6.0
Interventions 20 mg intravenously/month and methylprednisolone (1 g intravenously/month) (n. 21)
methylprednisolone alone (1 g intravenously/month) (n. 21)
Outcomes Relapses at 6 months.
Notes Funding: not reported
Risk of bias
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Edan 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk “The allocation of the treatmentwas done after inclusion by a central
randomisation service by fax”. Page 113
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “In the present study, ... neither the patients nor the clinical inves-
tigators were blinded during the study. Blinding of patients was not
possible in this trial, as obvious side effects of mitoxantrone were
experienced in almost all cases. Blinding of the physician was made
difficult by the fall in white cell count that always accompanies mi-
toxantrone treatment”. Page 116
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Blind clinical observers might have been appointed, but this could
not be done for economic reasons”. Page 116
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 withdrawals “due to pronounced clinical worsening” (all in the
methylprednisolone group) were included in analysis
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias High risk Sustained disability progression confirmed at 2 months’ follow-
up. It’s unclear if this study was sponsored
Ellison 1989
Methods RCT
Participants Mean age: 32 years; definite SPMS or PPMS; disease duration 5-15 years; EDSS 2.5-6.
5; ≤ 1 relapses in the 2 years before randomisation
Interventions Azathioprine 3 mg/kg body weight oral daily (n. 31)
Azathioprine 3 mg/kg body weight oral daily and methylprednisolone for 36 weeks (n.
34)
Placebo (n. 34)
Outcomes Relapses at 12, 24 and 36 months. Progression at 36 months
Notes Funding: Wellcome Company and Upjohn Company
Risk of bias
Bias Authors’ judgement Support for judgement
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Ellison 1989 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Patient sequence was the order of presenting the initial prescription
to the pharmacy”. Page 1019
Allocation concealment (selection bias) Unclear risk “The statistician told the examining neurologists that the treatments
would be allocated by a randomisation process to blocks of 4 successive
patients, but the assignment rules were not revealed”. Page 1019
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Monitoring neurologist, study nurse, clinic coordinator, technician
and patients were masked to the treatment assigned”. Page 1019
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Observer neurologist was masked to the treatment assigned”. Page
1019
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up at 1 year; 2 placebo and 1 methylpred-
nisolone+ azathioprine arm at 2 years; 6 placebo, 5 azathioprine
and 6 methylprednisolone+ azathioprine at 3 years
Selective reporting (reporting bias) Low risk Primary outcomes of interest were reported completely.
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up
Etemadifar 2006
Methods RCT
Participants Age: 15-50 years; clinical or laboratory-supported definite RRMS;mean disease duration
3 years; EDSS ≤ 5.0; ≥ 2 relapses in the 2 years before randomisation
Interventions IFNß-1b 250 µg subcutaneous every other day for 24 months (n. 30)
IFNß-1a (Avonex) 30 µg intramuscular once a week for 24 months (n. 30)
IFNß-1a (Rebif ) 44 µg subcutaneous three times a week for 24 months (n. 30)
Outcomes Relapses at 24 months
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients “were assigned randomly and equally to one of the three
treatment groups”. Page 284
Allocation concealment (selection bias) Unclear risk Not described.
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Etemadifar 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The trial was single-blinded in that patients were aware”. Page
284
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Physicians who assessed the outcome were unaware of the treatment
type that the patient had received”. Page 284
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients were included in the study analysis.
Selective reporting (reporting bias) High risk Progression at 2 years was not reported.
Other bias Unclear risk It’s unclear if this study was sponsored.
European Study Group 1998
Methods
Participants Age: 18-55 years; clinical definite SPMS; ≥ 2 relapses or ≥ 1.0 EDSS points in the 2
years before randomisation; EDSS 3.0-6.5; mean disease duration 13 years
Interventions Subcutaneous injection every other day of IFN-1b 250 ug (8.0 million international
units [MIU]), for 36 months (n. 360)
Placebo (unspecified) for 36 months (n. 358).
Outcomes Relapses at 36 months. Progression at 36 months
Notes Funding: Schering AG, Berlin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Central randomisation schedule assigned placebo or IFNß-1b to
blocks of six patients in a 1/1 ratio”. Page 1492
Allocation concealment (selection bias) Low risk “Access to the code was strictly limited according to study protocol”.
Page 1492
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Separate treating and examining physicians were employed...
IFNß-1b was indistinguishable from placebo”. Page 1492
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Evaluating physicians received no potentially unmasking informa-
tion from the treating physicians, and were allowed to speak to pa-
tients only as necessary to carry out neurological tests”. Page 1492
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European Study Group 1998 (Continued)
It is unclear if the 3 years evaluation was double blind or open
for the early study termination
Incomplete outcome data (attrition bias)
All outcomes
High risk 90 (25%) of 360 patients in the treatment group and 97 (27%)
of 358 controls had not completed the scheduled 3 years’ follow-
up because the study had ended prematurely for benefit
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias High risk Schering AG, Berlin performed the statistical analysis.
EVIDENCE 2007
Methods RCT
Participants Age: 18-55 years; clinical or laboratory-supported definite RRMS; EDSS 0-5.5; median
disease duration 4 years; ≥ 2 relapses in the 2 years before randomisation
Interventions IFNß-1a (Rebif ) 44 µg subcutaneous three times a week (n. 339)
IFNß-1a (Avonex) 30 µg intramuscular once a week (n. 338)
Outcomes Relapses at 12 months
Notes Funding: Serono Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated scheme with block size of 6 followed by
block size of 4”. Page 2033
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients and a treating physician who was not involved in end
point assessment were aware of treatment assignments”. Page 2033
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Evaluating physicians who were blinded to the patients’ treatment
and symptoms performed all clinical exams”. Page 2033
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up not included in analysis: IFN-β1a (Avonex)
9.5%; IFN-β1a (rebif ) 12%
Selective reporting (reporting bias) High risk Only relapses at 12 months were reported.
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EVIDENCE 2007 (Continued)
Other bias High risk Data management and study analysis were done by Serono. Sus-
tained disability progression confirmed at 3 months’ follow-up
Fazekas 1997
Methods
Participants Age: 15-64 years; clinical definite RRMS; EDSS, range 1.0-6.0; disease duration, range:
5.7-8.6 years; ≥ 2 relapses in the 2 years before randomisation
Interventions Immunoglobulins 0.15-0.20 gm/kg body weight intravenously monthly (n. 75)
Placebo (n. 73).
Outcomes Relapses at 24 months.
Notes Funding: Sero-Merieux (Vienna, Austria)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Centralised computer-generated randomisation schedule with
stratification by centre, age, sex, and deterioration rate.” Page 590
Allocation concealment (selection bias) Low risk “Randomly and centrally allocated”. Page 590
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Infusions of intravenous immunoglobulinsand placebo were
identical in appearance and were stored in plastic bags for conceal-
ment during administration”. Page 590
The treating physician was aware of treatment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The assessing physician was unaware of treatment assignment”.
Page 590
Incomplete outcome data (attrition bias)
All outcomes
High risk 64 (85%) patients in the intravenous immunoglobulins group
and 56 (75%) in the placebo group completed the trial
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias Unclear risk Definition of sustained disability progression was not clearly
reported
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Fazekas 2008
Methods RCT
Participants Age: 15-64 years; clinical definite RRMS; mean EDSS 2.0; disease duration 1.3-1.6
years; ≥ 2 relapses in the 2 years before randomisation
Interventions Immunoglobulins 0.2 gm/kg body weight intravenously monthly (n. 45)
Immunoglobulins 0.4 gm/kg body weight intravenously monthly (n. 42)
Placebo (n. 41).
Outcomes Relapses at 12 months.
Notes Funding: Bayer HealthCare AG.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The random code number was computer generated by the Statistics
and Data System Department of Bayer.” Page 266
Allocation concealment (selection bias) Low risk “Randomisation performed by an unblinded pharmacist who as-
signed code numbers from sealed envelopes in a sequential manner”.
Page 266
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not clearly reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Endpoints “assessed by an evaluating physician who was otherwise
not involved in patient care”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts: intravenous immunoglobulins 0.2 g: 7/45 (15%);
intravenous immunoglobulins 0.4 g: 4/42 (9%); placebo 4/41
(10%)
Selective reporting (reporting bias) High risk Only relapses at 12 months were reported.
Other bias High risk Bayer HealthCare AG supported the study.
Ghezzi 1989
Methods RCT
Participants Age not reported; definite RRMS or SPMS; disease duration 5-15 years; EDSS 2.5-6.5;
≤ 1 relapses in the 2 years before randomisation
60Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ghezzi 1989 (Continued)
Interventions Azathioprine 2.5 mg/Kg/body weight oral daily (n. 93)
Placebo (n. 92)
Outcomes Relapses 24 months. Progression at 24 months
Notes Funding: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examining neurologist blinded to treatment arm.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up not included in the study analysis: treatment
26%; placebo 28%
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
and those outcomes that were pre-speci ed in the methods sec-
tion
Other bias Unclear risk Definition of sustained disability progression not clearly re-
ported. It is unclear if the study was sponsored
Goodkin 1991
Methods RCT
Participants Mean age: 30 years; definite RRMS; disease duration 5-15 years; EDSS 2.5-6.5; ≤ 1
relapses in the 2 years before randomisation
Interventions Azathioprine 3.0 mg/Kg/body weight oral daily for 24 moths (n. 30)
Placebo for 24 months (n. 29)
Outcomes Relapses 12 and 24 months. Progression at 24 months
Notes Funding: Wellcome Company
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Goodkin 1991 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomised by the statistician using random number tables”.
Page 21
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients and personnel were blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The examining neurologist was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7 (12%) people were lost to 2 years follow-up (3 azathioprine,
4 placebo)
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias Unclear risk Definition of sustained disbility progression not clearly reported
Goodkin 1995
Methods RCT
Participants Age: 21-60 years; definite PPMS or SPMS ; disease duration >1 years; EDSS 3.0-6.5; ≤
1 relapses in the 2 years before randomisation
Interventions Methotrexate 7.5 mg oral weekly for 24 months (n. 31)
Placebo for 24 months (n. 29)
Outcomes Relapses at 12 and 24 months. Progression at 24 months
Notes Funding: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The randomisation scheme was developed prior to the initiation of
the study and was blocked in groups of 10”. Page 32
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Goodkin 1995 (Continued)
Allocation concealment (selection bias) High risk “Treatment assignments were made by the unblinded study coordi-
nator who appeared to be not responsible for patients’ recruitment”.
Page 32
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was not clearly reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The examining neurologist performed all neurological examina-
tions without reference to earlier examinations and was not per-
mitted to talk to the patient or treating physician about the general
progress of the study, clinical events, or therapy provided to any study
participants.” Page 32
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up not included in the study analysis: treatment
2/31; placebo 0/29
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
and those outcomes that were pre-speci ed in the methods sec-
tion
Other bias High risk “Sustained” disability progression was confirmed at≥ 2 months
of follow-up
Hartung 2002
Methods RCT
Participants Age: 18-65 years; definite SPMS or PRMS; mean disease duration 10 years;≥ 1.0 EDSS
n the 18 months before randomisation; no clinical relapses or treatment with steroids
for at least 8 weeks before enrolment; EDSS 3.0-6.0
Interventions Mitoxantrone 5 mg/m² body surface area intravenously every 3 months (n. 66)
Mitoxantrone 12 mg/m² body surface area intravenously every 3 months (n. 63)
Placebo (n. 65).
Outcomes Relapses at 24 months. Progression at 24 months.
Notes Funding: Wyeth-Lederle Benelux and Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation by a computer-generated schedule, block size of
three”. Page 2019
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Hartung 2002 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “A separate treating physician was aware of treatment assignment.
” Page 2019
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Neurologist who assessed outcome measures was unaware of treat-
ment assignment (assessing physician).” Page 2019
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up not included in the study analysis: treatment
arms 3/63 (5%) and 2/66 (3%); placebo 1/65 (1.5%)
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias High risk Wyeth-Lederle Benelux and Germany sponsored the trial and
financially supported statistical analysis
Hommes 2004
Methods RCT
Participants Age: 18-55 years; clinical definite SPMS; progression ≥ 1.0 EDSS points in the 2 years
before randomisation; EDSS 3.0-6.5; disease duration ≥ 3 years
Interventions Immunoglobulins 1 gm/kg body weight intravenously monthly (n. 159)
Placebo (n. 159).
Outcomes Relapses at 12 and 24 months. Progression at 24 months.
Notes Funding: Bayer Corporation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The randomisation was done centrally as block randomisation with
stratification by centre.” Page 1150
Allocation concealment (selection bias) Unclear risk “Concealment of treatment was guaranteed by use of an albumin
solution identical in appearance to the study medication, with iden-
tical labelling and opaque plastic wrapping.” Page 1150
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Concealment of treatment was guaranteed by use of an albumin
solution
identical in appearance to the study medication, with identical
labelling and opaque plastic wrapping...a treating neurologist or
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Hommes 2004 (Continued)
a study nurse administered the study drug.. Physicians and study
nurses were unaware of treatment allocation.” Page 1150
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The clinical assessment of the patients was made by an evaluating
neurologist, who was not allowed to discuss therapy or adverse effects
with the patients.” Page 1150
Incomplete outcome data (attrition bias)
All outcomes
Low risk “32 patients (10%) withdrew from the study.Thus, complete
data for 27 months were available for 280 (90%) patients.” Page
1152
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias High risk Bayer Corporation was involved in every phase of the trial. Sus-
tained disability progression confirmed at 3 months’ follow-up
IFNB MS Group 1993
Methods RCT
Participants Age: 18-50 years; clinical or laboratory-supported definite RRMS; EDSS ≤ 5.5; disease
duration > 1 year; ≥ 2 relapses in the 2 years before randomisation; no relapses for at
least 1 month before randomisation
Interventions IFNß -1b (Betaseron) 50 µg subcutaneously every other day (n. 125)
IFNß -1b (Betaseron) 250 µg subcutaneously every other day (n. 124)
Placebo (n. 123).
Outcomes Relapses at 24 months. Progression at 24 months.
Notes Funding: Triton Biosciences, Inc., Alameda, CA and Berlex Laboratories Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “One treating neurologist who knew about side effects, reviewed
laboratory findings for toxicity, and was responsible for overall care”.
Page S4
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Endpoints were measured by “One examining neurologist who
was not aware of drug side effects”. Page S4
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IFNB MS Group 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals and losses to follow-up were difficult to find, and
different data were given in different articles about the same
trial. Specifically, 2 years after randomisation, withdrawals plus
losses to follow-up in the treated group were described as either
18 or 20 in the 1.6 million IU interferon group and as 24 or
25 in the 8 million IU group. Patients included into analysis in
the treated group were described as either 184 or 205 in the 1.6
million IU interferon group and as 244 or 255 in the 8 million
IU group
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
and those outcomes that were pre-speci ed in the methods sec-
tion
Other bias High risk “Sustained” disability progression was confirmed at 3 months’
follow-up. The role of the study sponsor was unclear
IMPACT 2002
Methods RCT
Participants Age: 18-55 years; clinical definite SPMS; progression not reported; EDSS 3.5-6.5; mean
disease duration 16 years
Interventions IFNß -1a (Avonex) 60 µg intramuscular injections weekly (n. 217)
Placebo (n. 219)
Outcomes Relapses at 24 months. Progression at 24 months.
Notes Funding: BIOGEN INC.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The contract research organization computer generated two mini-
mization schemes, one for North America and one for Europe and
Israel”. Page 680
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “A treating nurse and neurologist were responsible for clinical man-
agement of the subjects”. Page 680
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The examining neurologist was not involved with any other aspect
of subject care, and neither had access to the results of prior examina-
tions or to clinical information that might compromise blinding”.
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IMPACT 2002 (Continued)
Page 680
Incomplete outcome data (attrition bias)
All outcomes
High risk “Twenty-three (11%) subjects in the placebo group and 29 (13%)
subjects in the IFN-1a group failed to complete 24 months of follow-
up.The between-group difference in reason for study discontinuation
was subject request (six placebo subjects vs 16 IFN-1a subjects, p <
0.05)” Page 682
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up. Unclear the role of Biogen Inc. The FDA letters of July 23,
1998, December 6, 1999, and March 8, 2000 informed Biogen
that the primary study endpoint, the Multiple Sclerosis Func-
tional Composite (MSFC), is not a validated efficacy outcome
measure and therefore is not appropriate as a primary efficacy
endpoint in this Phase 3 study (FDA 2001)
INCOMIN 2002
Methods RCT
Participants Age: 18-50 years; clinical definite RRMS; mean disease duration 6 years; EDSS 1.0-3.
5; ≥ 2 relapses in the 2 years before randomisation; in remission at randomisation
Interventions IFNß -1b 250 µg subcutaneously every other day for 24 months (n. 96)
IFNß -1a (Avonex) 30 µg by weekly intramuscular injections for 24 months (n. 92)
Outcomes Relapses at 12 and 24 months. Progression at 24 months
Notes Funding: The Italian Ministry of Health and the Italian MS Society
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation followed computer-generated random sequences of
digits that were different for each centre and for each sex, to achieve
centre and sex stratification”. Page 1454
Allocation concealment (selection bias) Low risk “The codes were randomly assigned to treatments by an independent
team of statisticians unaware of the patient’s clinical characteristics”.
Page 1454
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “All clinical outcomes were assessed in an open-label manner”. Page
1454
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INCOMIN 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “All clinical outcomes were assessed in an open-label manner”. Page
1454
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up not included in analysis: IFNß -1a 4/92
(4%); IFNß -1b 2/96 (2%)
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias Low risk The study appears to be free of other sources of bias.
Johnson 1995
Methods RCT
Participants Age: 18-45 years; clinical or laboratory-supported definite RRMS; EDSS 0-5.0; ≥ 2
relapses in the 2 years before randomisation
Interventions Glatiramer acetate 20 mg subcutaneously every day (n. 125).
Placebo (n. 126)
Outcomes Relapses at 24 months. Progression at 24 months.
Notes Funding: Teva Pharmaceutical.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk “A centralized randomization scheme was used”. Page 1270
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Treating neurologists were blinded”. Page 1270
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Examining neurologists were blinded”. Page 1270
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals: glatiramer acetate = 19 (15%); placebo = 17 (13%)
.They were included in the analyses
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
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Johnson 1995 (Continued)
Other bias High risk “Sustained” disability progression confirmed at 3 months’ fol-
low-up
Knobler 1993
Methods RCT
Participants Age: 18-50 years; clinical definite RRMS; EDSS ≤ 5.5; disease duration ≥ 1 and ≤ 15
years; ≥ 2 relapses in the 2 years before randomisation; in remission at randomisation
Interventions IFNß -1b 25 µg subcutaneous three times weekly for three years (n. 6)
IFNß -1b 125 µg subcutaneous three times weekly for three years (n. 6)
IFNß -1b 250 µg subcutaneous three times weekly for three years (n. 6)
IFNß -1b 500 µg subcutaneous three times weekly for three years (n. 6)
Placebo for three years (n. 7)
Outcomes Relapses at 12 months
Notes Funding: Triton Biosciences, Inc., Alameda, CA and Berlex Laboratories Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “One treating neurologist not blinded”. Page 335
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An examining neurologist blinded to treatment arms”. Page
335
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals and losses to follow-up not described
Selective reporting (reporting bias) High risk Progression was not reported.
Other bias Unclear risk The role of the study sponsor was unclear.
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Koch-Henriksen 2006
Methods RCT
Participants Age: 18-55 years; clinical definite RRMS; disease duration 0-35; ≥ 2 relapses within 2
years before randomisation; EDSS ≤ 5.5
Interventions IFNß -1b 250 µg subcutaneous every other day for 24 months. (n. 158)
IFNß -1a (Rebif ) 22 µg subcutaneous weekly for 24 months (n. 143)
Outcomes Progression at 24 months
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk “A central computerized randomization schedule assigned patients
to treatment”. Page 1057
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial. “Blinding was abandoned because it could not
be maintained owing to the different administration schemes of the
two study drugs”. Page 1057
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label trial. Page 1057
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up not included in analysis: IFNß -1b 28%;
IFNß -1a 23%
Selective reporting (reporting bias) High risk Relapses were not reported.
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up. Is is unclear if the study was sponsored
Leary 2003
Methods RCT
Participants Age: 25-59 years; definite PPMS; disease duration 2-21 years; EDSS 2.0-7.0
Interventions IFNß-1a (Avonex) 30 µg intramuscular weekly for 24 months (n. 15)
IFNß-1a (Avonex) 60 µg intramuscular weekly for 24 months (n. 15)
Placebo for 24 months (n. 20)
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Leary 2003 (Continued)
Outcomes Progression at 24 months
Notes Funding: BIOGEN
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The randomization was carried out off-site by Biogen using a ran-
domization block method.”Page 44
Allocation concealment (selection bias) Low risk “The study drug was blinded off-site by Biogen and delivered to the
study centre with the study numbers already allocated. Subjects were
allocated by study number consecutively as they were entered into
the study. A copy of the randomization codes was kept in pharmacy
and by Biogen, but no codes were broken until the study and analysis
was completed”.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “All personnel at the study site (dispensing pharmacists, treating
physicians and EDSS physicians) were blinded to the study drug.”
Page 44
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “EDSS and clinical assessments were performed by an independent
evaluating physician blinded to all clinical information.” Page 44
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one patient (arm IFN 60µg ) was lost to follow-up.
Selective reporting (reporting bias) High risk Relapses were not reported.
Other bias High risk “Sustained” disability progression was confirmed at 3 months’
follow-up. Funding: Biogen, Multiple Sclerosis Society of Great
Britain and Northern Ireland
Lewanska 2002
Methods RCT
Participants Age: 18-55 years; clinical definite RRMS; EDSS 0-6.5; mean disease duration >2 years;
≥ 2 relapses in the 2 years before randomisation
Interventions Intravenous immunoglobulins 0.2 g/kg/body weight intravenous monthly for 12
months.(n. 17)
Intravenous immunoglobulins 0.4 g/kg/bodyweight intravenousmonthly for 12months
(n. 16)
Placebo (saline) for 12 months (n. 18)
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Lewanska 2002 (Continued)
Outcomes Relapses at 12 months
Notes Funding: Supported by the KBN (State Research Committee)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The generation of allocation sequence was based on random-num-
ber table.” Page 566
Allocation concealment (selection bias) Unclear risk Infusions of intravenous immunoglobulins and placebo were
stored in identical opaque plastic bags for concealment during
administration. No more information about treatment alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Infusions of intravenous immunoglobulinsand placebo were
stored in identical opaque plastic bags for concealment.” Page 566
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Evaluating physician was unaware of the actual treatment alloca-
tion...Monitoring and recording of relapses, con-
comitant treatment, side-e ects or other medical events were docu-
mented throughout the study.” Page 566
Incomplete outcome data (attrition bias)
All outcomes
Low risk 49 patients completed the trial: 15/16 in the intravenous im-
munoglobulins 0.4 g/kg arm; 17/17 in the intravenous im-
munoglobulins 0.2 g/kg arm; 17/18 in the placebo arm
Selective reporting (reporting bias) High risk Progression was not reported.
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up. Supported by the KBN (State Research
Committee).
Likosky 1991
Methods RCT
Participants Age: 18-60 years; SPMS, PPMS or PRMS; progression ≥ 1.0 EDSS in the year before
randomisation; disease duration 1-29 years; EDSS 2.0-7.0
Interventions “short course” of cyclophosphamide 500 mg administered intravenously five days per
week; (n. 22)
Folic acid (1 mg) administered intravenously five days per week (n. 21)
Outcomes Progression at 24 months
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Likosky 1991 (Continued)
Notes Funding: The Community Service Program of Kaiser Foundation Hospitals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Evaluating physicians were unaware of the treatment status of the
patients they evaluated”. Page 1056
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up not included in the study analysis: treatment
3/22 (15%); placebo 3/21 (14%). Losses appear to be balanced
between the groups
Selective reporting (reporting bias) Low risk The published report included expected efficacy outcome.
Other bias Unclear risk Definition of sustained disability progression not clearly re-
ported
“The research was supported in part by the Community Service Pro-
gram of Kaiser FoundationHospitals. Evansville, Indiana, provided
cyclophosphamide as Cytoxan.” Page 1060
Milanese 1993
Methods RCT
Participants Mean age: 30 years; definite RRMS, SPMS or PPMS; disease duration 5-15 years; EDSS
2.5-6.5; ≤ 1 relapses in the 2 years before randomisation
Interventions Azathioprine 2.5 mg/Kg/body weight oral daily for 3 years (n. 19)
Placebo (lactose) in identical form (50 mg tablets) for three years (n. 21)
Outcomes Relapses at 12, 24 and 36 months. Progression at 24 and 36 months
Notes Funding: Wellcome Company.
Risk of bias
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Milanese 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Wellcome Italia provided the randomisation code”. Page 295
Allocation concealment (selection bias) Unclear risk “Patients were allocated to azathioprineor placebo groups according
to a list of random code numbers”. Page 295
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “azathioprineand placebo tablets in identical form were supplied
by Wellcome Company”. Page 295
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “EDSS and relapses evaluated by the same blinded neurologist”.
Page 295
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up not included in the study analysis: azathio-
prine 26%; placebo 14%
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up. Funding: Wellcome Company
Millefiorini 1997
Methods RCT
Participants Age: 18-45 years; clinical or laboratory-supported definite RRMS; disease duration 1-
10 years; EDSS 2.0-5.0; ≥ 1 relapses in the 2 years before randomisation
Interventions 12 pulses of mitoxantrone 8 mg/m²/body surface every month for 1 year (total dosage
of 96 mg/m2 of body surface over 1 year) (n. 27)
Placebo (n. 24)
Outcomes Relapses at 12 and 24 months, Progression at 24 months
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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Millefiorini 1997 (Continued)
Allocation concealment (selection bias) Low risk ”Central allocation and the intravenous bag and tubing were black
to ensure no differences between the treatment groups.“ Page 154.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treating physicians were not blinded. Unclear blinding of pa-
tients
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ”The interaction of the EDSS physicians with the patient was strictly
restricted to the neurological examination. The neurologist was not
allowed to talk with the patient about adverse events, or any other
issue which could potentially disclose the patient’s treatment...The
assessment of exacerbations was monitored by treating physicians not
blinded to study treatment.” Page 154, 157
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients were included in the analysis.
Selective reporting (reporting bias) Low risk The published reports included all expected efficacy outcomes
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up. It’s unclear if this study was sponsored
Miller 1961
Methods RCT
Participants Mean age: 33 years; SPMS, or PRMS; mean disease duration 10-13 years; EDSS not
reported
Interventions Prednisolone tablets 15 mg oral daily for 8 months then 10 mg/day for 10 months (n.
29)
Calcium aspirin 9 tablets (54 g) oral daily (n. 27)
Placebo corresponding number of “dummy” tablets (n. 30)
Outcomes Progression at 24 months
Notes No funding.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Miller 1961 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not clearly described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clearly described
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up: prednisolone 3/29 (10%); “dummy” tablets
1/30 (3%); calcium aspirin 3/27 (11%)
Selective reporting (reporting bias) Low risk The published report included the expected efficacy outcome.
Other bias Unclear risk Definition of sustained disability progression not clearly re-
ported
Montalban 2009
Methods RCT
Participants Age: 18-65 years; definite PPMS or “transitional” MS; mean disease duration 11 years;
EDSS 3.0-7.0
Interventions IFNß -1b 250 µg subcutaneously every other day for 2 years (n. 36)
Placebo for 2 years (n. 37)
Outcomes Progression at 24 months
Notes Funding: SCHERING ESPANA S.A
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...Using a randomisation list. This randomization was performed
in blocks of 6 and for each treatment was assigned in a 1:1 ratio”.
Page 1196
Allocation concealment (selection bias) Unclear risk Not clearly described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All personnel at the study site (dispensing pharmacists, treating
physicians and participants) were blinded to the outcome assessment
and study drug.” Page 1197
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “EDSS physicians were blinded to the outcome assessment and study
drug.” Page 1197
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Montalban 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 patients dropped out the study: 1 in the IFNß -1b arm; 2 in
the placebo arm
Selective reporting (reporting bias) Low risk The published report included the expected efficacy outcome.
Other bias High risk “An external company (MDS Pharma Services Espana) named and
funded by the study sponsor produced the statistical analyses under
supervision from the principal investigator”.
MSCRG 1996
Methods RCT
Participants Age: 18-55 years; definite RRMS; EDSS 1-3.5; disease duration≥ 1 year;≥ 2 relapses in
the 3 years before randomisation; no relapses for at least 2 months before randomisation
Interventions IFNß-1a (Avonex) 30 µg intramuscular weekly (n. 158).
Placebo (n. 143).
Outcomes Relapses at 12 and 24 months. Progression at 24 months.
Notes Funding: Biogen, Inc, Cambridge, MA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomisation performed at statistical centre of Buffalo General
Hospital, one of the participating centres (biased coin assignment
used for sequence generation”. Page 286
Allocation concealment (selection bias) Unclear risk “schedule sent to each clinical centre, included patients were sequen-
tially assigned the next ID number from the schedule.” Page 286
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Personnel and participants were blinded to treatment status.” Page
286
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Evaluating physicians were blinded to treatment status.” Page 286
Incomplete outcome data (attrition bias)
All outcomes
High risk The study stopped early for benefit without a formal-stopping
rule. 73 (46%) of 158 patients in the treatment group and 56
(39%) of 143 controls had not completed the scheduled 2 years
of follow-up. At 2 years’ follow-up primary outcomes were avail-
able for only 57% of randomised participants
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MSCRG 1996 (Continued)
Selective reporting (reporting bias) Low risk Expected efficacy outcomes were reported.
Other bias High risk “Supported by National Institutes of Health, National Institute of
NeurologicalDisorders and Stroke (NINDS) andBiogen, Inc, Cam-
bridge, MA. Personnel of the study sponsor (Biogen) were involved
in the conduct and data analysis”. Page 293
NASP 2004
Methods RCT
Participants Age 18-65 years, clinically definite SPMS of at least 2 years’ duration; ≥ 1.0 EDSS
increase in the 2 years before randomisation; ≥ 1.0 relapses followed by progressive
deterioration sustained for at least 6 months; EDSS 3.0-6.5
Interventions IFNß -1b (Betaseron) 250 µg subcutaneously every other day (n. 317)
INFß -1b (Betaseron) 160 µg/m² body surface area (mean administered dose 220 µg)
every other day (n. 314)
Placebo (n. 308)
Outcomes Relapses at 36 months. Progression at 36 months.
Notes Funding: Berlex Laboratories (Richmond, CA)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation schedule was generated by the Biostatistics and
Data Management Group of Berlex Laboratories (Richmond, CA)
using an SAS program (Cary, NC)... Each block allocated 2 subjects
to fixed-dose Betaseron, 2 to Body Surface Area (BSA)-adjusted
Betaseron, 1 to fixed placebo, and 1 to BSA-adjusted placebo. Each
site received an adequate number of blocks, based on projected subject
recruitment, to ensure sequential subject numbering within each
site.” Page 1789
Allocation concealment (selection bias) Low risk “The biostatistician and supporting programmers were the only in-
dividuals with access to the randomisation codes” (FDA page 9).
“The active study drug was indistinguishable from placebo in ap-
pearance, smell and color, and labels and packages for active study
agent and placebo were indistinguishable” (FDA page 9)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All sponsor personnel directly involved in the conduct of the study,
investigators, and subjects remained blinded to subject treatment
assignment throughout the study”. (FDA page 9)
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NASP 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Investigators remained blinded to subject treatment assignment
throughout the study”. (FDA page 9)
Incomplete outcome data (attrition bias)
All outcomes
High risk “The study had ended prematurely based on the results of a planned
interim analysis indicating that ”continuing the trial was unlikely
to change the results“. The study initiated in August 2, 1995, in-
terrupted November 22, 1999. The last patient enrolled on April
1, 1997. The final patient visit occurred on November 15, 1999”.
(FDA report page 21). “Only 72% of randomised patients com-
pleted 33 months or more on study and could be included in anal-
ysis” (FDA 2001 page 26).
Selective reporting (reporting bias) Unclear risk The published reports included relapses and progression at 36
months (no data at 24 months)
Other bias High risk Funding: Berlex Laboratories (Richmond, CA).
OWIMS 1999
Methods RCT
Participants Age: 18-50 years; clinical or laboratory-supported definite RRMS; EDSS 0-5.0; disease
duration ≥ 1 year; ≥ 1 relapses in the 2 years before randomisation; no relapses for at
least 2 months before randomisation
Interventions IFNß -1a (Rebif ) 22 µg subcutaneous three times/week for 48 weeks (n. 95)
IFNß -1a (Rebif ) 44 µg subcutaneous three times/week for 48 weeks (n. 98)
Placebo (human albumin and mannitol) for 48 weeks (n. 100)
Outcomes Relapses at 12 months
Notes Funding: Ares-Serono International SA, Geneva, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation performed at Corporate Biometrics Department of
Ares-Serono (computer-generated list).” Page 680
Allocation concealment (selection bias) Unclear risk “Sealed envelopes were used but it was unclear whether envelopes
were sequentailly numbered and opaque.” Page 680
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants were blinded to treatment” Page 681
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OWIMS 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The evaluating physician was responsible for neurologic assessments
and remained unaware of adverse event profiles and any changes in
safety assessments.” Page 681
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up: treatment arms 13% and 8%; placebo arm
3%. Reason for missing data was likely related to outcome with
imbalance in numbers across intervention groups
Selective reporting (reporting bias) High risk Only relapses at 12 months were reported.
Other bias High risk Sponsored by Ares-Serono International SA, Geneva, Switzer-
land
Pohlau 2007
Methods
Participants Age: 18-65 years; SPMS, or PPMS; progression ≥ 0.5 EDSS point in the year before
randomisation; disease duration > 2 years; EDSS 3.0-7.0
Interventions IVIg 0.4 gm/kg body weight intravenous monthly (n. 116).
Placebo (n. 115).
Outcomes Progression at 24 months.
Notes Fundings: Novartis Pharma GmbH and ZLB Behring.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was performed by the Biometric Department No-
vartis Germany using a scheme, which provided balanced blocks of
patient numbers for both treatment groups and the two diagnostic
layers.” Page 1109
Allocation concealment (selection bias) Unclear risk Not clearly described. Only “randomly assigned” Page 1109
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not clearly described. Only “intravenous immunoglobulinsand
placebo could not visually be distinguished.” Page 1109
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Pohlau 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “113 patients (49%) completed the 112 weeks of the study, and 118
(51%) discontinued their participation prematurely.” Page 1110
. Follow-up of the participants who discontinued participation
was not reported
Selective reporting (reporting bias) Low risk Progression at 24 months is the expected efficacy outcome.
Other bias High risk Sustained disability progression confirmed at 16 weeks’ follow-
up. Supported by Novartis Pharma GmbH, Nürnberg, Ger-
many and ZLB Behring, Bern Switzerland
PRISMS 1998
Methods RCT
Participants Age: 28-41 years; clinical or laboratory-supported definite RRMS; EDSS 0-5.0; disease
duration ≥ 1 year; at least 2 relapses in the 2 years before randomisation
Interventions IFNß -1a (Rebif ) 22 µg subcutaneous three times/week for 2 years (n. 189)
IFNß -1a (Rebif ) 44 µg subcutaneous three times/week for 2 years (n. 184)
Placebo (unspecified) for 2 years (n. 187)
Outcomes Relapses at 12 and 24 months. Progression at 24 months
Notes Fundng: Ares-Serono International SA, Geneva, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation at Corporate Biometrics Department of Ares-
Serono (computer-generated list, stratified by centre, equal alloca-
tion of the treatment groups by a block size of 6).” Page 1499
Allocation concealment (selection bias) Low risk “The study drug was packed accordingly to the randomisation list
and delivered to the centres so that treatment allocation remained
concealed”. Page 1499
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All personnel involved in the study were unaware of treatment
allocation”. Page 1499
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All personnel involved in the study were unaware of treatment al-
location. All injection sites were covered up at neurological exam-
inations to ensure that masking was not compromised because of
local reactions”. Page 1499
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PRISMS 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up excluded from study analysis: treatment arms
6% and 3%; placebo arm 5%
Selective reporting (reporting bias) Low risk The published report included all expected efficacy outcomes
Other bias High risk “Sustained” disability progression was confirmed at 3 months’
follow-up. Ares-Serono was involved in the trial
REGARD 2008
Methods RCT
Participants Mean age: 37 years; clinical or laboratory-supported definite RRMS; EDSS 0-5.5; mean
disease duration 6 years; ≥ 1 relapses in the year before randomisation
Interventions IFNß -1a (Rebif ) 44 µg subcutaneous three times/week for 96 weeks (n. 386)
Glatiramer acetate 20 mg subcutaneous every day for 96 weeks (n. 378)
Outcomes Relapses at 24 months. Progression at 24 months
Notes Funding: EMD Serono and P zer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomisation list stratified by centre”. Page
904
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Neither the patients nor the treating physicians were blinded to
treatment.” Page 904
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The physicians who assessed patients ...were blinded to treatment
and communicated with the patients only as needed to complete
the EDSS, Kurtzke functional scale (KFS), and relapse assessments.
Patients were asked not to discuss their treatment with the assessing
physician and they covered their injection sites.” Page 904
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up: IFNß -1a 20/386 (5%); glatiramer acetate
5/378 (1%)
Selective reporting (reporting bias) Low risk The published report included all expected efficacy outcomes
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REGARD 2008 (Continued)
Other bias High risk “The study protocol was drafted and developed by the study
sponsors, EMD Serono and P zer, in conjunction with the in-
vestigator steering committee. Data management and analysis
were done by the study sponsors.” Page 907
SENTINEL 2006
Methods RCT
Participants Age: 18-55 years; clinical definite RRMS; disease duration 1-34 years; EDSS 0-5.0; ≥ 1
relapses in the year before randomisation
Interventions Natalizumab 300 mg intravenous monthly and IFNß-1a (Avonex) 30 µg intramuscular
weekly for 116 weeks.(n. 589)
Placebo and IFNß-1a (Avonex) 30 µg intramuscular weekly for 116 weeks.(n. 582)
Outcomes Relapses at 12 and 24 months. Progression at 24 months
Notes Funding: Biogen Idec, Inc. and Elan Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was stratified according to study site in blocks of
four (two active and two placebo) with the use of a computer-
generated schedule and a multidigit identification number”. Page
912
Allocation concealment (selection bias) Low risk “An interactive voice-response system was used”. Page 912
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All study personnel, patients, sponsor personnel involved in the
conduct of the study, and members of the investigator advi-
sory committee were blinded to the treatment assignments through-
out the study.” Page 912 “The treating neurologists were responsible
for all patient care, including the management of adverse events and
relapses of multiple sclerosis”. Page 913
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Examining neurologists performed the EDSS and neurologic ex-
aminations but were otherwise not involved in the patients’ medical
care.” Page 913
Incomplete outcome data (attrition bias)
All outcomes
Low risk 516/589 (88%) in the natalizumab + IFNß-1a group and 487/
582 (84%) in the placebo+ IFNß-1a group completed the 120-
week study
Selective reporting (reporting bias) Low risk The published report included all expected efficacy outcomes
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SENTINEL 2006 (Continued)
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up
The study protocol was developed by the investigator advisory
committee and the sponsors (Biogen Idec and Elan Pharmaceu-
ticals). Datawere analyzed by the sponsor. Relapses were assessed
also as adverse events
SPECTRIMS 2001
Methods RCT
Participants Age: 18-55 years; clinical definite SPMS; progression ≥ 1 EDSS over the previous 2
years, with or without superimposed relapses before randomisation; EDSS 3.0-6.5; mean
disease duration 14 years
Interventions IFNß -1a (Rebif ) 22 µg subcutaneous three times/week for 3 years (n. 209)
IFNß -1a (Rebif ) 44 µg subcutaneous three times/week for 3 years (n. 204)
Placebo (unspecified) for 3 years (n. 205)
Outcomes Progression at 24 and 36 months
Notes Funding: Serono International, Geneva, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated randomisation list provided by Serono, strat-
ified by center; treatments were equally allocated with a block size
of six”. Page 1497
Allocation concealment (selection bias) Unclear risk “The block size was not revealed to the investigators. The manu-
facturer labelled containers of study medication with patient iden-
tification numbers based on the randomisation list, and patients
received the medication labelled with their numbers.” Page 1497
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “A treating physician supervised drug administration, monitored
safety, and managed adverse events”. Page 1497
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A separate evaluating physician conducted neurologic assessments
and followed-up exacerbations. Patients were instructed to cover in-
jection sites and to discuss only neurologic matters during neurologic
evaluations. Clinical and neurologic data
were recorded in separate binders.” Page 1497
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SPECTRIMS 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 195/209 (93%) in the IFNß -1a 22 µg group, 190/204 (93%)
in the IFNß -1a 44µg group and 186/205 (91%) in the placebo
group completed 3 years’ follow-up
Selective reporting (reporting bias) Low risk The published report included all expected efficacy outcomes
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up. Serono Biometrics (Geneva) performed statistical analysis
Wolinsky 2007
Methods RCT
Participants Age: 30-65 years; definite chronic progressive MS; EDSS 3.0-6.5; progression ≥ 6
months; ≤ 2 relapses in the 2 years before randomisation
Interventions Glatiramer acetate 20 mg subcutaneous every day for 3 years (n. 627)
Placebo (unspecified) for 3 years (n. 316)
Outcomes Progression at 24 months
Notes Funding: Teva Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “All patients were attended by a treating neurologist and an ex-
amining neurologist who were blinded to treatment. The treating
neurologist supervised drug administration, recorded and treated
adverse events, and coordinated MRI testing.” Page 16
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “... examining neurologist was blinded to treatment.” Page 16
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study stopped early for futility. 376/627 (60%) of participants in
the glatiramer acetate group and 186/315 (59%) in the placebo
group had received study drugs for 24 months. Insufficient in-
formation to judge whether withdrawals and lost to follow-up
were included in data analysis
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Wolinsky 2007 (Continued)
Selective reporting (reporting bias) Unclear risk Progression at 24 months was reported.
Other bias High risk Sustained disability progression confirmed at 3 months’ follow-
up. Funding: Teva Pharmaceutical
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnason 1999 Study on TNF neutralization (Lenercept).
Barkhof 2003 ETOMS trial MRI subgroup analysis.
Baum 2006 Study evaluating two formulations of interferon b (IFNbeta-1b-G or the refrigeration-free formulation
(IFNbeta-1b-M) without a control group
BENEFIT 2006 Study on interferon beta 1b for clinically isolated syndromes (CIS)
Boiko 2001 Trial on short course of antibodies to IFN gamma or antibodies to tumour necrosis factor alpha
Burton 2009 A Cochrane review on oral versus Intravenous steroids for treatment of relapses in multiple sclerosis
CHAMPS 2000 Study on interferon beta 1a for clinically isolated syndromes (CIS)
Christodoulou 2006 Study on donepezil.
Clanet 2002 A dose-comparison study of interferon beta-1a without a control group
Durelli 1994 Study on interferon alfa for multiple sclerosis.
ETOMS 2001 Study on interferon beta 1a for clinically isolated syndromes (CIS)
Fernandez 2002 Prospective study evaluating combination therapy with interferon beta 1b and azathioprine in MS
Filippi 2004 ETOMS trial MRI subgroup analysis.
Filippi 2006 Study on oral glatiramer acetate for multiple sclerosis.
GLANCE 2009 Active treatment with natalizumab was confounded by glatiramer acetate
Goodkin 2000 Study on complex of human leukocyte antigen-DR2 with myelin basic protein84-102
Hauser 1983 Active treatment with cyclophosphamide was confounded by other treatments
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(Continued)
Hoogervorst 2002 A phase II study evaluating the safety, tolerability and MRI effects of oral interferon beta-1a
Labetouelle 2001 Review about CHAMPS study.
Liu 2010 A Cochrane review on daclizumab for multiple sclerosis.
Myhr 1999 Study on interferon alfa for multiple sclerosis.
Patti 1999 Study on natural interferon beta derived from human fibroblasts (Ares-Serono@)
Rio 2007 Open label, non-randomised, observational study.
Skurkovich 2001 A trial comparing antibodies to TNF-a, to IFN-γ and placebo.
Steultjens 2003 A Cochrane review on occupational therapy for multiple sclerosis
Tejani 2010 A Cochrane review on carnitine for fatigue in multiple sclerosis
Tubridy 1999 Study on natalizumab with a dosage of 3 mg/kg.
Van de Wyngaert 2001 Study on mitoxantrone in which participants’ inclusion criteria were not described
Wender 1988 Active treatment with cyclophosphamide was confounded by other treatments
Zavalishin 2003 Multicentre non-randomised study evaluating the effect of interferon alfa
Zivadinov 2001 A dose-comparison trial of long-term corticosteroids without a control group
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D A T A A N D A N A L Y S E S
Comparison 1. Comparisons for relapse over 12 months
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse over 12 months in MS
of all types
21 Odds Ratio (IV, Random, 95% CI) Subtotals only
1.1 IFNß-1b (Betaseron)
versus placebo
1 25 Odds Ratio (IV, Random, 95% CI) 0.6 [0.10, 3.49]
1.2 IFNß-1a (Avonex) versus
placebo
1 301 Odds Ratio (IV, Random, 95% CI) 0.72 [0.45, 1.14]
1.3 IFNß-1a (Rebif ) versus
placebo
2 853 Odds Ratio (IV, Random, 95% CI) 0.66 [0.25, 1.78]
1.4 Glatiramer acetate versus
placebo
2 289 Odds Ratio (IV, Random, 95% CI) 0.34 [0.06, 2.05]
1.5 Natalizumab versus
placebo
1 942 Odds Ratio (IV, Random, 95% CI) 0.38 [0.28, 0.51]
1.6 Mitoxantrone versus
placebo
1 51 Odds Ratio (IV, Random, 95% CI) 0.14 [0.04, 0.48]
1.7 Azathioprine versus
placebo
4 547 Odds Ratio (IV, Random, 95% CI) 0.63 [0.44, 0.89]
1.8 Immunoglobulins versus
placebo
4 537 Odds Ratio (IV, Random, 95% CI) 0.56 [0.20, 1.60]
1.9 Corticosteroids versus
placebo
1 36 Odds Ratio (IV, Random, 95% CI) 0.46 [0.12, 1.84]
1.10 IFNß-1a (Avonex) versus
IFNß-1b (Betaseron)
1 188 Odds Ratio (IV, Random, 95% CI) 1.53 [0.86, 2.72]
1.11 IFNß-1a (Rebif ) versus
IFNß-1a (Avonex)
1 677 Odds Ratio (IV, Random, 95% CI) 0.79 [0.58, 1.07]
1.12 Natalizumab versus
IFNß-1a (Avonex)
1 1171 Odds Ratio (IV, Random, 95% CI) 0.40 [0.32, 0.51]
1.13 Corticosteroids versus
Mitoxantrone
1 42 Odds Ratio (IV, Random, 95% CI) 4.0 [1.11, 14.43]
2 Relapse over 12 months in
relapsing-remitting MS
16 4806 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.49, 0.62]
2.1 IFNß-1b (Betaseron)
versus placebo
1 25 Odds Ratio (M-H, Fixed, 95% CI) 0.6 [0.10, 3.49]
2.2 IFNß-1a (Avonex) versus
placebo
1 301 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.45, 1.14]
2.3 IFNß-1a (Rebif ) versus
placebo
2 853 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.43, 0.81]
2.4 Glatiramer acetate versus
placebo
2 289 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.37, 0.93]
2.5 Natalizumab versus
placebo
1 942 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.28, 0.51]
2.6 Mitoxantrone versus
placebo
1 51 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.04, 0.48]
88Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.7 Azathioprine versus
placebo
1 54 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.25, 2.38]
2.8 Immunoglobulins versus
placebo
3 219 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.38, 1.21]
2.9 Corticosteroids versus
placebo
1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.12, 1.84]
2.10 IFNß-1a (Avonex) versus
IFNß-1b (Betaseron)
1 188 Odds Ratio (M-H, Fixed, 95% CI) 1.53 [0.86, 2.72]
2.11 IFNß-1a (Rebif ) versus
IFNß-1a (Avonex)
1 677 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.58, 1.07]
2.12 Natalizumab versus
IFNß-1a (Avonex)
1 1171 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.32, 0.51]
3 Relapse over 12 months in
progressive MS
3 459 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.70, 1.54]
3.1 Azathioprine versus
placebo
1 99 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.16, 1.12]
3.2 Immunoglobulins versus
placebo
1 318 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.66, 1.68]
3.3 Corticosteroids versus
Mitoxantrone
1 42 Odds Ratio (M-H, Fixed, 95% CI) 4.0 [1.11, 14.43]
Comparison 2. Comparisons for relapse over 24 months
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse over 24 months in MS
of all types
25 Odds Ratio (IV, Random, 95% CI) Subtotals only
1.1 IFNß-1b (Betaseron)
versus placebo
1 372 Odds Ratio (IV, Random, 95% CI) 0.55 [0.31, 0.99]
1.2 IFNß-1a (Avonex) versus
placebo
2 737 Odds Ratio (IV, Random, 95% CI) 0.76 [0.56, 1.05]
1.3 IFNß-1a (Rebif ) versus
placebo
1 560 Odds Ratio (IV, Random, 95% CI) 0.45 [0.28, 0.71]
1.4 Glatiramer acetate versus
placebo
2 301 Odds Ratio (IV, Random, 95% CI) 0.49 [0.18, 1.36]
1.5 Natalizumab versus
placebo
1 942 Odds Ratio (IV, Random, 95% CI) 0.32 [0.24, 0.43]
1.6 Mitoxantrone versus
placebo
2 245 Odds Ratio (IV, Random, 95% CI) 0.35 [0.09, 1.42]
1.7 Azathioprine versus
placebo
5 737 Odds Ratio (IV, Random, 95% CI) 0.64 [0.44, 0.94]
1.8 Immunoglobulins versus
placebo
4 705 Odds Ratio (IV, Random, 95% CI) 0.70 [0.40, 1.22]
1.9 Corticosteroids versus
placebo
1 36 Odds Ratio (IV, Random, 95% CI) 1.13 [0.06, 19.50]
1.10 Methotrexate versus
placebo
1 60 Odds Ratio (IV, Random, 95% CI) 1.15 [0.31, 4.28]
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1.11 IFNß-1a (Avonex) versus
IFNß-1b (Betaseron)
2 248 Odds Ratio (IV, Random, 95% CI) 2.26 [1.33, 3.83]
1.12 IFNß-1a (Rebif ) versus
IFNß-1a (Avonex)
1 60 Odds Ratio (IV, Random, 95% CI) 0.19 [0.06, 0.60]
1.13 Natalizumab versus
IFNß-1a (Avonex)
1 1171 Odds Ratio (IV, Random, 95% CI) 0.28 [0.22, 0.36]
1.14 IFNß-1a (Rebif ) versus
Interferon beta 1b
1 60 Odds Ratio (IV, Random, 95% CI) 0.58 [0.21, 1.62]
1.15 Glatiramer acetate versus
IFNß-1b (Betaseron)
1 2244 Odds Ratio (IV, Random, 95% CI) 1.05 [0.85, 1.29]
1.16 Glatiramer acetate versus
IFNß-1a (Rebif )
1 764 Odds Ratio (IV, Random, 95% CI) 0.93 [0.69, 1.25]
2 Relapse over 24 months in
relapsing-remitting MS
16 Odds Ratio (IV, Random, 95% CI) Subtotals only
2.1 IFNß-1b (Betaseron)
versus placebo
1 372 Odds Ratio (IV, Random, 95% CI) 0.55 [0.31, 0.99]
2.2 IFNß-1a (Avonex) versus
placebo
1 301 Odds Ratio (IV, Random, 95% CI) 0.83 [0.46, 1.49]
2.3 IFNß-1a (Rebif ) versus
placebo
1 560 Odds Ratio (IV, Random, 95% CI) 0.45 [0.28, 0.71]
2.4 Glatiramer acetate versus
placebo
2 301 Odds Ratio (IV, Random, 95% CI) 0.49 [0.18, 1.36]
2.5 Natalizumab versus
placebo
1 942 Odds Ratio (IV, Random, 95% CI) 0.32 [0.24, 0.43]
2.6 Mitoxantrone versus
placebo
1 51 Odds Ratio (IV, Random, 95% CI) 0.15 [0.04, 0.54]
2.7 Azathioprine versus
placebo
1 59 Odds Ratio (IV, Random, 95% CI) 0.36 [0.11, 1.21]
2.8 Immunoglobulins versus
placebo
2 190 Odds Ratio (IV, Random, 95% CI) 0.22 [0.03, 1.90]
2.9 Corticosteroids versus
placebo
1 36 Odds Ratio (IV, Random, 95% CI) 1.13 [0.06, 19.50]
2.10 IFNß-1a (Avonex) versus
IFNß-1b (Betaseron)
2 248 Odds Ratio (IV, Random, 95% CI) 2.26 [1.33, 3.83]
2.11 IFNß-1a (Rebif ) versus
IFNß-1a (Avonex)
1 60 Odds Ratio (IV, Random, 95% CI) 0.19 [0.06, 0.60]
2.12 Natalizumab versus
IFNß-1a (Avonex)
1 1171 Odds Ratio (IV, Random, 95% CI) 0.28 [0.22, 0.36]
2.13 IFNß-1a (Rebif ) versus
IFNß-1b (Betaseron)
1 60 Odds Ratio (IV, Random, 95% CI) 0.58 [0.21, 1.62]
2.14 Glatiramer acetate versus
IFNß-1b (Betaseron)
1 2244 Odds Ratio (IV, Random, 95% CI) 1.05 [0.85, 1.29]
2.15 Glatiramer acetate versus
IFNß-1a (Rebif )
1 764 Odds Ratio (IV, Random, 95% CI) 0.93 [0.69, 1.25]
3 Relapse over 24 months in
progressive MS
6 Odds Ratio (IV, Random, 95% CI) Subtotals only
3.1 IFNß-1a (Avonex) versus
placebo
1 436 Odds Ratio (IV, Random, 95% CI) 0.74 [0.51, 1.08]
3.2 Mitoxantrone versus
placebo
1 194 Odds Ratio (IV, Random, 95% CI) 0.65 [0.35, 1.20]
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3.3 Azathioprine versus
placebo
1 99 Odds Ratio (IV, Random, 95% CI) 0.56 [0.24, 1.33]
3.4 Immunoglobulins versus
placebo
2 515 Odds Ratio (IV, Random, 95% CI) 0.93 [0.66, 1.32]
3.5 Methotrexate versus
placebo
1 60 Odds Ratio (IV, Random, 95% CI) 1.15 [0.31, 4.28]
Comparison 3. Comparisons for relapse over 36 months
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse over 36 months in MS
of all types
6 Odds Ratio (IV, Random, 95% CI) Subtotals only
1.1 IFNß-1b (Betaseron)
versus placebo
2 1657 Odds Ratio (IV, Random, 95% CI) 0.71 [0.56, 0.90]
1.2 IFNß-1a (Rebif ) versus
placebo
1 371 Odds Ratio (IV, Random, 95% CI) 1.28 [0.85, 1.93]
1.3 Azathioprine versus
placebo
3 493 Odds Ratio (IV, Random, 95% CI) 0.45 [0.27, 0.76]
Comparison 4. Comparisons for disability progression over 24 months
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disability progression over 24
months in MS of all types
30 Odds Ratio (IV, Random, 95% CI) Subtotals only
1.1 IFNß-1b (Betaseron)
versus placebo
2 445 Odds Ratio (IV, Random, 95% CI) 0.89 [0.59, 1.36]
1.2 IFNß-1a (Avonex) versus
placebo
3 787 Odds Ratio (IV, Random, 95% CI) 0.94 [0.71, 1.25]
1.3 IFNß-1a (Rebif ) versus
placebo
2 1178 Odds Ratio (IV, Random, 95% CI) 0.71 [0.56, 0.92]
1.4 Glatiramer acetate versus
placebo
4 1350 Odds Ratio (IV, Random, 95% CI) 0.76 [0.49, 1.17]
1.5 Natalizumab versus
placebo
1 942 Odds Ratio (IV, Random, 95% CI) 0.56 [0.42, 0.74]
1.6 Mitoxantrone versus
placebo
2 245 Odds Ratio (IV, Random, 95% CI) 0.34 [0.08, 1.44]
1.7 Azathioprine versus
placebo
3 284 Odds Ratio (IV, Random, 95% CI) 0.77 [0.48, 1.24]
1.8 Immunoglobulins versus
placebo
4 739 Odds Ratio (IV, Random, 95% CI) 0.78 [0.48, 1.25]
1.9 Cyclophosphamide versus
placebo
1 44 Odds Ratio (IV, Random, 95% CI) 0.80 [0.22, 2.94]
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1.10 Corticosteroids versus
placebo
1 86 Odds Ratio (IV, Random, 95% CI) 1.58 [0.64, 3.87]
1.11 Methotrexate versus
placebo
1 60 Odds Ratio (IV, Random, 95% CI) 0.67 [0.24, 1.87]
1.12 IFNß-1a (Avonex) versus
IFNß-1b (Betaseron)
1 188 Odds Ratio (IV, Random, 95% CI) 2.88 [1.43, 5.79]
1.13 IFNß-1a (Rebif ) versus
IFNß-1b (Betaseron)
1 301 Odds Ratio (IV, Random, 95% CI) 0.98 [0.62, 1.54]
1.14 Natalizumab versus
IFNß-1a (Avonex)
1 1171 Odds Ratio (IV, Random, 95% CI) 0.62 [0.49, 0.78]
1.15 Glatiramer acetate versus
IFNß-1b (Betaseron)
1 2244 Odds Ratio (IV, Random, 95% CI) 0.86 [0.69, 1.06]
1.16 Glatiramer acetate versus
IFNß-1a (Rebif )
1 764 Odds Ratio (IV, Random, 95% CI) 0.53 [0.34, 0.83]
1.17 Corticosteroids versus
Mitoxantrone
1 42 Odds Ratio (IV, Random, 95% CI) 8.00 [0.87, 73.68]
2 Disability progression over 24
months in relapse-remitting
MS
15 Odds Ratio (IV, Random, 95% CI) Subtotals only
2.1 IFNß-1b (Betaseron)
versus placebo
1 372 Odds Ratio (IV, Random, 95% CI) 0.96 [0.61, 1.52]
2.2 IFNß-1a (Avonex) versus
placebo
1 301 Odds Ratio (IV, Random, 95% CI) 0.93 [0.59, 1.47]
2.3 IFNß-1a (Rebif ) versus
placebo
1 560 Odds Ratio (IV, Random, 95% CI) 0.65 [0.45, 0.93]
2.4 Glatiramer acetate versus
placebo
2 301 Odds Ratio (IV, Random, 95% CI) 0.50 [0.14, 1.74]
2.5 Natalizumab versus
placebo
1 942 Odds Ratio (IV, Random, 95% CI) 0.56 [0.42, 0.74]
2.6 Mitoxantrone versus
placebo
1 51 Odds Ratio (IV, Random, 95% CI) 0.13 [0.03, 0.70]
2.7 Azathioprine versus
placebo
1 59 Odds Ratio (IV, Random, 95% CI) 0.52 [0.17, 1.54]
2.8 Immunoglobulins versus
placebo
2 190 Odds Ratio (IV, Random, 95% CI) 0.62 [0.30, 1.29]
2.9 IFNß-1a (Avonex) versus
IFNß-1b (Betaseron)
1 188 Odds Ratio (IV, Random, 95% CI) 2.88 [1.43, 5.79]
2.10 IFNß-1a (Rebif ) versus
IFNß-1b (Betaseron)
1 301 Odds Ratio (IV, Random, 95% CI) 0.98 [0.62, 1.54]
2.11 Natalizumab versus
IFNß-1a (Avonex)
1 1171 Odds Ratio (IV, Random, 95% CI) 0.62 [0.49, 0.78]
2.12 Glatiramer acetate versus
IFNß-1b (Betaseron)
1 2244 Odds Ratio (IV, Random, 95% CI) 0.86 [0.69, 1.06]
2.13 Glatiramer acetate versus
IFNß-1a (Rebif )
1 764 Odds Ratio (IV, Random, 95% CI) 0.53 [0.34, 0.83]
3 Disability progression over 24
months in progressive MS
13 Odds Ratio (IV, Random, 95% CI) Subtotals only
3.1 IFNß-1b (Betaseron)
versus placebo
1 73 Odds Ratio (IV, Random, 95% CI) 0.62 [0.22, 1.69]
3.2 IFNß-1a (Avonex) versus
placebo
2 486 Odds Ratio (IV, Random, 95% CI) 0.95 [0.66, 1.36]
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3.3 IFNß-1a (Rebif ) versus
placebo
1 618 Odds Ratio (IV, Random, 95% CI) 0.78 [0.55, 1.10]
3.4 Glatiramer acetate versus
placebo
2 1049 Odds Ratio (IV, Random, 95% CI) 0.94 [0.73, 1.23]
3.5 Mitoxantrone versus
placebo
1 194 Odds Ratio (IV, Random, 95% CI) 0.61 [0.27, 1.34]
3.6 Immunoglobulins versus
placebo
2 549 Odds Ratio (IV, Random, 95% CI) 0.83 [0.39, 1.74]
3.7 Cyclophosphamide versus
placebo
1 44 Odds Ratio (IV, Random, 95% CI) 0.80 [0.22, 2.94]
3.8 Corticosteroids versus
placebo
1 86 Odds Ratio (IV, Random, 95% CI) 1.58 [0.64, 3.87]
3.9 Methotrexate versus
placebo
1 60 Odds Ratio (IV, Random, 95% CI) 0.67 [0.24, 1.87]
3.10 Corticosteroids versus
Mitoxantrone
1 42 Odds Ratio (IV, Random, 95% CI) 8.00 [0.87, 73.68]
Comparison 5. Comparisons for disability progression over 36 months
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disability progression over 36
months in progressive MS
7 Odds Ratio (IV, Random, 95% CI) Subtotals only
1.1 IFNß-1b (Betaseron)
versus placebo
2 1657 Odds Ratio (IV, Random, 95% CI) 0.87 [0.57, 1.33]
1.2 IFNß-1a (Rebif ) versus
placebo
2 989 Odds Ratio (IV, Random, 95% CI) 1.10 [0.68, 1.80]
1.3 Azathioprine versus
placebo
2 139 Odds Ratio (IV, Random, 95% CI) 0.47 [0.19, 1.17]
1.4 Cyclophosphamide versus
placebo
1 111 Odds Ratio (IV, Random, 95% CI) 1.60 [0.76, 3.39]
Comparison 6. Comparison for adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events 14 5785 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.96, 1.35]
1.1 Interferons versus placebo 5 1866 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.80, 1.39]
1.2 Glatiramer acetate versus
placebo
3 1046 Odds Ratio (M-H, Random, 95% CI) 1.71 [0.87, 3.39]
1.3 Natalizumab versus
placebo
2 2110 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.87, 1.50]
1.4 Mitoxantrone versus
placebo
1 131 Odds Ratio (M-H, Random, 95% CI) 2.58 [0.48, 13.81]
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1.5 Intravenous
immunoglobulins versus
placebo
3 632 Odds Ratio (M-H, Random, 95% CI) 2.28 [0.54, 9.74]
2 Withdrawals due to adverse
events
26 8332 Odds Ratio (M-H, Random, 95% CI) 2.41 [1.92, 3.03]
2.1 Interferons versus placebo 10 3711 Odds Ratio (M-H, Random, 95% CI) 3.08 [2.23, 4.26]
2.2 Glatiramer acetate versus
placebo
4 1096 Odds Ratio (M-H, Random, 95% CI) 3.48 [1.55, 7.84]
2.3 Natalizumab versus
placebo
2 2110 Odds Ratio (M-H, Random, 95% CI) 1.36 [0.99, 1.85]
2.4 Azathioprine versus
placebo
4 513 Odds Ratio (M-H, Random, 95% CI) 6.35 [2.50, 16.11]
2.5 Mitoxantrone versus
placebo
1 131 Odds Ratio (M-H, Random, 95% CI) 3.15 [0.61, 16.22]
2.6 Intravenous
immunoglobulins versus
placebo
5 771 Odds Ratio (M-H, Random, 95% CI) 1.99 [1.07, 3.71]
Analysis 1.1. Comparison 1 Comparisons for relapse over 12 months, Outcome 1 Relapse over 12 months
in MS of all types.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 1 Comparisons for relapse over 12 months
Outcome: 1 Relapse over 12 months in MS of all types
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
Knobler 1993 8/18 4/7 100.0 % 0.60 [ 0.10, 3.49 ]
Subtotal (95% CI) 18 7 100.0 % 0.60 [ 0.10, 3.49 ]
Total events: 8 (Experimental), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 IFN -1a (Avonex) versus placebo
MSCRG 1996 88/158 91/143 100.0 % 0.72 [ 0.45, 1.14 ]
Subtotal (95% CI) 158 143 100.0 % 0.72 [ 0.45, 1.14 ]
Total events: 88 (Experimental), 91 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
3 IFN -1a (Rebif) versus placebo
OWIMS 1999 130/193 65/100 48.8 % 1.11 [ 0.67, 1.85 ]
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
PRISMS 1998 226/373 148/187 51.2 % 0.41 [ 0.27, 0.61 ]
Subtotal (95% CI) 566 287 100.0 % 0.66 [ 0.25, 1.78 ]
Total events: 356 (Experimental), 213 (Control)
Heterogeneity: Tau2 = 0.45; Chi2 = 9.16, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 0.81 (P = 0.42)
4 Glatiramer acetate versus placebo
Bornstein 1987 7/25 19/25 44.9 % 0.12 [ 0.03, 0.44 ]
Comi 2001 53/119 61/120 55.1 % 0.78 [ 0.47, 1.29 ]
Subtotal (95% CI) 144 145 100.0 % 0.34 [ 0.06, 2.05 ]
Total events: 60 (Experimental), 80 (Control)
Heterogeneity: Tau2 = 1.46; Chi2 = 7.01, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.18 (P = 0.24)
5 Natalizumab versus placebo
AFFIRM 2006 126/627 126/315 100.0 % 0.38 [ 0.28, 0.51 ]
Subtotal (95% CI) 627 315 100.0 % 0.38 [ 0.28, 0.51 ]
Total events: 126 (Experimental), 126 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.41 (P < 0.00001)
6 Mitoxantrone versus placebo
Millefiorini 1997 8/27 18/24 100.0 % 0.14 [ 0.04, 0.48 ]
Subtotal (95% CI) 27 24 100.0 % 0.14 [ 0.04, 0.48 ]
Total events: 8 (Experimental), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0019)
7 Azathioprine versus placebo
British and Dutch 1988 84/174 107/180 69.4 % 0.64 [ 0.42, 0.97 ]
Ellison 1989 11/65 11/34 13.1 % 0.43 [ 0.16, 1.12 ]
Goodkin 1991 18/29 17/25 9.7 % 0.77 [ 0.25, 2.38 ]
Milanese 1993 10/19 12/21 7.9 % 0.83 [ 0.24, 2.90 ]
Subtotal (95% CI) 287 260 100.0 % 0.63 [ 0.44, 0.89 ]
Total events: 123 (Experimental), 147 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0094)
8 Immunoglobulins versus placebo
Achiron 1998 12/20 19/20 14.2 % 0.08 [ 0.01, 0.71 ]
Fazekas 2008 38/87 13/41 31.0 % 1.67 [ 0.76, 3.65 ]
Hommes 2004 55/159 53/159 34.9 % 1.06 [ 0.66, 1.68 ]
Lewanska 2002 17/33 16/18 19.8 % 0.13 [ 0.03, 0.67 ]
Subtotal (95% CI) 299 238 100.0 % 0.56 [ 0.20, 1.60 ]
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 122 (Experimental), 101 (Control)
Heterogeneity: Tau2 = 0.77; Chi2 = 12.76, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 1.08 (P = 0.28)
9 Corticosteroids versus placebo
BPSM 1995 10/19 12/17 100.0 % 0.46 [ 0.12, 1.84 ]
Subtotal (95% CI) 19 17 100.0 % 0.46 [ 0.12, 1.84 ]
Total events: 10 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
10 IFN -1a (Avonex) versus IFN -1b (Betaseron)
INCOMIN 2002 48/92 40/96 100.0 % 1.53 [ 0.86, 2.72 ]
Subtotal (95% CI) 92 96 100.0 % 1.53 [ 0.86, 2.72 ]
Total events: 48 (Experimental), 40 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
11 IFN -1a (Rebif) versus IFN -1a (Avonex)
EVIDENCE 2007 188/339 207/338 100.0 % 0.79 [ 0.58, 1.07 ]
Subtotal (95% CI) 339 338 100.0 % 0.79 [ 0.58, 1.07 ]
Total events: 188 (Experimental), 207 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
12 Natalizumab versus IFN -1a (Avonex)
SENTINEL 2006 165/589 286/582 100.0 % 0.40 [ 0.32, 0.51 ]
Subtotal (95% CI) 589 582 100.0 % 0.40 [ 0.32, 0.51 ]
Total events: 165 (Experimental), 286 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.35 (P < 0.00001)
13 Corticosteroids versus Mitoxantrone
Edan 1997 14/21 7/21 100.0 % 4.00 [ 1.11, 14.43 ]
Subtotal (95% CI) 21 21 100.0 % 4.00 [ 1.11, 14.43 ]
Total events: 14 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Chi2 = 46.02, df = 12 (P = 0.00), I2 =74%
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Analysis 1.2. Comparison 1 Comparisons for relapse over 12 months, Outcome 2 Relapse over 12 months
in relapsing-remitting MS.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 1 Comparisons for relapse over 12 months
Outcome: 2 Relapse over 12 months in relapsing-remitting MS
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 IFN -1b (Betaseron) versus placebo
Knobler 1993 8/18 4/7 0.5 % 0.60 [ 0.10, 3.49 ]
Subtotal (95% CI) 18 7 0.5 % 0.60 [ 0.10, 3.49 ]
Total events: 8 (Experimental), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 IFN -1a (Avonex) versus placebo
MSCRG 1996 88/158 91/143 6.0 % 0.72 [ 0.45, 1.14 ]
Subtotal (95% CI) 158 143 6.0 % 0.72 [ 0.45, 1.14 ]
Total events: 88 (Experimental), 91 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
3 IFN -1a (Rebif) versus placebo
OWIMS 1999 130/193 65/100 4.0 % 1.11 [ 0.67, 1.85 ]
PRISMS 1998 226/373 148/187 11.0 % 0.41 [ 0.27, 0.61 ]
Subtotal (95% CI) 566 287 15.0 % 0.59 [ 0.43, 0.81 ]
Total events: 356 (Experimental), 213 (Control)
Heterogeneity: Chi2 = 9.17, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 3.28 (P = 0.0010)
4 Glatiramer acetate versus placebo
Bornstein 1987 7/25 19/25 1.9 % 0.12 [ 0.03, 0.44 ]
Comi 2001 53/119 61/120 4.8 % 0.78 [ 0.47, 1.29 ]
Subtotal (95% CI) 144 145 6.7 % 0.59 [ 0.37, 0.93 ]
Total events: 60 (Experimental), 80 (Control)
Heterogeneity: Chi2 = 7.02, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 2.27 (P = 0.024)
5 Natalizumab versus placebo
AFFIRM 2006 126/627 126/315 19.0 % 0.38 [ 0.28, 0.51 ]
Subtotal (95% CI) 627 315 19.0 % 0.38 [ 0.28, 0.51 ]
Total events: 126 (Experimental), 126 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.41 (P < 0.00001)
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Mitoxantrone versus placebo
Millefiorini 1997 8/27 18/24 1.9 % 0.14 [ 0.04, 0.48 ]
Subtotal (95% CI) 27 24 1.9 % 0.14 [ 0.04, 0.48 ]
Total events: 8 (Experimental), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0019)
7 Azathioprine versus placebo
Goodkin 1991 18/29 17/25 1.0 % 0.77 [ 0.25, 2.38 ]
Subtotal (95% CI) 29 25 1.0 % 0.77 [ 0.25, 2.38 ]
Total events: 18 (Experimental), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
8 Immunoglobulins versus placebo
Achiron 1998 12/20 19/20 1.1 % 0.08 [ 0.01, 0.71 ]
Fazekas 2008 38/87 13/41 1.4 % 1.67 [ 0.76, 3.65 ]
Lewanska 2002 17/33 16/18 1.4 % 0.13 [ 0.03, 0.67 ]
Subtotal (95% CI) 140 79 3.9 % 0.67 [ 0.38, 1.21 ]
Total events: 67 (Experimental), 48 (Control)
Heterogeneity: Chi2 = 12.68, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.33 (P = 0.18)
9 Corticosteroids versus placebo
BPSM 1995 10/19 12/17 0.9 % 0.46 [ 0.12, 1.84 ]
Subtotal (95% CI) 19 17 0.9 % 0.46 [ 0.12, 1.84 ]
Total events: 10 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
10 IFN -1a (Avonex) versus IFN -1b (Betaseron)
INCOMIN 2002 48/92 40/96 2.7 % 1.53 [ 0.86, 2.72 ]
Subtotal (95% CI) 92 96 2.7 % 1.53 [ 0.86, 2.72 ]
Total events: 48 (Experimental), 40 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
11 IFN -1a (Rebif) versus IFN -1a (Avonex)
EVIDENCE 2007 188/339 207/338 13.1 % 0.79 [ 0.58, 1.07 ]
Subtotal (95% CI) 339 338 13.1 % 0.79 [ 0.58, 1.07 ]
Total events: 188 (Experimental), 207 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
12 Natalizumab versus IFN -1a (Avonex)
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SENTINEL 2006 165/589 286/582 29.4 % 0.40 [ 0.32, 0.51 ]
Subtotal (95% CI) 589 582 29.4 % 0.40 [ 0.32, 0.51 ]
Total events: 165 (Experimental), 286 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.35 (P < 0.00001)
Total (95% CI) 2748 2058 100.0 % 0.55 [ 0.49, 0.62 ]
Total events: 1142 (Experimental), 1142 (Control)
Heterogeneity: Chi2 = 66.51, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 9.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 36.94, df = 11 (P = 0.00), I2 =70%
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Analysis 1.3. Comparison 1 Comparisons for relapse over 12 months, Outcome 3 Relapse over 12 months
in progressive MS.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 1 Comparisons for relapse over 12 months
Outcome: 3 Relapse over 12 months in progressive MS
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azathioprine versus placebo
Ellison 1989 11/65 11/34 24.5 % 0.43 [ 0.16, 1.12 ]
Subtotal (95% CI) 65 34 24.5 % 0.43 [ 0.16, 1.12 ]
Total events: 11 (Experimental), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
2 Immunoglobulins versus placebo
Hommes 2004 55/159 53/159 70.7 % 1.06 [ 0.66, 1.68 ]
Subtotal (95% CI) 159 159 70.7 % 1.06 [ 0.66, 1.68 ]
Total events: 55 (Experimental), 53 (Control)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.24 (P = 0.81)
3 Corticosteroids versus Mitoxantrone
Edan 1997 14/21 7/21 4.8 % 4.00 [ 1.11, 14.43 ]
Subtotal (95% CI) 21 21 4.8 % 4.00 [ 1.11, 14.43 ]
Total events: 14 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Total (95% CI) 245 214 100.0 % 1.04 [ 0.70, 1.54 ]
Total events: 80 (Experimental), 71 (Control)
Heterogeneity: Chi2 = 7.51, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 7.51, df = 2 (P = 0.02), I2 =73%
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Analysis 2.1. Comparison 2 Comparisons for relapse over 24 months, Outcome 1 Relapse over 24 months
in MS of all types.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 2 Comparisons for relapse over 24 months
Outcome: 1 Relapse over 24 months in MS of all types
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
IFNB MS Group 1993 190/249 105/123 100.0 % 0.55 [ 0.31, 0.99 ]
Subtotal (95% CI) 249 123 100.0 % 0.55 [ 0.31, 0.99 ]
Total events: 190 (Experimental), 105 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
2 IFN -1a (Avonex) versus placebo
IMPACT 2002 86/217 103/219 70.6 % 0.74 [ 0.51, 1.08 ]
MSCRG 1996 127/158 119/143 29.4 % 0.83 [ 0.46, 1.49 ]
Subtotal (95% CI) 375 362 100.0 % 0.76 [ 0.56, 1.05 ]
Total events: 213 (Experimental), 222 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.098)
3 IFN -1a (Rebif) versus placebo
PRISMS 1998 268/373 159/187 100.0 % 0.45 [ 0.28, 0.71 ]
Subtotal (95% CI) 373 187 100.0 % 0.45 [ 0.28, 0.71 ]
Total events: 268 (Experimental), 159 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.40 (P = 0.00067)
4 Glatiramer acetate versus placebo
Bornstein 1987 11/25 19/25 36.9 % 0.25 [ 0.07, 0.83 ]
Johnson 1995 83/125 92/126 63.1 % 0.73 [ 0.43, 1.25 ]
Subtotal (95% CI) 150 151 100.0 % 0.49 [ 0.18, 1.36 ]
Total events: 94 (Experimental), 111 (Control)
Heterogeneity: Tau2 = 0.35; Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.37 (P = 0.17)
5 Natalizumab versus placebo
AFFIRM 2006 225/627 200/315 100.0 % 0.32 [ 0.24, 0.43 ]
Subtotal (95% CI) 627 315 100.0 % 0.32 [ 0.24, 0.43 ]
Total events: 225 (Experimental), 200 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.89 (P < 0.00001)
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
6 Mitoxantrone versus placebo
Hartung 2002 70/129 42/65 57.6 % 0.65 [ 0.35, 1.20 ]
Millefiorini 1997 10/27 19/24 42.4 % 0.15 [ 0.04, 0.54 ]
Subtotal (95% CI) 156 89 100.0 % 0.35 [ 0.09, 1.42 ]
Total events: 80 (Experimental), 61 (Control)
Heterogeneity: Tau2 = 0.77; Chi2 = 4.03, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 1.47 (P = 0.14)
7 Azathioprine versus placebo
British and Dutch 1988 109/174 135/180 39.2 % 0.56 [ 0.35, 0.88 ]
Ellison 1989 20/65 15/34 16.2 % 0.56 [ 0.24, 1.33 ]
Ghezzi 1989 54/93 51/92 29.1 % 1.11 [ 0.62, 1.99 ]
Goodkin 1991 19/30 24/29 8.9 % 0.36 [ 0.11, 1.21 ]
Milanese 1993 12/19 17/21 6.6 % 0.40 [ 0.10, 1.69 ]
Subtotal (95% CI) 381 356 100.0 % 0.64 [ 0.44, 0.94 ]
Total events: 214 (Experimental), 242 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 5.14, df = 4 (P = 0.27); I2 =22%
Test for overall effect: Z = 2.26 (P = 0.024)
8 Immunoglobulins versus placebo
Achiron 1998 13/20 20/20 3.4 % 0.04 [ 0.00, 0.83 ]
Fazekas 2008 35/75 49/75 28.6 % 0.46 [ 0.24, 0.90 ]
Hommes 2004 77/159 83/159 36.6 % 0.86 [ 0.55, 1.34 ]
Pohlau 2007 37/99 35/98 31.4 % 1.07 [ 0.60, 1.92 ]
Subtotal (95% CI) 353 352 100.0 % 0.70 [ 0.40, 1.22 ]
Total events: 162 (Experimental), 187 (Control)
Heterogeneity: Tau2 = 0.17; Chi2 = 7.42, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 1.25 (P = 0.21)
9 Corticosteroids versus placebo
BPSM 1995 18/19 16/17 100.0 % 1.13 [ 0.06, 19.50 ]
Subtotal (95% CI) 19 17 100.0 % 1.13 [ 0.06, 19.50 ]
Total events: 18 (Experimental), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
10 Methotrexate versus placebo
Goodkin 1995 6/31 5/29 100.0 % 1.15 [ 0.31, 4.28 ]
Subtotal (95% CI) 31 29 100.0 % 1.15 [ 0.31, 4.28 ]
Total events: 6 (Experimental), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
11 IFN -1a (Avonex) versus IFN -1b (Betaseron)
Etemadifar 2006 24/30 17/30 21.1 % 3.06 [ 0.97, 9.66 ]
INCOMIN 2002 63/92 49/96 78.9 % 2.08 [ 1.15, 3.78 ]
Subtotal (95% CI) 122 126 100.0 % 2.26 [ 1.33, 3.83 ]
Total events: 87 (Experimental), 66 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
12 IFN -1a (Rebif) versus IFN -1a (Avonex)
Etemadifar 2006 13/30 24/30 100.0 % 0.19 [ 0.06, 0.60 ]
Subtotal (95% CI) 30 30 100.0 % 0.19 [ 0.06, 0.60 ]
Total events: 13 (Experimental), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
13 Natalizumab versus IFN -1a (Avonex)
SENTINEL 2006 303/589 460/582 100.0 % 0.28 [ 0.22, 0.36 ]
Subtotal (95% CI) 589 582 100.0 % 0.28 [ 0.22, 0.36 ]
Total events: 303 (Experimental), 460 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 9.69 (P < 0.00001)
14 IFN -1a (Rebif) versus Interferon beta 1b
Etemadifar 2006 13/30 17/30 100.0 % 0.58 [ 0.21, 1.62 ]
Subtotal (95% CI) 30 30 100.0 % 0.58 [ 0.21, 1.62 ]
Total events: 13 (Experimental), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
15 Glatiramer acetate versus IFN -1b (Betaseron)
BEYOND 2009 260/448 1023/1796 100.0 % 1.05 [ 0.85, 1.29 ]
Subtotal (95% CI) 448 1796 100.0 % 1.05 [ 0.85, 1.29 ]
Total events: 260 (Experimental), 1023 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
16 Glatiramer acetate versus IFN -1a (Rebif)
REGARD 2008 134/378 143/386 100.0 % 0.93 [ 0.69, 1.25 ]
Subtotal (95% CI) 378 386 100.0 % 0.93 [ 0.69, 1.25 ]
Total events: 134 (Experimental), 143 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 121.32, df = 15 (P = 0.00), I2 =88%
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Analysis 2.2. Comparison 2 Comparisons for relapse over 24 months, Outcome 2 Relapse over 24 months
in relapsing-remitting MS.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 2 Comparisons for relapse over 24 months
Outcome: 2 Relapse over 24 months in relapsing-remitting MS
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
IFNB MS Group 1993 190/249 105/123 100.0 % 0.55 [ 0.31, 0.99 ]
Subtotal (95% CI) 249 123 100.0 % 0.55 [ 0.31, 0.99 ]
Total events: 190 (Experimental), 105 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
2 IFN -1a (Avonex) versus placebo
MSCRG 1996 127/158 119/143 100.0 % 0.83 [ 0.46, 1.49 ]
Subtotal (95% CI) 158 143 100.0 % 0.83 [ 0.46, 1.49 ]
Total events: 127 (Experimental), 119 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.53)
3 IFN -1a (Rebif) versus placebo
PRISMS 1998 268/373 159/187 100.0 % 0.45 [ 0.28, 0.71 ]
Subtotal (95% CI) 373 187 100.0 % 0.45 [ 0.28, 0.71 ]
Total events: 268 (Experimental), 159 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.40 (P = 0.00067)
4 Glatiramer acetate versus placebo
Bornstein 1987 11/25 19/25 36.9 % 0.25 [ 0.07, 0.83 ]
Johnson 1995 83/125 92/126 63.1 % 0.73 [ 0.43, 1.25 ]
Subtotal (95% CI) 150 151 100.0 % 0.49 [ 0.18, 1.36 ]
Total events: 94 (Experimental), 111 (Control)
Heterogeneity: Tau2 = 0.35; Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.37 (P = 0.17)
5 Natalizumab versus placebo
AFFIRM 2006 225/627 200/315 100.0 % 0.32 [ 0.24, 0.43 ]
Subtotal (95% CI) 627 315 100.0 % 0.32 [ 0.24, 0.43 ]
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 225 (Experimental), 200 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.89 (P < 0.00001)
6 Mitoxantrone versus placebo
Millefiorini 1997 10/27 19/24 100.0 % 0.15 [ 0.04, 0.54 ]
Subtotal (95% CI) 27 24 100.0 % 0.15 [ 0.04, 0.54 ]
Total events: 10 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
7 Azathioprine versus placebo
Goodkin 1991 19/30 24/29 100.0 % 0.36 [ 0.11, 1.21 ]
Subtotal (95% CI) 30 29 100.0 % 0.36 [ 0.11, 1.21 ]
Total events: 19 (Experimental), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
8 Immunoglobulins versus placebo
Achiron 1998 13/20 20/20 30.7 % 0.04 [ 0.00, 0.83 ]
Fazekas 2008 35/75 49/75 69.3 % 0.46 [ 0.24, 0.90 ]
Subtotal (95% CI) 95 95 100.0 % 0.22 [ 0.03, 1.90 ]
Total events: 48 (Experimental), 69 (Control)
Heterogeneity: Tau2 = 1.60; Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 1.37 (P = 0.17)
9 Corticosteroids versus placebo
BPSM 1995 18/19 16/17 100.0 % 1.13 [ 0.06, 19.50 ]
Subtotal (95% CI) 19 17 100.0 % 1.13 [ 0.06, 19.50 ]
Total events: 18 (Experimental), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
10 IFN -1a (Avonex) versus IFN -1b (Betaseron)
Etemadifar 2006 24/30 17/30 21.1 % 3.06 [ 0.97, 9.66 ]
INCOMIN 2002 63/92 49/96 78.9 % 2.08 [ 1.15, 3.78 ]
Subtotal (95% CI) 122 126 100.0 % 2.26 [ 1.33, 3.83 ]
Total events: 87 (Experimental), 66 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
11 IFN -1a (Rebif) versus IFN -1a (Avonex)
Etemadifar 2006 13/30 24/30 100.0 % 0.19 [ 0.06, 0.60 ]
Subtotal (95% CI) 30 30 100.0 % 0.19 [ 0.06, 0.60 ]
Total events: 13 (Experimental), 24 (Control)
Heterogeneity: not applicable
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.82 (P = 0.0048)
12 Natalizumab versus IFN -1a (Avonex)
SENTINEL 2006 303/589 460/582 100.0 % 0.28 [ 0.22, 0.36 ]
Subtotal (95% CI) 589 582 100.0 % 0.28 [ 0.22, 0.36 ]
Total events: 303 (Experimental), 460 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 9.69 (P < 0.00001)
13 IFN -1a (Rebif) versus IFN -1b (Betaseron)
Etemadifar 2006 13/30 17/30 100.0 % 0.58 [ 0.21, 1.62 ]
Subtotal (95% CI) 30 30 100.0 % 0.58 [ 0.21, 1.62 ]
Total events: 13 (Experimental), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
14 Glatiramer acetate versus IFN -1b (Betaseron)
BEYOND 2009 260/448 1023/1796 100.0 % 1.05 [ 0.85, 1.29 ]
Subtotal (95% CI) 448 1796 100.0 % 1.05 [ 0.85, 1.29 ]
Total events: 260 (Experimental), 1023 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
15 Glatiramer acetate versus IFN -1a (Rebif)
REGARD 2008 134/378 143/386 100.0 % 0.93 [ 0.69, 1.25 ]
Subtotal (95% CI) 378 386 100.0 % 0.93 [ 0.69, 1.25 ]
Total events: 134 (Experimental), 143 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 124.89, df = 14 (P = 0.00), I2 =89%
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Analysis 2.3. Comparison 2 Comparisons for relapse over 24 months, Outcome 3 Relapse over 24 months
in progressive MS.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 2 Comparisons for relapse over 24 months
Outcome: 3 Relapse over 24 months in progressive MS
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1a (Avonex) versus placebo
IMPACT 2002 86/217 103/219 100.0 % 0.74 [ 0.51, 1.08 ]
Subtotal (95% CI) 217 219 100.0 % 0.74 [ 0.51, 1.08 ]
Total events: 86 (Experimental), 103 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Mitoxantrone versus placebo
Hartung 2002 70/129 42/65 100.0 % 0.65 [ 0.35, 1.20 ]
Subtotal (95% CI) 129 65 100.0 % 0.65 [ 0.35, 1.20 ]
Total events: 70 (Experimental), 42 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
3 Azathioprine versus placebo
Ellison 1989 20/65 15/34 100.0 % 0.56 [ 0.24, 1.33 ]
Subtotal (95% CI) 65 34 100.0 % 0.56 [ 0.24, 1.33 ]
Total events: 20 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
4 Immunoglobulins versus placebo
Hommes 2004 77/159 83/159 63.5 % 0.86 [ 0.55, 1.34 ]
Pohlau 2007 37/99 35/98 36.5 % 1.07 [ 0.60, 1.92 ]
Subtotal (95% CI) 258 257 100.0 % 0.93 [ 0.66, 1.32 ]
Total events: 114 (Experimental), 118 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
5 Methotrexate versus placebo
Goodkin 1995 6/31 5/29 100.0 % 1.15 [ 0.31, 4.28 ]
Subtotal (95% CI) 31 29 100.0 % 1.15 [ 0.31, 4.28 ]
Total events: 6 (Experimental), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 2.28, df = 4 (P = 0.68), I2 =0.0%
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Analysis 3.1. Comparison 3 Comparisons for relapse over 36 months, Outcome 1 Relapse over 36 months
in MS of all types.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 3 Comparisons for relapse over 36 months
Outcome: 1 Relapse over 36 months in MS of all types
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
European Study Group 1998 297/360 317/358 30.9 % 0.61 [ 0.40, 0.93 ]
NASP 2004 373/631 202/308 69.1 % 0.76 [ 0.57, 1.01 ]
Subtotal (95% CI) 991 666 100.0 % 0.71 [ 0.56, 0.90 ]
Total events: 670 (Experimental), 519 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0043)
2 IFN -1a (Rebif) versus placebo
Andersen 2004 112/188 98/183 100.0 % 1.28 [ 0.85, 1.93 ]
Subtotal (95% CI) 188 183 100.0 % 1.28 [ 0.85, 1.93 ]
Total events: 112 (Experimental), 98 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
3 Azathioprine versus placebo
British and Dutch 1988 126/174 147/180 64.0 % 0.59 [ 0.36, 0.97 ]
Ellison 1989 28/65 25/34 27.7 % 0.27 [ 0.11, 0.67 ]
Milanese 1993 14/19 19/21 8.3 % 0.29 [ 0.05, 1.75 ]
Subtotal (95% CI) 258 235 100.0 % 0.45 [ 0.27, 0.76 ]
Total events: 168 (Experimental), 191 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.43, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Chi2 = 10.29, df = 2 (P = 0.01), I2 =81%
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Analysis 4.1. Comparison 4 Comparisons for disability progression over 24 months, Outcome 1 Disability
progression over 24 months in MS of all types.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 4 Comparisons for disability progression over 24 months
Outcome: 1 Disability progression over 24 months in MS of all types
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
IFNB MS Group 1993 83/249 42/123 83.1 % 0.96 [ 0.61, 1.52 ]
Montalban 2009 9/36 13/37 16.9 % 0.62 [ 0.22, 1.69 ]
Subtotal (95% CI) 285 160 100.0 % 0.89 [ 0.59, 1.36 ]
Total events: 92 (Experimental), 55 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
2 IFN -1a (Avonex) versus placebo
IMPACT 2002 82/217 88/219 55.0 % 0.90 [ 0.62, 1.33 ]
Leary 2003 16/30 9/20 6.3 % 1.40 [ 0.45, 4.35 ]
MSCRG 1996 91/158 85/143 38.7 % 0.93 [ 0.59, 1.47 ]
Subtotal (95% CI) 405 382 100.0 % 0.94 [ 0.71, 1.25 ]
Total events: 189 (Experimental), 182 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
3 IFN -1a (Rebif) versus placebo
PRISMS 1998 120/373 79/187 47.3 % 0.65 [ 0.45, 0.93 ]
SPECTRIMS 2001 233/413 128/205 52.7 % 0.78 [ 0.55, 1.10 ]
Subtotal (95% CI) 786 392 100.0 % 0.71 [ 0.56, 0.92 ]
Total events: 353 (Experimental), 207 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
4 Glatiramer acetate versus placebo
Bornstein 1987 5/25 13/25 9.8 % 0.23 [ 0.07, 0.81 ]
Bornstein 1991 9/51 14/55 15.4 % 0.63 [ 0.24, 1.61 ]
Johnson 1995 27/125 31/126 27.8 % 0.84 [ 0.47, 1.52 ]
Wolinsky 2007 290/627 148/316 46.9 % 0.98 [ 0.74, 1.28 ]
Subtotal (95% CI) 828 522 100.0 % 0.76 [ 0.49, 1.17 ]
Total events: 331 (Experimental), 206 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 5.45, df = 3 (P = 0.14); I2 =45%
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.24 (P = 0.21)
5 Natalizumab versus placebo
AFFIRM 2006 206/627 147/315 100.0 % 0.56 [ 0.42, 0.74 ]
Subtotal (95% CI) 627 315 100.0 % 0.56 [ 0.42, 0.74 ]
Total events: 206 (Experimental), 147 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
6 Mitoxantrone versus placebo
Hartung 2002 17/129 13/65 62.1 % 0.61 [ 0.27, 1.34 ]
Millefiorini 1997 2/27 9/24 37.9 % 0.13 [ 0.03, 0.70 ]
Subtotal (95% CI) 156 89 100.0 % 0.34 [ 0.08, 1.44 ]
Total events: 19 (Experimental), 22 (Control)
Heterogeneity: Tau2 = 0.71; Chi2 = 2.61, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 1.46 (P = 0.14)
7 Azathioprine versus placebo
Ghezzi 1989 51/93 53/92 66.8 % 0.89 [ 0.50, 1.60 ]
Goodkin 1991 8/30 12/29 18.8 % 0.52 [ 0.17, 1.54 ]
Milanese 1993 8/19 11/21 14.4 % 0.66 [ 0.19, 2.31 ]
Subtotal (95% CI) 142 142 100.0 % 0.77 [ 0.48, 1.24 ]
Total events: 67 (Experimental), 76 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
8 Immunoglobulins versus placebo
Achiron 1998 3/20 3/20 6.7 % 1.00 [ 0.18, 5.67 ]
Fazekas 1997 12/75 19/75 21.7 % 0.56 [ 0.25, 1.26 ]
Hommes 2004 77/159 70/159 38.0 % 1.19 [ 0.77, 1.86 ]
Pohlau 2007 56/116 72/115 33.6 % 0.56 [ 0.33, 0.94 ]
Subtotal (95% CI) 370 369 100.0 % 0.78 [ 0.48, 1.25 ]
Total events: 148 (Experimental), 164 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 5.76, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 1.04 (P = 0.30)
9 Cyclophosphamide versus placebo
Likosky 1991 15/22 16/22 100.0 % 0.80 [ 0.22, 2.94 ]
Subtotal (95% CI) 22 22 100.0 % 0.80 [ 0.22, 2.94 ]
Total events: 15 (Experimental), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
10 Corticosteroids versus placebo
Miller 1961 16/29 25/57 100.0 % 1.58 [ 0.64, 3.87 ]
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 29 57 100.0 % 1.58 [ 0.64, 3.87 ]
Total events: 16 (Experimental), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
11 Methotrexate versus placebo
Goodkin 1995 13/31 15/29 100.0 % 0.67 [ 0.24, 1.87 ]
Subtotal (95% CI) 31 29 100.0 % 0.67 [ 0.24, 1.87 ]
Total events: 13 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
12 IFN -1a (Avonex) versus IFN -1b (Betaseron)
INCOMIN 2002 32/92 15/96 100.0 % 2.88 [ 1.43, 5.79 ]
Subtotal (95% CI) 92 96 100.0 % 2.88 [ 1.43, 5.79 ]
Total events: 32 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
13 IFN -1a (Rebif) versus IFN -1b (Betaseron)
Koch-Henriksen 2006 69/143 77/158 100.0 % 0.98 [ 0.62, 1.54 ]
Subtotal (95% CI) 143 158 100.0 % 0.98 [ 0.62, 1.54 ]
Total events: 69 (Experimental), 77 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
14 Natalizumab versus IFN -1a (Avonex)
SENTINEL 2006 267/589 334/582 100.0 % 0.62 [ 0.49, 0.78 ]
Subtotal (95% CI) 589 582 100.0 % 0.62 [ 0.49, 0.78 ]
Total events: 267 (Experimental), 334 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.12 (P = 0.000038)
15 Glatiramer acetate versus IFN -1b (Betaseron)
BEYOND 2009 166/448 730/1796 100.0 % 0.86 [ 0.69, 1.06 ]
Subtotal (95% CI) 448 1796 100.0 % 0.86 [ 0.69, 1.06 ]
Total events: 166 (Experimental), 730 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
16 Glatiramer acetate versus IFN -1a (Rebif)
REGARD 2008 35/378 62/386 100.0 % 0.53 [ 0.34, 0.83 ]
Subtotal (95% CI) 378 386 100.0 % 0.53 [ 0.34, 0.83 ]
Total events: 35 (Experimental), 62 (Control)
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
17 Corticosteroids versus Mitoxantrone
Edan 1997 6/21 1/21 100.0 % 8.00 [ 0.87, 73.68 ]
Subtotal (95% CI) 21 21 100.0 % 8.00 [ 0.87, 73.68 ]
Total events: 6 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Chi2 = 37.86, df = 16 (P = 0.00), I2 =58%
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Analysis 4.2. Comparison 4 Comparisons for disability progression over 24 months, Outcome 2 Disability
progression over 24 months in relapse-remitting MS.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 4 Comparisons for disability progression over 24 months
Outcome: 2 Disability progression over 24 months in relapse-remitting MS
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
IFNB MS Group 1993 83/249 42/123 100.0 % 0.96 [ 0.61, 1.52 ]
Subtotal (95% CI) 249 123 100.0 % 0.96 [ 0.61, 1.52 ]
Total events: 83 (Experimental), 42 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
2 IFN -1a (Avonex) versus placebo
MSCRG 1996 91/158 85/143 100.0 % 0.93 [ 0.59, 1.47 ]
Subtotal (95% CI) 158 143 100.0 % 0.93 [ 0.59, 1.47 ]
Total events: 91 (Experimental), 85 (Control)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(Continued . . . )
112Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.32 (P = 0.75)
3 IFN -1a (Rebif) versus placebo
PRISMS 1998 120/373 79/187 100.0 % 0.65 [ 0.45, 0.93 ]
Subtotal (95% CI) 373 187 100.0 % 0.65 [ 0.45, 0.93 ]
Total events: 120 (Experimental), 79 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
4 Glatiramer acetate versus placebo
Bornstein 1987 5/25 13/25 40.5 % 0.23 [ 0.07, 0.81 ]
Johnson 1995 27/125 31/126 59.5 % 0.84 [ 0.47, 1.52 ]
Subtotal (95% CI) 150 151 100.0 % 0.50 [ 0.14, 1.74 ]
Total events: 32 (Experimental), 44 (Control)
Heterogeneity: Tau2 = 0.59; Chi2 = 3.36, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.09 (P = 0.28)
5 Natalizumab versus placebo
AFFIRM 2006 206/627 147/315 100.0 % 0.56 [ 0.42, 0.74 ]
Subtotal (95% CI) 627 315 100.0 % 0.56 [ 0.42, 0.74 ]
Total events: 206 (Experimental), 147 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
6 Mitoxantrone versus placebo
Millefiorini 1997 2/27 9/24 100.0 % 0.13 [ 0.03, 0.70 ]
Subtotal (95% CI) 27 24 100.0 % 0.13 [ 0.03, 0.70 ]
Total events: 2 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
7 Azathioprine versus placebo
Goodkin 1991 8/30 12/29 100.0 % 0.52 [ 0.17, 1.54 ]
Subtotal (95% CI) 30 29 100.0 % 0.52 [ 0.17, 1.54 ]
Total events: 8 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
8 Immunoglobulins versus placebo
Achiron 1998 3/20 3/20 17.8 % 1.00 [ 0.18, 5.67 ]
Fazekas 1997 12/75 19/75 82.2 % 0.56 [ 0.25, 1.26 ]
Subtotal (95% CI) 95 95 100.0 % 0.62 [ 0.30, 1.29 ]
Total events: 15 (Experimental), 22 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
9 IFN -1a (Avonex) versus IFN -1b (Betaseron)
INCOMIN 2002 32/92 15/96 100.0 % 2.88 [ 1.43, 5.79 ]
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 92 96 100.0 % 2.88 [ 1.43, 5.79 ]
Total events: 32 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
10 IFN -1a (Rebif) versus IFN -1b (Betaseron)
Koch-Henriksen 2006 69/143 77/158 100.0 % 0.98 [ 0.62, 1.54 ]
Subtotal (95% CI) 143 158 100.0 % 0.98 [ 0.62, 1.54 ]
Total events: 69 (Experimental), 77 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
11 Natalizumab versus IFN -1a (Avonex)
SENTINEL 2006 267/589 334/582 100.0 % 0.62 [ 0.49, 0.78 ]
Subtotal (95% CI) 589 582 100.0 % 0.62 [ 0.49, 0.78 ]
Total events: 267 (Experimental), 334 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.12 (P = 0.000038)
12 Glatiramer acetate versus IFN -1b (Betaseron)
BEYOND 2009 166/448 730/1796 100.0 % 0.86 [ 0.69, 1.06 ]
Subtotal (95% CI) 448 1796 100.0 % 0.86 [ 0.69, 1.06 ]
Total events: 166 (Experimental), 730 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
13 Glatiramer acetate versus IFN -1a (Rebif)
REGARD 2008 35/378 62/386 100.0 % 0.53 [ 0.34, 0.83 ]
Subtotal (95% CI) 378 386 100.0 % 0.53 [ 0.34, 0.83 ]
Total events: 35 (Experimental), 62 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Chi2 = 34.14, df = 12 (P = 0.00), I2 =65%
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Analysis 4.3. Comparison 4 Comparisons for disability progression over 24 months, Outcome 3 Disability
progression over 24 months in progressive MS.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 4 Comparisons for disability progression over 24 months
Outcome: 3 Disability progression over 24 months in progressive MS
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
Montalban 2009 9/36 13/37 100.0 % 0.62 [ 0.22, 1.69 ]
Subtotal (95% CI) 36 37 100.0 % 0.62 [ 0.22, 1.69 ]
Total events: 9 (Experimental), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
2 IFN -1a (Avonex) versus placebo
IMPACT 2002 82/217 88/219 89.7 % 0.90 [ 0.62, 1.33 ]
Leary 2003 16/30 9/20 10.3 % 1.40 [ 0.45, 4.35 ]
Subtotal (95% CI) 247 239 100.0 % 0.95 [ 0.66, 1.36 ]
Total events: 98 (Experimental), 97 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
3 IFN -1a (Rebif) versus placebo
SPECTRIMS 2001 233/413 128/205 100.0 % 0.78 [ 0.55, 1.10 ]
Subtotal (95% CI) 413 205 100.0 % 0.78 [ 0.55, 1.10 ]
Total events: 233 (Experimental), 128 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
4 Glatiramer acetate versus placebo
Bornstein 1991 9/51 14/55 7.7 % 0.63 [ 0.24, 1.61 ]
Wolinsky 2007 290/627 148/316 92.3 % 0.98 [ 0.74, 1.28 ]
Subtotal (95% CI) 678 371 100.0 % 0.94 [ 0.73, 1.23 ]
Total events: 299 (Experimental), 162 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
5 Mitoxantrone versus placebo
Hartung 2002 17/129 13/65 100.0 % 0.61 [ 0.27, 1.34 ]
Subtotal (95% CI) 129 65 100.0 % 0.61 [ 0.27, 1.34 ]
Total events: 17 (Experimental), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
6 Immunoglobulins versus placebo
Hommes 2004 77/159 70/159 51.8 % 1.19 [ 0.77, 1.86 ]
Pohlau 2007 56/116 72/115 48.2 % 0.56 [ 0.33, 0.94 ]
Subtotal (95% CI) 275 274 100.0 % 0.83 [ 0.39, 1.74 ]
Total events: 133 (Experimental), 142 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 4.74, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.50 (P = 0.62)
7 Cyclophosphamide versus placebo
Likosky 1991 15/22 16/22 100.0 % 0.80 [ 0.22, 2.94 ]
Subtotal (95% CI) 22 22 100.0 % 0.80 [ 0.22, 2.94 ]
Total events: 15 (Experimental), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
8 Corticosteroids versus placebo
Miller 1961 16/29 25/57 100.0 % 1.58 [ 0.64, 3.87 ]
Subtotal (95% CI) 29 57 100.0 % 1.58 [ 0.64, 3.87 ]
Total events: 16 (Experimental), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
9 Methotrexate versus placebo
Goodkin 1995 13/31 15/29 100.0 % 0.67 [ 0.24, 1.87 ]
Subtotal (95% CI) 31 29 100.0 % 0.67 [ 0.24, 1.87 ]
Total events: 13 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
10 Corticosteroids versus Mitoxantrone
Edan 1997 6/21 1/21 100.0 % 8.00 [ 0.87, 73.68 ]
Subtotal (95% CI) 21 21 100.0 % 8.00 [ 0.87, 73.68 ]
Total events: 6 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Chi2 = 7.94, df = 9 (P = 0.54), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
116Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.1. Comparison 5 Comparisons for disability progression over 36 months, Outcome 1 Disability
progression over 36 months in progressive MS.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 5 Comparisons for disability progression over 36 months
Outcome: 1 Disability progression over 36 months in progressive MS
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 IFN -1b (Betaseron) versus placebo
European Study Group 1998 237/360 263/358 48.4 % 0.70 [ 0.51, 0.96 ]
NASP 2004 404/631 192/308 51.6 % 1.08 [ 0.81, 1.43 ]
Subtotal (95% CI) 991 666 100.0 % 0.87 [ 0.57, 1.33 ]
Total events: 641 (Experimental), 455 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.99, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.64 (P = 0.53)
2 IFN -1a (Rebif) versus placebo
Andersen 2004 117/188 98/183 48.2 % 1.43 [ 0.94, 2.16 ]
SPECTRIMS 2001 286/413 148/205 51.8 % 0.87 [ 0.60, 1.26 ]
Subtotal (95% CI) 601 388 100.0 % 1.10 [ 0.68, 1.80 ]
Total events: 403 (Experimental), 246 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.11, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.39 (P = 0.69)
3 Azathioprine versus placebo
Ellison 1989 29/65 19/34 70.3 % 0.64 [ 0.28, 1.47 ]
Milanese 1993 11/19 18/21 29.7 % 0.23 [ 0.05, 1.05 ]
Subtotal (95% CI) 84 55 100.0 % 0.47 [ 0.19, 1.17 ]
Total events: 40 (Experimental), 37 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 1.32, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.62 (P = 0.11)
4 Cyclophosphamide versus placebo
CCMSSG 1991 29/55 23/56 100.0 % 1.60 [ 0.76, 3.39 ]
Subtotal (95% CI) 55 56 100.0 % 1.60 [ 0.76, 3.39 ]
Total events: 29 (Experimental), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 4.64, df = 3 (P = 0.20), I2 =35%
0.01 0.1 1 10 100
Favours experimental Favours control
117Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.1. Comparison 6 Comparison for adverse events, Outcome 1 Serious adverse events.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 6 Comparison for adverse events
Outcome: 1 Serious adverse events
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferons versus placebo
Andersen 2004 51/188 49/183 13.6 % 1.02 [ 0.64, 1.61 ]
MSCRG 1996 25/158 14/143 5.9 % 1.73 [ 0.86, 3.48 ]
NASP 2004 86/317 86/308 23.2 % 0.96 [ 0.68, 1.37 ]
OWIMS 1999 7/98 3/100 1.5 % 2.49 [ 0.62, 9.91 ]
PRISMS 1998 19/184 25/187 7.1 % 0.75 [ 0.40, 1.41 ]
Subtotal (95% CI) 945 921 51.2 % 1.05 [ 0.80, 1.39 ]
Total events: 188 (Experimental), 177 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.84, df = 4 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.37 (P = 0.71)
2 Glatiramer acetate versus placebo
Comi 2001 10/119 6/120 2.6 % 1.74 [ 0.61, 4.96 ]
Johnson 1995 2/125 0/126 0.3 % 5.12 [ 0.24, 107.76 ]
Wolinsky 2007 18/371 6/185 3.2 % 1.52 [ 0.59, 3.90 ]
Subtotal (95% CI) 615 431 6.1 % 1.71 [ 0.87, 3.39 ]
Total events: 30 (Experimental), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
3 Natalizumab versus placebo
AFFIRM 2006 81/627 34/312 15.8 % 1.21 [ 0.79, 1.86 ]
SENTINEL 2006 77/589 70/582 23.8 % 1.10 [ 0.78, 1.55 ]
Subtotal (95% CI) 1216 894 39.6 % 1.14 [ 0.87, 1.50 ]
Total events: 158 (Experimental), 104 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
4 Mitoxantrone versus placebo
Hartung 2002 5/66 2/65 1.0 % 2.58 [ 0.48, 13.81 ]
Subtotal (95% CI) 66 65 1.0 % 2.58 [ 0.48, 13.81 ]
Total events: 5 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 Intravenous immunoglobulins versus placebo
Fazekas 2008 2/42 3/41 0.8 % 0.63 [ 0.10, 4.00 ]
Hommes 2004 6/159 1/159 0.6 % 6.20 [ 0.74, 52.07 ]
Pohlau 2007 4/116 1/115 0.6 % 4.07 [ 0.45, 36.99 ]
Subtotal (95% CI) 317 315 2.1 % 2.28 [ 0.54, 9.74 ]
Total events: 12 (Experimental), 5 (Control)
Heterogeneity: Tau2 = 0.55; Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 3159 2626 100.0 % 1.14 [ 0.96, 1.35 ]
Total events: 393 (Experimental), 300 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.55, df = 13 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 3.46, df = 4 (P = 0.48), I2 =0.0%
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Analysis 6.2. Comparison 6 Comparison for adverse events, Outcome 2Withdrawals due to adverse events.
Review: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Comparison: 6 Comparison for adverse events
Outcome: 2 Withdrawals due to adverse events
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferons versus placebo
Andersen 2004 16/188 6/183 5.0 % 2.74 [ 1.05, 7.18 ]
European Study Group 1998 45/360 15/358 10.6 % 3.27 [ 1.79, 5.98 ]
IFNB MS Group 1993 10/124 1/123 1.2 % 10.70 [ 1.35, 84.93 ]
IMPACT 2002 17/217 9/219 6.4 % 1.98 [ 0.86, 4.55 ]
Leary 2003 4/15 0/20 0.6 % 16.04 [ 0.79, 325.37 ]
MSCRG 1996 7/158 2/143 2.0 % 3.27 [ 0.67, 16.00 ]
NASP 2004 29/317 12/308 8.6 % 2.48 [ 1.24, 4.96 ]
OWIMS 1999 5/98 0/100 0.6 % 11.82 [ 0.64, 216.77 ]
PRISMS 1998 9/184 2/187 2.1 % 4.76 [ 1.01, 22.32 ]
SPECTRIMS 2001 18/204 5/205 4.6 % 3.87 [ 1.41, 10.64 ]
Subtotal (95% CI) 1865 1846 41.7 % 3.08 [ 2.23, 4.26 ]
Total events: 160 (Experimental), 52 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.49, df = 9 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 6.84 (P < 0.00001)
2 Glatiramer acetate versus placebo
Bornstein 1987 2/25 0/25 0.5 % 5.43 [ 0.25, 118.96 ]
Comi 2001 3/119 2/120 1.5 % 1.53 [ 0.25, 9.30 ]
Johnson 1995 5/125 1/126 1.1 % 5.21 [ 0.60, 45.23 ]
Wolinsky 2007 30/371 4/185 4.2 % 3.98 [ 1.38, 11.48 ]
Subtotal (95% CI) 640 456 7.4 % 3.48 [ 1.55, 7.84 ]
Total events: 40 (Experimental), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.08, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.01 (P = 0.0026)
3 Natalizumab versus placebo
AFFIRM 2006 57/627 18/312 12.2 % 1.63 [ 0.94, 2.83 ]
SENTINEL 2006 65/589 53/582 19.0 % 1.24 [ 0.84, 1.81 ]
Subtotal (95% CI) 1216 894 31.2 % 1.36 [ 0.99, 1.85 ]
Total events: 122 (Experimental), 71 (Control)
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(. . . Continued)
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
4 Azathioprine versus placebo
British and Dutch 1988 17/174 3/180 3.1 % 6.39 [ 1.84, 22.21 ]
Ellison 1989 3/31 0/34 0.6 % 8.47 [ 0.42, 170.95 ]
Goodkin 1991 6/29 1/25 1.1 % 6.26 [ 0.70, 56.10 ]
Milanese 1993 4/19 1/21 1.0 % 5.33 [ 0.54, 52.73 ]
Subtotal (95% CI) 253 260 5.7 % 6.35 [ 2.50, 16.11 ]
Total events: 30 (Experimental), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
5 Mitoxantrone versus placebo
Hartung 2002 6/66 2/65 1.9 % 3.15 [ 0.61, 16.22 ]
Subtotal (95% CI) 66 65 1.9 % 3.15 [ 0.61, 16.22 ]
Total events: 6 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
6 Intravenous immunoglobulins versus placebo
Achiron 1998 1/20 1/20 0.6 % 1.00 [ 0.06, 17.18 ]
Fazekas 1997 3/75 1/73 1.0 % 3.00 [ 0.30, 29.52 ]
Hommes 2004 10/159 5/159 3.9 % 2.07 [ 0.69, 6.19 ]
Lewanska 2002 1/16 0/18 0.5 % 3.58 [ 0.14, 94.30 ]
Pohlau 2007 16/116 9/115 6.0 % 1.88 [ 0.80, 4.46 ]
Subtotal (95% CI) 386 385 12.1 % 1.99 [ 1.07, 3.71 ]
Total events: 31 (Experimental), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
Total (95% CI) 4426 3906 100.0 % 2.41 [ 1.92, 3.03 ]
Total events: 389 (Experimental), 153 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 27.90, df = 25 (P = 0.31); I2 =10%
Test for overall effect: Z = 7.52 (P < 0.00001)
Test for subgroup differences: Chi2 = 19.85, df = 5 (P = 0.00), I2 =75%
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A D D I T I O N A L T A B L E S
Table 1. Number of participants in each treatment group
Type of treatment RCTs
N
RRMS
N = 9096
Progressive MS
N = 7726
RRMS and
progressive MS
combined
N = 579
All MS
N = 17401
Azathioprine 5 30 65 286 381
Cyclophosphamide 2 0 77 77
Corticosteroids 3 19 50 69
Glatiramer acetate 7 1095 678 1773
IFNß-1b
(Betaseron)
9 2347 1027 3374
IFNß-1a (Avonex) 7 1200 2647 3847
IFNß-1a (Rebif ) 8 1464 601 2065
IV immunoglobu-
lins
6 215 275 490
Methotrexate 1 0 31 31
Mitoxantrone 3 27 150 177
Natalizumab 2 1216 0 1216
placebo 36 1483 2125 293 3901
Table 2. Methods of adverse events monitoring
Study Risk of
bias
Did the researchers ac-
tively monitor for adverse
events (AEs) (low risk of
bias) or did they simply
provide spontaneous re-
porting of AEs that arose
(high risk of bias)?
Risk of bias Did the authors define serious AEs
(SAEs) according to an accepted interna-
tional classification and report the num-
ber of SAEs?
Achiron 1998 Unclear Not reported High SAEs not reported
AFFIRM 2006 Low ”Treating neurologists were re-
sponsible for all aspects of pa-
tient care, including the man-
Unclear Insuf cient information on SAEs
de nition
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Table 2. Methods of adverse events monitoring (Continued)
agement of adverse events“.
Participants”visited the clinic
every 12 weeks for ... blood
chemical and hematologic
analyses, evaluation of adverse
events...“
Andersen 2004 Low ”Adverse events and con-
comitant medications were
recorded throughout the study,
and clinical laboratory eval-
uation was performed at
months 1, 3, and 6, and then
at 6 monthly evaluation visits
or as needed“
Unclear Insuf cient information on SAEs
de nition
BEYOND 2009 Low ”Clinic visits were scheduled
every 3 months to assess ... sa-
fety, and tolerability. The oc-
currence of new neurological
symptoms and adverse events
was assessed by telephone, 6
weeks after each visit“
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
Bornstein 1987 High ”Self-evaluation reported to a
clinical assistant“
High SAEs not reported
Bornstein 1991 High ”Self-reporting reported to a
clinical assistant“
High SAEs not reported
BPSM 1995 Unclear Not reported Unclear Insuf cient information on SAEs
de nition
British and Dutch 1988 Unclear ”The occurrence of side effects
was notified to the trial centre
every 3 months“
High SAEs not reported
CCMSSG 1991 Unclear ”The external safety monitor-
ing committee monitored the
progress of the trial every 6
months (severe adverse experi-
ences, deaths, clinical status)“
High SAEs not reported
Comi 2001 Unclear ”The treating physician mon-
itored safety...“
Unclear Insuf cient information on SAEs
de nition
Edan 1997 Unclear Not reported Unclear Insuf cient information on SAEs
de nition
123Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Methods of adverse events monitoring (Continued)
Ellison 1989 Low Participants”were instructed
to call the clinic anytime they
suspected an adverse events
and then actively monitored
by neurologist“
High SAEs not reported
Etemadifar 2006 High ”Given the lack of safety assess-
ment of this trial, it is impor-
tant to recall that the safety of
IFN-b products in the treat-
ment of RRMS had already
been established for the three
drugs in previous studies“
High SAEs not reported
European Study Group
1998
Low ”Safety assessments included
adverse events, vital signs,
physical examinations, and
concomitant medication. An
independent advisory com-
mittee reviewed the results of
regular interim safety analyses
done after all participantshad
been in the study for at least
24 months“
High SAEs not reported
EVIDENCE 2007 High ”Adverse events were deter-
mined by spontaneous report-
ing and monthly laboratory
testing during the comparative
phase“
Unclear Insuf cient information on SAEs
de nition
Fazekas 1997 Low Participants”asked about sa-
fety monthly...“
High SAEs not reported
Fazekas 2008 Unclear Not reported Unclear Insuf cient information on SAEs
de nition
Ghezzi 1989 Unclear Not reported High SAEs not reported
Goodkin 1991 High ”Side effect were reported to
the treating neurologist every
6 months“
High SAEs not reported
Goodkin 1995 Low ”All participantsmaintained
a daily diary of undesirable
events… The adverse event
diary was checked every 3
months by the study nurse dur-
ing a clinical visit“
High SAEs not reported
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Table 2. Methods of adverse events monitoring (Continued)
Hartung 2002 Unclear Not reported Unclear Insuf cient information on SAEs
de nition
Hommes 2004 Unclear ”Several safety laboratory tests
were done...“
Unclear Insuf cient information on SAEs
de nition
IFNB MS Group 1993 Low ”Treating neurologist re-
viewed side effects, laboratory
findings for toxicity ...“
High SAEs not reported
IMPACT 2002 Unclear ”An in-
dependent external Data and
SafetyMonitoring Committee
reviewed safety data at three
time points during the trial
and performed a preplanned
interim analysis after all sub-
jects had been followed for 15
months“
High SAEs not reported
INCOMIN 2002 Low ”Sa-
fety assessments included ad-
verse events, vital signs, phys-
ical examination, and con-
comitant medications. Par-
ticipantsunderwent haema-
tology and biochemical tests,
including liver-function tests,
every 2 weeks for the first
8 weeks, and then every 3
months“
High SAEs not reported
Johnson 1995 Low ”The evaluating physician
monitored safety every 3
month...“
Unclear Insuf cient information on SAEs
de nition
Knobler 1993 Unclear Not reported High SAEs not reported
Koch-Henriksen 2006 Low Partici-
pants”were interviewed about
side effects and had routine
blood tests including hematol-
ogy and liver function tests
every 3 months and thyroid
tests and neutralizing anti-
bodies every 6 months“
High SAEs not reported
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Table 2. Methods of adverse events monitoring (Continued)
Leary 2003 Low ”AEsweremonitored through-
out the study...“
High SAEs not reported
Lewanska 2002 Unclear ”Laboratory safety examina-
tions were made at the begin-
ning and at the end of the
study period“
Unclear Insuf cient information on SAEs
de nition
Likosky 1991 Unclear Not reported High SAEs not reported
Milanese 1993 Unclear Not reported High SAEs not reported
Millefiorini 1997 Low ”The safety of the treatment
was assessed on the basis of ad-
verse events volunteered by the
patient either spontaneously or
on questioning and monitor-
ing of the main laboratory pa-
rameters“
Unclear Insuf cient information on SAEs
de nition
Miller 1961 Low ”An independent observer un-
connected with the trial, ob-
served every 3
months the prednisolone par-
ticipantsto detect toxic effects“
High SAEs not reported
Montalban 2009 Low ”Safety issues during the study
were monitored by an in-
dependent Safety Committee.
Participantswere asked to re-
port any adverse event,... the
presence of adverse events and
intercurrent illnesses was as-
sessed at all visits“
High SAEs not reported
MSCRG 1996 Low ”According to the FDA phase
III requirements...“
Unclear Insuf cient information on SAEs
de nition
NASP 2004 Unclear ”As required by protocol, an
Independent Data and Safety
Monitoring Board (IDSMB)
reviewed interim safety data
every 6 months“
Unclear Insuf cient information on SAEs
de nition
OWIMS 1999 Unclear ”The treating physician
recorded and treated AEs...“
Unclear Insuf cient information on SAEs
de nition
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Table 2. Methods of adverse events monitoring (Continued)
Pohlau 2007 Low ”Safety and tolerability of the
treatment were assessed by
recording adverse events, vital
signs and by laboratory find-
ings. All adverse events and
clinical symptoms related to
the disease or the study med-
ication were recorded every 4
weeks“
Unclear Insuf cient information on SAEs
de nition
PRISMS 1998 Unclear ”The treating physician
treated AEs...“
Unclear Insuf cient information on SAEs
de nition
REGARD 2008 Unclear ”Adverse events (including
pregnancy), withdrawals ow-
ing to adverse events, serious
adverse events, and laboratory
results were obtained for safety
comparisons“
Unclear Insuf cient information on SAEs
de nition
SENTINEL 2006 Low The treating neurologists were
responsible for all patient care,
including the management of
adverse events and relapses of
multiple sclerosis. Clinical vis-
its every 12 weeks included
(…) assessment of any adverse
events. Participantswere also
seen by a treating neurolo-
gist during unscheduled vis-
its within 72 hours after the
development of new symptoms
so that they could be assessed
for possible relapses or adverse
events”
Unclear Insuf cient information on SAEs
de nition
SPECTRIMS 2001 Low “A treating physician super-
vised drug administration,
monitored safety, and man-
aged adverse events”
High SAEs not reported
Wolinsky 2007 Low “The treating neurologist su-
pervised drug administration,
recorded and treated adverse
events”
Unclear Insuf cient information on SAEs
de nition
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Table 3. Model fit and parsimony measures for all the primary outcomes
Posterior Residual
Deviance
(consistency model)
Data
Points
DIC
(consistency model)
DIC
(inconsistency model)
Recurrence of relapses
over 12 months
45 42 83 84
Recurrence of relapses
over 24 months
60 51 104 106
Relapses over 36 months 12 12 22 22
Disability progression
over 24 months
60 60 109 112
Disability progression
over 36 months
14 14 28 28
Acceptability 54 57 85 86
Table 4. Network meta-analysis: summary results for recurrence of relapses at any time point, posterior ORs and their 95%
credible intervals of all active interventions versus placebo and SUCRA values
Recurrence of relapses
over 12 months
Recurrence of relapses
over 24 months
Recurrence of relapses
over 36 months
Median OR
(95%CrI)
SUCRA Median OR
(95%CrI)
SUCRA Median OR
(95%CrI)
SUCRA
Natalizumab 0.35
(0.12 to 1.06)
72% 0.29
(0.17 to 0.51)
92% - -
IFNß-1a (Rebif ) 0.65
(0.27 to 1.59)
40% 0.44
(0.24 to 0.70)
73% 1.28
(0.40 to 4.05)
13%
Mitoxantrone 0.12
(0.03 to 0.55)
95% 0.43
(0.20 to 0.87)
71% - -
Glatiramer
acetate
0.40
(0.11 to 1.15)
65% 0.48
(0.38 to 0.75)
66% - -
IFNß-1b
(Betaseron)
0.54
(0.14 to 2.15)
50% 0.48
(0.29 to 0.78)
65% 0.69
(0.29 to 1.47)
64%
Azathioprine 0.63
(0.27 to 1.45)
42% 0.63
(0.39 to 0.97)
46% 0.43
(0.17 to 0.88)
94%
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Table 4. Network meta-analysis: summary results for recurrence of relapses at any time point, posterior ORs and their 95%
credible intervals of all active interventions versus placebo and SUCRA values (Continued)
Immunoglobu-
lins
0.61
(0.22 to 1.31)
44% 0.69
(0.40 to 1.04)
41% - -
Corticosteroids 0.48
(0.10 to 2.29)
53% 1.13
(0.03 to 47.93)
36% - -
Methotrexate - - 1.16
(0.27 to 5.35)
23% - -
IFNß-1a
(Avonex)
0.81
(0.33 to 1.99)
26% 0.96
(0.64 to 1.50)
19% - -
SUCRA: Surface below the Cumulative Ranking Curve. The larger the SUCRA value for a treatment, the higher its rank among the
available treatment options.
Table 5. Network meta-analysis: summary results for disability progression at any time point, posterior ORs and their 95%
credible intervals of all active intervnetions versus placebo and SUCRA values
Disability progression over 24
months
Disability progression over 36 months
Median OR (95%CrI) SUCRA Median OR (95%CrI) SUCRA
Mitoxantrone 0.42 (0.20 to 0.87) 89% - -
Natalizumab 0.61 (0.41 to 0.91) 74% - -
Glatiramer acetate 0.67 (0.49 to 0.88) 67% - -
Methotrexate 0.67 (0.22 to 2.04) 58% - -
Immunoglobulins 0.79 (0.53 to 1.17) 58% - -
IFNß-1b (Betaseron) 0.74 (0.54 to 1.00) 54% 0.87 (0.35 to 2.09) 59%
Azathioprine 0.75 (0.42 to 1.30) 54% 0.45 (0.13 to 1.31) 92%
Cyclophosphamide 0.79 (0.19 to 3.27) 49% 1.62 (0.40 to 6.56) 18%
IFNß-1a (Rebif ) 0.79 (0.60 to 1.04) 47% 1.10 (0.45 to 2.79) 36%
IFNß-1a (Avonex) 1.06 (0.78 to 1.51) 18% - -
Corticosteroids 1.58 (0.58 to 4.35) 11% - -
SUCRA: Surface below the Cumulative Ranking Curve. The larger the SUCRA value for a treatment, the higher its rank among the
available treatment options.
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Table 6. Network meta-analysis: summary results for patients with RRMS for recurrence of relapses over 12 and 24 months
and disability progression over 24 months, posterior ORs (95% credible intervals) of all active interventions versus placebo
and SUCRA values
Recurrence of relapses
over 12 months
Recurrence of relapses
over 24 months
Disability progression
over 24 months
Median OR
(95%CrI)
SUCRA Median OR
(95%CrI)
SUCRA Median OR (95%CrI) SUCRA
Mitoxantrone 0.13 (0.01 to 1.
32)
85% 0.14 (0.03 to 0.55) 92% 0.11 (0.01 to 0.65) 96%
Natalizumab 0.35 (0.07 to 1.
67)
65% 0.31 (0.19 to 0.55) 75% 0.62 (0.33 to 1.24) 55%
Immunoglobu-
lins
0.36 (0.08 to 1.
28)
63% 0.34 (0.13 to 0.69) 70% 0.63 (0.24 to 1.67) 52%
Azathioprine 0.76 (0.08 to 7.
40)
36% 0.34 (0.08 to 1.30) 65% 0.51 (0.13 to 1.95) 61%
IFNß-1a (Rebif ) 0.65 (0.19 to 2.
29)
46% 0.46 (0.25 to 0.71) 53% 0.74 (0.40 to 1.32) 40%
Glatiramer
acetate
0.36 (0.07 to 1.
54)
63% 0.50 (0.29 to 0.71) 46% 0.52 (0.28 to 0.88) 70%
IFNß-1b
(Betaseron)
0.54 (0.09 to 3.
33)
47% 0.50 (0.31 to 0.82) 45% 0.67 (0.38 to 1.13) 50%
Corticosteroids 0.44 (0.04 to 4.
86)
54% 1.17 (0.02 to 50.
83)
31% - -
IFNß-1a
(Avonex)
0.81 (0.23 to 2.
90)
29% 1.10 (0.69 to 1.82) 10% 1.11 (0.64 to 2.16) 10%
SUCRA: Surface below the Cumulative Ranking Curve. The larger the SUCRA value for a treatment, the higher its rank among the
available treatment options.
Table 7. Network meta-analysis: summary results for patients who dropped out (withdrawals or lost to follow-up) due to
adverse events (posterior ORs and 95% credible intervals of all active interventions versus placebo and SUCRA values)
Median OR (95%CrI) SUCRA
Cyclophosphamide 0.51 (0.08 to 2.75) 82%
Mitoxantrone 0.70 (0.31 to 1.56) 81%
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Table 7. Networkmeta-analysis: summary results for patients who dropped out (withdrawals or lost to follow-up) due to adverse
events (posterior ORs and 95% credible intervals of all active interventions versus placebo and SUCRA values) (Continued)
Glatiramer acetate 0.93 (0.69 to 1.25) 70%
IFNß-1b (Betaseron) 0.94 (0.72 to 1.22) 69%
Natalizumab 1.04 (0.52 to 2.17) 57%
Azathioprine 1.34 (0.39 to 4.82) 43%
Immunoglobulins 1.23 (0.82 to 1.84) 40%
IFNß-1a (Rebif ) 1.23 (0.85 to 1.74) 39%
IFNß-1a (Avonex) 1.37(0.86 to 2.25) 32%
Corticosteroids 2.95 (0.62 to 17.66) 17%
Methotrexate 4.37 (0.86 to 37.96) 8%
SUCRA: Surface below the Cumulative Ranking Curve. The larger the SUCRA value for a treatment, the higher its rank among the
available treatment options.
A P P E N D I C E S
Appendix 1. Search Strategy for CDSR
#1MeSH descriptor Multiple Sclerosis, this term only
#2MeSH descriptor Multiple Sclerosis, Chronic Progressive, this term only
#3MeSH descriptor Multiple Sclerosis, Relapsing-Remitting, this term only
#4MeSH descriptor Myelitis, Transverse explode trees 3, 5 and 7
#5MeSH descriptor Optic Neuritis explode all trees
#6MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only
#7MeSH descriptor Demyelinating Autoimmune Diseases, CNS, this term only
#8“multiple sclerosis”:ti,ab,kw or “chronic progressive multiple sclerosis”:ti,ab,kw or “progressive relapsing multiple sclerosis”:ti,ab,kw
or “secondary progressive multiple sclerosis”:ti,ab,kw or “primary progressive multiple sclerosis”:ti,ab,kw
#9“relapsing remitting multiple sclerosis”:ti,ab,kw or “remitting-relapsing multiple sclerosis”:ti,ab,kw or “acute relapsing multiple
sclerosis”:ti,ab,kw or “neuromyelitis optica”:ti,ab,kw or “optic neuritis”:ti,ab,kw
#10“devic disease”:ti,ab,kw or “demyelinating disease”:ti,ab,kw or (adem):ti,ab,kw or “demyelinating disorder”:ti,ab,kw or “clinically
isolated syndrome”:ti,ab,kw
#11“transverse myelitis”:ti,ab,kw or “acute disseminated encephalomyelitis”:ti,ab,kw or (encephalomyelitis):ti,ab,kw
#12MeSH descriptor Demyelinating Diseases, this term only
#13(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14(#13) in Cochrane Reviews
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Appendix 2. Keywords for searching for direct comparison studies
Interferon v Glatiramer Acetate
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{copolymer-1} OR {cop-1} OR {copaxone} OR {glatiramer acetate} OR {cpx} OR {cop1} OR {copolymer} OR {glatiramer} OR
{immunomodulation\*} OR {immunomodulator\*} OR {immunosuppression}
Interferon v Methotrexate
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{methotrexate} OR {mexate} OR {dicesium salt methotrexate} OR {disodium salt methotrexate} OR {sodium salt methotrexate} OR
{methotrexate hydrate} OR {(D)-isomer methotrexate} OR {(DL)-isomer methotrexate}
Interferon v Azathioprine
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{azathioprine} OR {azathioprine} OR {immuran} OR {imuran} OR {imurel}
Interferon v Cyclophosphamide
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{cyclophosphamide} OR {phosphoramide mustard\*}
Interferon v Natalizumab
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{antegren} OR {natalizumab} OR {tysabri}
Interferon v Mitoxantrone
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{novantrone} OR {novantron} OR {onkotrone} OR {pralifan} OR {mitozantrone} OR {mitoxantrone}
Interferon v Corticosteroids
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{adrenal cortex hormones} OR {steroid\*} OR {methylprednisolone} OR {prednisolone} OR {dexamethasone} OR {corticosteroid\*}
OR {acth} OR {prednisone} OR {Adrenocorticotropic Hormone}
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Interferon v Immunoglobulins
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*}
AND
{immunoglobulin\*} OR {intravenous immunoglobulin\*} OR {iV immunoglobulin\*}
Avonex v Rebif®
{beta-1a interferon} OR {beta 1a interferon} OR {interferon beta-1a} OR {rebif }
AND
{beta-1a interferon} OR {beta 1a interferon} OR {interferon beta-1a} OR {avonex}
Avonex v Betaseron
{beta-1a interferon} OR {beta 1a interferon} OR {interferon beta-1a} OR {avonex}
AND
{Betaseron} OR {beta-seron} OR {beta 1b interferon} OR {interferon beta1b } OR {IFNb-1b} OR {IFNbeta-1b} OR {interferon beta-
1b}
H I S T O R Y
Protocol first published: Issue 1, 2011
Review first published: Issue 6, 2013
Date Event Description
17 January 2013 Amended Converted to Intervention review format. Title changed accordingly
C O N T R I B U T I O N S O F A U T H O R S
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